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Amyotrophic Lateral Sclerosis (ALS) is an incurable late onset 
neurodegenerative disorder characterised by the specific loss of motor 
neurones (MNs). It has been recently demonstrated that Transactive 
response DNA-binding protein (TDP-43) is the dominant disease protein in 
both ALS and a sub-group of frontotemporal lobar degeneration (FTLD-
TDP). Moreover, the identification of TARDBP mutations in familial ALS 
confirms a mechanistic link between the observed mis-accumulation of 
TDP-43 and neurodegeneration but also provides an opportunity to establish 
an in vitro platform to model these diseases, based on patient-derived 
induced pluripotent stem cells (iPSCs). This study presents the optimization 
of an iPSC-based platform to study the consequences of TDP-43 M337V 
mutation in human functional populations of MNs and astrocytes in 
isolation as well as in co-culture.  
To develop this platform, two protocols to differentiate patient-derived 
iPSCs into functional MNs and astrocytes were first optimized, and the 
obtained cellular populations were then used to characterize the behaviour 
of mutant TDP-43 and its effect on the different cell types. 
This study show that it is possible to use iPSC-based platforms to 
recapitulate in vitro key aspects of TDP-43 proteinopathies such as MN cell 
autonomous toxicity and TDP-43 accumulation, but they can also be used to 
highlight previously unrecognised disease specific mechanisms and to test 
novel therapeutic approaches. Moreover, by performing co-culture 
experiments it was possible to evaluate the effects of M337V astrocytes on 
the survival of wild-type and M337V TDP-43 motor neurons, showing that 
mutant TDP-43 astrocytes do not adversely affect survival of co-cultured 
neurons. This iPSC-based platform represents an in vitro model to study 
both the effect of somatic mutations on isolated patient-specific cultures, but 
also to investigate cellular autonomy and neurodegeneration in the context 
of TDP-43 proteinopathies.  
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Chapter 1: Introduction 
 
1.1) Genetics and pathology of Amyotrophic Lateral Sclerosis 
1.1.1) Introduction to the Pathology 
Motor neurone diseases (MND) are a class of untreatable neurodegenerative 
disorders, characterized by a premature loss of motor neurons in the spinal 
cord and brain stem 1,2. Within the spectrum of MNDs, amyotrophic lateral 
sclerosis (ALS) is an adult onset disease that starts as focal muscular 
weakness caused by specific loss of motor neurons (MNs), and 
progressively spreads to affect all muscle groups eventually causing death 
by respiratory failure3 or complications of the treatment involved (i.e. 
mechanical ventilation). The mechanism(s) that lead to specific loss of 
motor neurons is at present unclear. 
This form of motor neuron disease has a typical age of onset between 50 
and 60 years and leads to spasticity, hyper-reflexia (upper motor neurons), 
generalized weakness, muscle atrophy (lower motor neurons), and 
paralysis4; ultimately death occurs in consequence to fatal respiratory 
paralysis typically within 1 to 5 years from clinical diagnosis. The lifetime 
risk for this neurodegenerative disorder is approximately 1 in 2000, with a 
UK prevalence of 4.0 to 4.7 per 100.000 population 5.  
Pathologically, loss of motor neurons is accompanied by reactive gliosis6 , 
intracytoplasmic neurofilament abnormalities, and axonal spheroids7. In 
end-stage disease, there is significant loss of large myelinated fibers in the 
corticospinal tracts and ventral roots as well as evidence of Wallerian 
degeneration and atrophy of the myelinated fibers 8. Selectivity of death 
occurs even among motor neurons: the neurons that control the bladder (i.e., 
Onuf’s nucleus in the sacral cord) and eye movements are relatively spared 
9. From a neuropathological point of view, the main feature of all cases of 
ALS is the presence of large insoluble protein aggregates in the cytoplasm 
and nucleus of dying motor neurons. These neuronal cytoplasmic inclusions 
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(NCI) have been demonstrated to be positive for ubiquitin, and are more 
commonly found in the lower motor neurons, mostly observed as either 
filamentous skeins or compact round bodies10 
The only available treatment for ALS is Riluzole, that modulates pre-
synaptic glutamate release11 and prolongs survival by two or three months. 
The lack of effective treatments reflects our poor understanding of the 
ethiopathogenesis of ALS12 
1.1.2) The genetics of ALS: Sporadic vs. Familial  
The vast majority of ALS cases present as sporadic (sALS), however ~10% 
of patients present an inherited familial form of the disease (fALS). Given 
the lack of knowledge regarding the pathological mechanism(s) behind 
ALS, studying this minority of inherited cases offers probably the best 
method to interrogate the mechanism of motor neuron degeneration. 
The understanding of fALS pathogenesis began with the discovery of 
dominant causative mutations in the gene encoding a copper/zinc 
superoxide dismutase 1 (SOD1) in ~20% of familial ALS cases and ~1% of 
sporadic cases13. SOD1 is a ubiquitously expressed protein and its main 
function is to convert superoxide radicals to molecular oxygen and 
hydrogen peroxide. So far, more than 100 different mutations have been 
identified in cases of fALS14. 
For the last 20 years, most of the efforts done to gain an understanding of 
ALS pathogenesis have been focused on the SOD1-determined cases of 
fALS and SOD-1 based animal models.  
Since the original discovery that SOD1 mutations cause fALS, pathogenic 
variants in several other genes have been associated with this disease. 
 
Starting from 2008, several groups reported a series of dominant mutations 
in the TARDBP gene (encoding for a DNA-RNA binding protein, TDP-43) 
as causative of fALS 15-19. Collectively these studies provided evidence that 
the aberrant form of TDP-43 can directly trigger neurodegeneration. To this 
day, 30 different mutations are now known in 22 unrelated families (~3% of 
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familial ALS cases) and in 29 sporadic cases of ALS (~1.5% of sporadic 
cases)5.  
Following the identification of TDP-43 mutations as genetic determinants of 
fALS, two separate groups reported that mutations in another DNA/RNA-
binding protein called FUS (fused in sarcoma) or TLS (translocation in 
liposarcoma) are responsible for causing fALS 20,21. Linkage in this 
particular region had already been reported, and crucial for the identification 
of FUS/TLS within it was the previous discoveries of fALS causative 
mutations in TDP-43, which is a DNA/RNA-binding protein. Vance and co-
workers prioritized the sequencing of genes within the linkage region 
identified in a large family with fALS so as to target genes encoding 
DNA/RNA-binding proteins, leading to the identification of a dominant 
missense mutation (R521C) in the FUS/TLS gene. This result was then 
replicated analysing several other fALS cases, which lead to the 
identification of the same R521C mutation in four additional families, as 
well as two additional missense mutations in another four families.  
More recently, another fALS-linked gene (responsible for a previously 
reported linkage on chromosome 9p21) was identified by two separate 
studies 22,23. The particular genetic variant highlighted was a non-coding 
hexanucleotide repeat expansion within the promoter or first intron of the 
alternatively spliced C9ORF72 gene. Importantly, this expansion was 
reported to be a relatively common fALS causing genetic variants, 
particularly in the Finnish population, and it was estimated to account for 
46 % of Finnish fALS cases and between 22.5 %23 and  38 %22 of all fALS 
cases worldwide24.  
1.2) Transactive Response DNA Binding Protein 43 (TDP-43) 
1.2.1) TDP-43 Biology and Functions  
In 2008 mutations on Transactive Response Dna Binding Protein (TARDP) 
were shown to be causative of some cases of fALS15. TARDP encodes for a 
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43 KDa protein that binds to DNA and RNA, first described in 1995 as a 
novel protein that regulates HIV-1 gene expression in human cells25. 
This gene is highly conserved throughout evolution, and is found in all 
higher eukaryotic species, including animal models Drosophila 
Melanogaster, Xenopus Laevis, and Caenorhabditis Elegans26. Human 
Tardbp is located in 1p36.22, and is constituted by 6 exons; the protein is 
encoded by the first 5 exons, and it is ubiquitously expressed, with a 
predominant nuclear localization. TDP-43 contains two RNA recognition 
motifs highly conserved among species, and a glycine rich C-terminal 
domain, typical of the heterogeneous nuclear ribonucleoprotein (hnRNP) 
family, to which TDP-43 belongs27. The C-terminal domain is a very 
important feature of this protein, for two reasons: first, its sequence varies 
considerably between species, reflecting species-specific functions; 
secondarily, all but one of the ALS causative mutations identified in Tardbp 
are located in this region5.  
TDP-43 is able to bind both mRNA and DNA, and although a clear 
consensus TDP-43 binding site in vivo has yet to be established, in early in 
vitro studies this protein seemed to preferentially bound RNAs via a GU 
dinucleotide repeat element 28. Moreover, analyses of global TDP-43 
binding sites showed that the most significant RNA binding occurred at 
either uninterrupted GU repeats29 or a GU-rich motif interrupted by a single 
adenin30.  
This protein has been shown to play key roles in the regulation of gene 
transcription, pre-mRNA splicing, mRNA stability and transport28. 
Particularly, it has been reported that TDP-43 contributes to the splicing of 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene, 
promoting exon skipping 31,32, and in the splicing of Survival of Motor 
Neurons 2 (SMN2) gene, promoting exon 7 inclusion 33. 
TDP-43 has also been implicated to have a role in mitochondrial function, 
as abnormal expression of the mitochondria fission/fusion proteins MFN1 
and Fis1 was observed in transgenic (Tg) mice constitutively expressing a 
human wild-type TDP-43 transgene driven by the mouse prion promoter 34. 
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A direct or indirect link between TDP-43 and mitochondria is also 
supported by the discovery that HDAC6, a downstream RNA target of TDP-
4335 has recently been implicated in mitophagy36. 
In 2012, Chiang and co-workers highlighted another role for TDP-43, by 
performing transcriptional profiling of TDP-43 deficient embryonic stem 
(ES) cells. Their study identified as a putative target of TDP-43 the RAB 
GTPase Tbc1d1, a gene linked to cellular metabolism and obesity37.  
Another TDP-43 role proposed recently is more directly linked to neuronal 
survival and neurodegeneration: Tollervey and colleagues showed that 
TDP-43 bound RNAs that encode proteins which regulate neuronal 
development and survival, and identified the noncoding RNAs MALAT1 
and NEAT1 as disease relevant TDP-43 targets38. Although further studies 
are necessary to clarify the splicing regulatory role of this exciting class of 
noncoding RNAs in the survival and degeneration of neurons, direct binding 
of TDP-43 to a wide range of target RNAs relevant to neuronal survival 
suggests that TDP- 43 is involved in neuronal function and integrity in 
health and disease. 
In the last 2 years, TDP-43 has been also shown to have a crucial role 
during development; two independent studies demonstrated that TDP-43 is 
essential during early embryonal stages, in particular for blastocyst implant 
and inner cell mass growth27,39. Sephton and co-workers in particular, 
demonstrated by in situ hybridization how TDP-43 is present throughout 
embryonic development and it is particularly expressed in the 
neuroepithelium and neural progenitors of the developing embryo27. 
Importantly this protein has been shown to relocate at the terminals of 
electrophysiologically active neurons40. 
Finally, several studies have reported that TDP-43 levels have particularly 
tight regulatory control mechanisms, to prevent cellular toxicity due 
variations in TDP-43 levels41. One such report increased TDP-43 expression 
in Tg mouse models or cultured cells led to a prominent reduction in 
endogenous TDP-43 levels 42-44   providing evidence that TDP-43 regulates 
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its expression via direct binding of the TDP-43 protein to its own 3’UTR 
sequence and contributes to TDP-43 mRNA instability and degradation.  
Importantly, accumulating evidence indicates that TDP-43 has –amongst the 
other roles described – a key function in mRNA triage and stress-responsive 
RNA-associated factor. In particular, it has been demonstrated that exposure 
to oxidative stressors –such as zinc- leads to accumulation of insoluble 
TDP-43 aggregates in cultured cells45. More recently using a variety of 
cultured cells it has also been demonstrated that exposure to stress causes 
TDP-43 relocalisation to cytoplasmic foci called stress granules (SGs) 46-48. 
SGs represent a cellular regulatory mechanism that triages stalled RNA 
regulation and sorting49,50. Other groups reported relocalisation of 
endogenous or ectopically expressed TDP-43 to SGs in human cell lines, 
NSC-34 cells (a motor neuron-like cell line) or cultured primary glia, in 
response to a variety of stresses including arsenite and sorbitol 48 51. 
Although the descriptive nature of SG localization reveals a physical 
incorporation of TDP-43 within SGs, whether TDP-43 has an active role 
within SGs or a causal role in SG assembly remains uncertain.  
1.2.2) TDP-43 Pathology, TDP Proteinopathy and the ALS-FTLD 
Spectrum 
As described in the first part of this section, ALS is the most frequent form 
of motor neuron disease and the absence of available treatments is a 
reflection of our poor understanding of the ethiopathogenesis of this disease. 
A characteristic feature of degenerating neurons in ALS, and one of the 
most used pathological classification criteria, is the presence of cytoplasmic 
inclusions positive for ubiquitin (neuronal cytoplasmic inclusions, NCI). 
Interestingly, these NCIs are commonly found in another class of 
neurodegenerative disorders, termed Frontotemporal lobar degeneration 
(FTLD). FTLD is a focal, non-Alzheimer form of dementia, that can present 
either behavioural or aphasic symptoms 52 53 and is the second most frequent 
cause of presenile dementia54. 
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Interestingly, besides the presence of NCIs, there is a degree of clinical 
overlap between dementia and ALS, demonstrated by the presence of 
cognitive and behavioural dysfunction in up to 50% of ALS patients55,56. 
These findings indicated for the first time that ALS and FTLD might 
represent two points in a spectrum of clinical phenotypes, related by 
common neuropathological mechanisms 57. Further evidence for a clinical 
overlap between these two diseases is the presence of ALS cases displaying 
progressive aphasia 58 59 and  frontotemporal atrophy 60. 
Definitive evidence that ALS and FTLD are linked came in 2006, from a 
study by Neumann and colleagues.  In this study the characterization of 
post-mortem samples presenting ubiquitin positive NCIs led to the 
identification of TDP-43 as the main component of pathological protein 
aggregates in 50% cases of FTLD-U (renamed as FTLD-TDP)13 and  in the 
vast majority of ALS cases (ALS-TDP) 61-63. Besides the colocalisation of 
TDP-43 and ubiquitin in the pathological inclusions and specificity of TDP-
43 immuno-reactivity for the NCI in these conditions these common 
pathology was also characterised by abnormal fragments of TDP-43 in post-
mortem tissue, ubiquitination and hyperphosphorylation of TDP-43 and loss 
of the normal nuclear TDP-43 staining in cells harbouring NCIs55. 
These common pathological hallmarks confirm that ALS and FTLD are part 
of the same clinical manifestation spectrum and also provide a unifying 
pathology that allows the classification of both neurodegenerative disorders 
as  “TDP proteinopathies”. 
In 2007 Mackenzie and colleagues demonstrated that even if SOD1 fALS 
has been extremely important in the understanding of ALS pathological 
mechanism, it might not represent the perfect model to obtain general 
insights on ALS mechanism: in their study they compared five different 
groups of patients (sporadic ALS, fALS with and without mutations in 
SOD1, and ALS with dementia) forming a cohort representative of the most 
common cases of ALS, and then analysed the presence of TDP-43 
proteinopathy among the different groups. The results of this study 
demonstrated that SOD1 fALS is the only form of this disorder that does not 
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present ubiquitinated TDP-43 positive NCI cannot therefore be classified 
within the TDP proteinopathies 64. This study indicated for the first time in a 
systematic way that studying of TDP-43 fALS cases has potentially a much 
wider relevance to our understanding of the vast majority of ALS cases. 
 
1.2.3) Models of TDP-43 Proteinopathies 
The role of mutated TDP-43 in the pathogenesis of ALS remain still 
unclear; however, in the last years several studies have shed some light on 
the mechanism of motor neuron toxicity in the presence of mutations on 
Tardbp.  
 
In Vitro Models of TDP Proteinopathies 
Since the original identification of TDP-43 as the component of the NCIs, 
several in vitro models have been established to elucidate the cellular 
pathways involved in TDP-43 toxicity and the mechanism of 
neurodegeneration. A number of different systems have been used, from 
immortalized cell lines such as HEK-293 cells and HeLa cells, to primary 
neuronal cultures and unicellular organisms such as yeasts. 
In 2008 Winton and co-workers demonstrated that in the context of QBI-
HEK 293A cells (an immortalized line of primary human embryonic kidney 
cells) the expression of a truncated form of TDP-43, lacking the nuclear 
localization sequence, was sufficient to disturb the nuclear localization of 
normal TDP-43, and to induce the formation of aggregate, sequestering the 
wild type form44. More recently Nishimura and co-workers, have conducted 
similar experiments on neuroblastoma cell lines, showing that impairment 
of the nuclear import of TDP-43 causes accumulations, suggestive of a 
mechanistic role for nuclear transport machinery in ALS and FTLD 
pathogenesis65. 
Immortalised cell lines have also been used by Igaz and co-workers in 2009 
to show that the expression of C-terminal fragments of TDP-43 
recapitulated features of TDP proteinopathies, with alteration of splicing 
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and accumulation of insoluble protein aggregates66. Interestingly, these 
studies demonstrated that it was possible to reproduce in vitro some of the 
aspects of the proteinopathies observed in patient, but they were not yet able 
to answer the question of possible mechanisms of aggregation. In the same 
year Johnson and collaborators demonstrated that TDP-43 is intrinsically 
aggregation prone, and mutations simply accelerate the aggregation process 
and increase the basal level of toxicity67; this particular study was conducted 
in a yeast model, and was crucial to highlight the behaviour of this protein 
in relation to specific mutations in the glycine rich domain and also to 
suggest that TDP-43 itself can initiate aggregate formation under certain 
conditions.   
Another in vitro study published in the same year showed that in cultured 
neuroblastoma cells, the suppression of Tardbp expression induced cell 
death by disregulating three GTPase from the Rho family68.  
In vitro studies also indicated an important link between TDP-43 and 
cellular stress, as they demonstrated that this protein is part of the stress 
granules that are formed in response to certain adverse conditions in the 
cellular environment 46-48. Interestingly, Cohen and colleagues showed that 
particularly redox signalling can promote TDP-43 cross-linking via direct 
cysteine oxidation, increasing the chances of insoluble aggregates formation 
69. 
Cellular models based on primary rodent neuronal cultures have also been 
particularly useful to understand TDP-43 toxicity. Amongst these, a system 
developed by Barmada and co-workers suggested that TDP-43 toxicity 
might be more directly linked to its localisation than to the formation of 
ubiquitinated aggregates70. 
In summary, several useful observations on the mechanisms involved in 
TDP-43 aggregation and toxicity have been derived from cellular models. 
However, these findings need to be further verified by both animal models 
and also by the development of further in vitro models, based on more 
relevant cell types. 
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Mouse models of TDP-43 proteinopathies 
The first murine model developed to address the physiological role for 
TDP-43, were reported after 2009, and consisted mainly of Tardbp null 
mice. Because TDP-43 is an essential protein for embryonic development, 
in all instances embryonic lethality was observed, occurring between 
embryonic days 3.5 and 8.5 27 39. Interestingly, heterozygous Tardbp null 
mice showed deficits in motor function, although without any displaying 
any apparent MN degeneration, suggesting that reductions in TDP-43 
physiological levels are sufficient to cause a motor weakness phenotype 71. 
To overcome the problems of total knockout mice a recent study developed 
a conditional Tardbp knockout mouse model, showing that postnatal 
deletion determines an array of different deficits. Interestingly, this study 
identified a role for TDP-43 in metabolism: in fact, amongst the identified 
problems caused by postnatal Tardbp deletion loss of body fat was noted. 
Moreover, these mice exhibited also a transcriptional profile consistent with 
what observed in metabolic dysfunction and obesity, and researchers were 
able to identify one of the crucial genes of this pathway, Tbc1d1, as a target 
of TDP-43 37. More recently, a study reported that specific deletion of 
Tardbp from the spinal cord MNs determines a motor deficit with 
pathological features similar to those observed in ALS72. As in many 
different diseases before TDP proteinopathies, deletion models can offer 
insight in the biological relevance of the studied protein in key cellular 
pathways, but there are limitations to the extent to which these knockout 
mice model the human pathology. For this reason the subsequent generation 
of animal models of TDP-43 toxicity was focused on creating appropriate 
transgenic mice. The following table present the list of transgenic mice 
reported in various study from 2009 till now, together with a brief 


























































































































































































































































































































































































































































































































































































































































































































































































































   
   
   















































































   
   
   


























































































Four separate TDP-43 transgenic mice lines described in the table have been 
engineered to express the transgene under the control of the mouse prion 
protein (PrP) promoter which drives high expression in central nervous 
system. In particular, the mouse model generated by Wegorzewska and 
colleagues 73 overexpresses a flag-tagged mutant version of human TDP-43, 
and present a progressive motor dysfunction associated with weight loss, 
that cause the death of the animal by 5 months of age. Interestingly, even if 
the PrP promoter drives the transgene expression throughout all CNS areas, 
neurotoxicity is observed only in layer V cortical neurons and in spinal 
motor neurons.  
However, Xu and colleagues reported similar results in their PrP-driven 
TDP-43 line overexpressing the wild-type human protein, with reduced 
body weight and motor impairment associated with spinal cord degeneration 
and reduced viability. These two studies indicated that the overexpression of 
either the wild-type or mutant versions of TDP-43 can induce a pathology in 
mice that presents several of the observed ALS characteristics (motor 
involvement, specific neurodegeneration, etc.). In this context, the study of 
more independently generated transgenic mice lines shed light on the 
differential toxicity of mutant and wild-type TDP-43. Stallings and co-
workers reported that while at high expression levels there was no 
significant distinction between wild-type and mutant TDP-43 transgenic 
mice, at lower expression levels only the mutant TDP-43 expressing mice 
developed an observable pathology. Additional evidence supporting the idea 
of a differential toxicity between mutant and wild-type TDP-43 came from 
the analysis of transgenic rats, engineered to express a BAC-derived mini 
version of either M337V or wild-type TDP-43. Zhou and colleagues 
demonstrated that in this system the M337V mutant version of the protein 
was able to determine a observable motor deficit with associated specific 
neurodegeneration of spinal cord, cerebellum and cortex in transgenic rats. 
The same group also showed that postnatal expression of the mutant 
M337V-TDP-43 mini gene (using a inducible expression system) in rats 
caused MNs degeneration and progressive paralysis74. The same group 
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generated also a murine transgenic mouse model, that expresses either the 
mutant or wild-type TDP-43 under the control of the ubiquitous CAG 
promoter. This particular system confirmed what they already observed in 
the transgenic rats: the mutant version of the protein causes a significantly 
increased pathology compared to the mild deficits observed in wild-type 
overexpressing mice75. 
Another strategy to generate TDP-43 transgenic mice, adopted by some 
groups to overcome the overt embryonic and developmental toxicity of 
TDP-43 overexpression while maintaining a meaningful expression pattern, 
is to drive the transgene expression under the control of the Thy1 promoter, 
which ensure postnatal expression targeted in neurons. 
Transgenic mice that express wild-type TDP-43 under control of the mouse 
Thy1 promoter, develop a dose- dependent degeneration and motor 
phenotype similar to what observed in PrP promoter transgenic lines 76,77. In 
particular a dose-dependently influence  the onset and rate of progression 
was observed by  Wils and co-workers, while in the lines generated by Shan 
and colleagues the severity of the phenotypes correlates with the copy 
number of the transgene. 
Another different strategy, used independently by two groups to generate 
transgenic murine models of TDP proteinopathies is to control the 
expression of TDP-43 with the Ca2+/calmodulin-dependent kinase II 
(CaMKII) promoter, which drives neuronal expression predominantly in the 
forebrain but not in the spinal cord. Interestingly, these mice develop 
progressive motor deficits with impairments in motor coordination, balance, 
and grip strength by six months of age 78. Igaz and colleagues also reported 
that the CaMKII-mTDP-43 mice develop abnormal limb- clasping reflexes 
when suspended by their tails43. 
Several of the transgenic models presented above show several 
commonalities in the observed pathology, despite numerous variations in 
their design (i.e. selection of promoter driving transgene expression and, 
consequently, the regional expression, in the form of TDP-43 being 
expressed) and even in the species chosen for the model (mouse vs. rat). 
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Most of these consistently models show a motor pathology similar to what 
observed in ALS, but there are also several divergences in the pathological 
features they present. 
One example of particular interest is the presence of TDP-43 positive 
ubiquitinated aggregates, which represents probably the most characteristic 
feature of TDP-43 proteinopathies. In the context of the Prp-promoter based 
models, Wegorzewska and colleagues observed ubiquitin-positive 
aggregates selectively in cortical layer V and spinal cord motor neurons, but 
in all cases these structures were TDP-43 negative73. Conversely, the mice 
generated by Stallings and co-workers present phosphorylated TDP-43 
within ubiquitin-positive inclusions in late stage spinal cord motor neurons79. 
In general, TDP-43 immunopositive cytoplasmic inclusions are seldom 
observed when immunostaining of brain or spinal cord sections is carried 
out using the same phosphorylation-independent TDP-43 antibodies used to 
detect human pathology 34,43,73,75-77,79,80. These observations would suggests 
that TDP-43 aggregates per se are not necessary for the development of a 
neurodegeneration dependent motor deficit, although this does not excludes 
that they might contribute to the overall toxicity. This concept is partially in 
contrast with what observed in the yeast model of TDP proteinopathies81, 
where only the aggregates forming variants of the protein are shown to be 
toxic, but it finds support in the cellular system developed by Barmada and 
co-workers70. 
Another pathological hallmark of ALS and TDP proteinopathies in general 
is the change in localisation of TDP-43. In particular, in ALS patient 
samples it is possible to observe redistribution of TDP-43 from the nucleus 
to the cytoplasm, although it appears to be an early event in the 
pathogenesis of these disease 82, and eventually loss of nuclear TDP-43 
staining61. 
Cytoplasmic TDP-43 staining is occasionally observed in some of the 
published transgenic murine models, but they mainly display a nuclear 
localization of the exogenous protein 77-80. Similarly loss of nuclear TDP- 43 
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can be observed in selectively vulnerable neurons is observed prior to 
obvious signs of degeneration in some models 73,77,78. 
In particular, Igaz and colleagues generated transgenic mice that inducibly 
overexpress, within the forebrain, human TDP-43 with a mutated nuclear 
localization signal (iTDP-43ΔNLS) using the CaMKII tetracycline-off 
inducible system 43. 
An interesting observation that arose from the analysis of these transgenic 
models was the presence of mitochondrial abnormalities. 
In particular, Xu and co-workers observed eosinophilic aggregates within 
the axons of spinal cord motor neurons in their transgenic model, that were 
revealed to be composed of abnormal clusters of mitochondria present, 
suggesting a causative link between overexpression of TDP-43 and 
mitochondrial dysfunction.  
Shan and colleagues reported similar accumulations of mitochondria within 
the cytoplasm of motor neurons in their Thy1-drived TDP-43 transgenic76.  
 
Other Animal Models of TDP-proteinopathies 
Besides the murine models described above, a number of other strategies 
have been used to model TDP proteinopathies. Since 2009 a number of 
groups published Drosophila Melanogaster based models that revealed 
particularly useful confirm several observation that emerged from the 
analysis of the murine models. Interestingly, most of the fruit fly models 
recapitulate the observations made in transgenic mice, and in particular the 
dose-dependent toxicity caused by overexpression of TDP-43 or its fruit-fly 
analogue TBPH 83. 
For example, several Drosophila models support the hypothesis that TDP-43 
toxicity also depends on its ability to bind RNA targets implying that the 
toxicity might be based on a “loss of function” mechanism 84,85 86. 
Moreover, some of the Drosophila models of TDP-43-pathologies described 
in this paper support the hypothesis that age-dependent degeneration can 
increase the TBPH/TDP-43 toxicity 87 88. However, even if several 
important information have been derived from analysis of  these models 
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additional studies are required to understand how much of what learnt from 
Drosophila models can be generalized to humans83. 
Other species that have been used to model TDP-43 proteinopathies include 
Danio Rerio, the zebrafish and Caenorhabditis elegans, the flatworm . 
Examples include the study published in 2010 by Kabashi and collaborators, 
in which they demonstrated that disruption of Tardbp expression during 
development caused a motor phenotype. They also showed that the ectopic 
expression of human wild type TDP-43 was able to rescue this motor 
system abnormality, whereas expressing the human mutated form did not 
have any rescue effect 89. More recently, both the zebrafish and C. elegans 
have been used to test compounds that might protect from TDP-43 and FUS 
neuronal toxicity 90. 
Given that ultimately all these models need to be able to provide 
information useful to develop new therapeutic approaches for the human 
pathology, it is interesting to note that non human primates have started to 
be used in comparison to rodents to establish ALS and FTLD models. In 
particular, in 2012 a Japanese research published a study describing the 
analysis of a wild-type TDp-43 overexpressing Macaca fascicularis 
monkey. Their results showed that the primate model recapitulated several 
aspects of the human pathologies and also several molecular features 
observed in equivalent rodent models. The TDP-43 overexpressing primates 
presented a progressive motor pathology, accompanied by cytoplasmic 
TDP-43 localisation and loss of nuclear TDP-43 without any aggregates91. 
TDP-43 Proteinopathies: Proposed models of toxicity 
Based on what observed in the in vitro and in vivo models published so far, 
it has not been possible to derive a consensus on the exact mechanism of 
TDP-43 toxicity. Some of the observations derived from these models 
seems to support a toxic gain of function mechanism, while other studies 




TDP-43-mediated toxicity via toxic gain of function 
The most distinctive molecular features of TDP-43 pathology are the 
cytoplasmic deposition of TDP-43 aggregates, the loss of nuclear TDP-43 
and post-translational modifications such as phosphorylation and cleaved 61. 
Similar to other protein-misfolding diseases, TDP-43-mediated toxicity may 
be the result, of  a toxic gain of function from the aggregates. Traditionally, 
the toxic potential of protein aggregates is tested by overexpressing the 
protein of interest in animal models, however as reported in the previous 
section, in the transgenic mice analysed the presence of TDP-43+ 
accumulations in the cytoplasm of neurons (analogous to those observed in 
the post-mortem patients samples) is inconsistent between different lines, 
and constitutes a rare event. As an interesting example, Wegorzewska and 
colleagues observe ubiquitin-positive, but TDP-43-negative, aggregates73. 
In this particular mice however, as it is the case with most of the rodent 
model presented, it is possible to observe specific neurodegeneration and a 
motor phenotype consistent to that reported for ALS. This would suggest 
that toxicity can occur even in the absence of TDP-43 aggregation without 
the requirement for formation of cytoplasmic TDP-43 aggregates. This does 
not, however eliminate the possibility for a the cytotoxic potential of TDP-
43 aggregates nor the possibility that their formation would enhance TDP-
43-mediated neurodegeneration92, shown with the yeast models. Moreover, 
overexpression of C-terminal fragments in vitro can cause aggregation of 
TDP-43 in several cell lines, ultimately leading to toxicity66. 
Therefore despite the evidence that TDP-43 aggregates might represent a 
important factor for cytotoxicity future studies will need to further 
investigate this question. 
 
TDP-43-mediated toxicity via loss of function 
Although the exact roles of TDP-43 remain largely unknown, a number of 
studies have indicated several cellular mechanisms that require TDP-43 
function (see TDP-43 Functions above), like splicing, mRNA triage, 
mitochondrial stability and synaptic function. Given the observed loss of 
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nuclear TDP-43 observed in the disease, and considering that the formation 
of aggregates could further deplete the pool of functional TDP-43 available 
to participate to cellular functions, one of the proposed mechanism for TDP 
toxicity is the loss of function41. 
Most studies have so far concentrated on the nuclear properties of TDP-43 
and its involvement in specific pre-mRNA splicing and transcription events, 
but it is in particular in the Drosophila models that the loss of function 
hypothesis find several supporting evidences. In fact, the depletion of the 
TDP-43 homologue causes synaptic toxicity and adversely affects motor 
neurone presynaptic terminals at neuromuscular junctions, ultimately 
determining deficits in locomotive behaviours and reduces life span 93. 
Moreover, loss of TBPH decreases dendritic branching in Drosophila larvae, 
that is actively rescued by over-expressing either TBPH or human TDP-4394. 
Similar evidence can be obtained also by neuroblastoma lines based studies, 
as reported above68. 
 
1.3) Astrocytes 
Astrocytes (collectively known as astroglia) are specialized glial cells 
present in the entire central nervous system (CNS), that out-number neurons 
by over fivefold, accounting for the majority of the raw cellular mass of the 
brain and spinal cord95. These cells were originally identified as the CNS 
“connective tissue”, have been regarded for decades as passive support cells 
in the brain, affording structural and metabolic support to neurons. In recent 
years however, it has become clear that astrocytes are key players in the 
regulation of the brain microenvironment, in particular as regards 
neurotransmitter and ionic homeostasis, metabolic support of neurons, 
regulation of energy metabolism, synaptic transmission and neuronal 
excitability, synaptic generation, detoxification, free-radical scavenging, 
metal sequestration, development and maintenance of the blood-brain 
barrier, guidance of neuronal migration and immune function96. 
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1.3.1) Gliogenesis 
All three major cell types, neurons, astrocytes and oligodendrocytes, in the 
central nervous system (CNS) are generated from multipotent self-renewing 
Neural stem cells (NSCs) 97. However, during CNS development the 
differentiation of NSCs into the three different lineages is precisely 
regulated both spatially and temporally. In particular early gestation NSCs 
do not present multipotentiality and differentiate exclusively into neurons 
until mid-gestation; they then gradually begin to display multi- potentiality 
and differentiate into glial cells during late gestation, after most of the 
neuronal networks have already been established 98. This specific timing 
mechanism in NSCs fate determination is controlled by extracellular cues, 
as cytokine signalling98, and transcriptional states 99 but also by intracellular 
programs, in particular epigenetic gene regulation 100 101,102. 
 
Extracellular Cues 
Many secreted protein have been reported to play a role in the induction of 
gliogenesis. In particular, it has been know for over a decade that JAK-
STAT pathway regulates the induction of astroglial differentiation and 
specification103,104. The JAK-STAT pathway is activated by leukaemia 
inhibitory factor (LIF), a member of IL-6 interleukin family, through the 
heterodimeric receptor LIFRβ and gp130, and can in turn significantly 
induce astroglial differentiation. Evidence in support of this include the 
results of gene knock-outs for LIF, LIFRβ, gp130 or STAT3105-107 showing 
impaired astrocyte differentiation in vivo, suggesting that JAK-STAT 
signalling contributes to astrogliogenesis in the developing CNS gene 
knock-outs of LIF, LIFRβ, gp130 or STAT3 results in impaired astrocyte 
progenitors pool generation and ultimately impaired astrogliogenesis105-107. 
Interestingly, it has been also demonstrated that it is the activity of EGFR 
that controls the competence of NPC to interpret LIF signalling as a 
astrocyte induced in vivo108. }. 
Bone morphogenetic proteins (BMPs) are a family of pleiotropic cytokines 
active in many tissues (including the CNS) that belongs to the transforming 
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growth factor-β (TGFβ) superfamily109. It has been recently shown that 
BMPs can induce astrocyte differentiation by forming complexes between 
STATs and BMP-activated transcription factor Smads, bridged by the 
transcriptional coactivators, p300/CBP110.  
Several growth factors have also been shown to have an important role in 
the determination of gliogenesis onset, and in particular epidermal growth 
factor (EGF) and fibroblast growth factor 2 (FGF2) play a key role in the 
determination of neural progenitors potency. 
FGF2 in particular is a widely used mitogen to expand neural stem cells in 
vitro, and its role in the maintenance of neural stem cells in developing 
brain has been demonstrated previously111. FGF signalling has many roles 
during development, but it exerts its function in a context dependent 
manner, as it has been previously shown with an analysis of different FGF 
receptors and their influence over self-renewal and differentiation of neural 
progenitors112.  
Previous studies have demonstrated that in the developing mouse brain it is 
possible to isolate different populations of progenitors in neurosphere 
formation assays, using either FGF2 or EGF 113,114. A later study from the 
van der Kooy group demonstrated that FGF-responsive stem cells divide 
symmetrically between E11 and E14, and then switch to asymmetrical cell 
divisions between E14 and E17; at the same time EGF-responsive 
progenitors arise from asymmetric division of the FGF-responsive pool of 
stem cells, hence mainly at E14 115. These results are in line with previous 
studies reporting that between E13 and E16 in the developing mouse brain 
there is a change in responsiveness to EGF-family ligands, reflecting a 
increased level of expression of EGFR116,117. Interestingly this timing 
coincide with the late onset gliogenesis during development, when neural 
progenitors acquire the potency to generate astrocytes and other glial cells 
trough several mechanism (one example is the demethylation of GFAP 
promoter, after E14 118). Moreover, it has been demonstrated by Sanalkumar 
and co-workers, that in vitro neuronal versus glial specification in ES 
derived NPCs is largely determined during their proliferation trough 
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exposure to either FGF2 or EGF119. Moreover, this study clearly 
demonstrates that EGF-responsive NPC in vitro are capable of generating 6-




Transcription factors have also been shown to play an important role in 
determining the ability of NSCs to differentiate into astrocytes. In particular 
neurogenic basic helix-loop-helix (bHLH) transcription factors 
Neurogenein1 and Neurogenin2 have been shown to regulate astrocyte 
differentiation during early neural development by competitively binding to 
p300/CBP-Activated Smad complexes, preventing their binding to activated 
STAT3. Preventing STAT3-Smad complexes to form, this mechanism 
restrict astrocyte differentiation in NSCs, which are only capable of 
generating neurons under the influence of high-level neurogenic bHLH 
during the neurogenic period 99. 
 
Intracellular Programmes 
In addition to these extracellular cues and transcription factors, 
astrogliogenesis fine timing is also highly dependent on the epigenetic 
regulations in NSCs, in particular the regulation of CpG methylation state 
100. In NSCs during the waves of neurogenesis a CpG dinucleotide within a 
STAT-binding element (TTC CGA GAA) in the gene promoter of the 
astrocytic marker glial fibrillary acidic protein (GFAP) is highly methylated, 
preventing the binding of activated STAT3-Smad complexes and thus 
preventing astroglial gene expression 118. As an effect of this regulatory 
mechanism, neural progenitors at mid-gestation are not able to express 
GFAP even when stimulated by STAT-activating IL-6 family cytokines. As 
gestation proceeds, the STAT-binding site becomes gradually demethylated 




Gliogenesis in vitro 
Generally proliferation and propagation of NPC in vitro is maintained by 
FGF2 and EGF, for both monolayer NPC cultures120-123 and neurospheres124-
126. FGF2 in particular is a widely used mitogen to expand neural stem cells 
in vitro, and its role in the maintenance of neural stem cells in developing 
brain has been demonstrated previously111. FGF signalling has many roles 
during development, but it exerts its function in a context dependent 
manner, as it has been previously shown with an analysis of different FGF 
receptors and their influence over self-renewal and differentiation of neural 
progenitors112.  
Previous studies have demonstrated that in developing mouse brain it is 
possible to isolate different populations of progenitors in neurosphere 
formation assays, using either FGF2 or EGF 113,114. A later study from the 
van der Kooy group demonstrated that FGF-responsive stem cells divide 
symmetrically between E11 and E14, and then switch to asymmetrical cell 
divisions between E14 and E17; at the same time EGF-responsive 
progenitors arise from asymmetric division of the FGF-responsive pool of 
stem cells, hence mainly at E14 115. These results are in line with previous 
studies reporting that between E13 and E16 in the developing mouse brain 
there is a change in responsiveness to EGF-family ligands, reflecting a 
increased level of expression of EGFR116,117. Interesting this timing coincide 
with the late onset gliogenesis during development, when neural progenitors 
acquire the potency to generate astrocytes and other glial cells trough 
several mechanism (one example is the demethylation of GFAP promoter, 
after E14 118). Moreover, it has been demonstrated by Sanalkumar and co-
workers, that in vitro neuronal versus glial specification in ES derived NPCs 
is largely determined during their proliferation trough exposure to either 
FGF2 or EGF119. Moreover, this study clearly demonstrates that EGF-
responsive NPC in vitro are capable of generating 6-fold more GFAP+ cells 
than their FGF-responsive counterparts. 
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There is therefore an increasing body of information pointing to the 
possibility to increase the efficiency of gliogenesis in vitro by culturing the 
NPC in EGF alone.  
1.3.2) Functions 
Although astrocytes have a key role in several different functions within the 
CNS, their role is essentially to maintain homeostasis and ensure the 
continuity of function and cellular health for the neuronal networks. In order 
to perform this role, astroglial cells express numerous receptors that enable 
them to respond to neurotransmitters, neuropeptides, growth factors, 
cytokines, small molecules and toxins; not only enabling them to participate 
in signal processing, but also to sense any changes in the extracellular 
environment 127,128. 
Astrocytes are able to secrete a variety of neurotrophic factors essential for 
the proliferation, survival and maturation of committed neuroblasts 129, 
including nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), glia-derived neurotrophic factor (GDNF), ciliary neurotrophic 
factor (CNTF), glia-derived nexin (protease nexin-1) and epidermal growth 
factor (EGF) 128 130. 
Astrocytes can also control neuronal health more directly, by regulating the 
production of synapses and taking part in synaptic transmission. 
In particular, it has been shown that astrocytes can promote the formation 
and stabilisation of synapses in CNS neurons and are able to control 
synaptic modulating synaptic activity 131-134. 
Moreover, in the last decade the term “Tripartite synapse” has been 
proposed, to properly describe the bidirectional communication between 
neurons and astrocytes 135. In fact, astrocytes are able to express many 
neurotransmitter receptors which are stimulated during synaptic activity and 
can initiate calcium signalling within the astrocytes135 In conditions of a 
high calcium concentration, increased release of neurotransmitters such as 
glutamate, D-serine and also ATP is observed, 128,129,136.  
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Astrocytes also have a direct contact with neurons via gap-junction channels 
that allow direct electrical and biochemical communication and support 
astrocytic key functions, such as shuttle of metabolic substrates and spatial 
K+ buffering 129 137 138. Finally, astrocytes are also involved in synaptic 
elimination via the reduction of synaptic contacts 96,135. 
Moreover, astrocytes are responsible for re-uptaking the excess glutamate at 
the synaptic cleft, thus preventing excitotoxicity 127. 
Astrocytes play also a role in CNS metabolisms, as they are able to release 
molecular mediators that influence the blood flow 139 and represent the 
principal storage sites of glycogen granules in the CNS. 
Another role of astroglial cells is the production of cytokines in response to 
certain CNS stimuli, including tumour necrosis factor-a (TNF-a), 
interleukin-1b (IL- 1b) and TGF- β 96. 
In response to several diverse forms of CNS injury, astroglial cells can 
undergo a morphological and transcriptional transformation referred to as 
reactive astrocytosis or astrogliosis. Reactive astrogliosis is normally 
associated with increased production of the intermediate filaments glial 
GFAP, vimentin and nestin, together with astrocyte proliferation, 
hypertrophy and cellular process extension 140 141  is observed. Reactive 
astrogliosis entails a radical change in astrocytes properties, including a loss 
in some essential functions (i.e. glutamate uptake, increased inflammation 
due to loss of astrocytes barrier functions) and also the gain of some 
detrimental effects (i.e. inhibition of axonal regeneration, increase 
inflammation via cytokines production, production of reactive oxygen 
species)95 
1.4) Astrocytes In Disease and Neurodegeneration 
1.4.1) Non-Cell Autonomy in Neurodegenerative Diseases 
Astroglial cells are –as presented above- responsible for maintaining the 
environment in which neuronal populations survive and function. However, 
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as observed in reactive astrogliosis, astrocytes can also contribute to the 
generation of neuronal toxicity, following an injury or during disease. 
Interestingly, the classic view of neurotoxicity is based upon the idea that 
specific neuronal populations are progressively exposed to toxic insults—
for example, in dominantly inherited disease, accumulation of a toxic 
mutant protein or toxic by-products of a mutant enzyme. Over time, this 
increasing burden of neurotoxic insults combined with aging is able to 
overcome the neuron’s defensive mechanisms, triggering degeneration and 
neuronal death142. Initially this process was thought to be largely cell 
autonomous: that is, a situation in which the toxicity causing neuronal death 
is directly caused by a loss of function or gain of toxic function within the 
cellular machinery of the neuron itself, independent of other cell types that 
interact with the affected neurons2. 
In recent years, thanks to multiple evidence coming from animal models of 
diverse human neurodegenerative diseases, including ALS, spinocerebellar 
ataxia (SCA), Huntington’s disease (HD), Multiple System Atrophy (MSA) 
and Parkinson’s disease (PD), this view of the neurotoxicity in 
neurodegenerative diseases has been radically changed to include the 
contribution of cell types other than the degenerating neurons themselves. 
Non-cell autonomous mechanisms in neurodegenerative disease are now an 
important area of research, and provide an explanation for the 
ethiopathogenesis of several neurodegenerative disorders, termed Non Cell 
Autonomous Neurodegenerative Diseases (NCA-ND).  The concept behind 
NCA-ND is that the overall neurodegeneration observed is strongly 
influenced by toxicity or mutant protein expression in both neuronal and 
non-neuronal cells in the vicinity of the vulnerable neurons, as 
oligodendrocytes 143 144, and especially astrocytes 145 146-148, with evidences 
also from the study of multiple sclerosis (MS). 
In general it is possible to conceive three different mechanisms of non-cell-
autonomous toxicity/degeneration2:  
• Toxicity within the affected neurons induces damaging responses 
from glia that are not otherwise directly involved in the pathology 
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(as an example, a mutant protein is specifically produced in neurons, 
and progressive neurodegeneration triggers reactive astrogliosis that 
in turn increases inflammation)  
• Glial cells produce mutant proteins or another toxicity mediator, that 
determines a loss of normal glial function, amplifying initial cell-
autonomous damage to the vulnerable neurons 
• Mutant proteins or other toxicity mediators directly and exclusively 
produced within the glial cells determines a loss of function or a 
toxic gain of function, thus becoming a primary source of 
neurotoxicity, independent of cell autonomous toxicity within the 
neurons at risk.  
Interestingly, the latter two possibilities present a link between diseases 
previously thought to be of primary neuronal origin (as SCA and HD) and 
those that are of known primary glial origin, accompanied by secondary 
neurodegeneration (as Multiple Sclerosis, MS). 
1.4.2) Astrocytes, ALS and the question of Cell-Autonomy 
In recent years accumulating evidence from different experimental systems 
has suggested that astrocytes might have an important role to play in ALS 
pathogenesis. The first evidence for an potential non-cell autonomous effect 
in ALS came from a study in 2006 reporting that in a SOD1-fALS murine 
model the deletion of mutant SOD1 from cells other than the MNs did not 
change the onset of symptoms but it significantly slowed the progression1. 
These results where further refined in another study from the same authors, 
published two years later, reporting that the progression of symptoms in 
SOD1-fALS animal models was not due to mutant SOD1 expressed in 
either MNs or oligodendrocytes, leaving as the “prime suspects” astrocytes 
and microglial cells. The astrocytes carrying SOD1 mutations were then 
identified as responsible for the progression of the disease in the murine 
model used149,150. These findings were then replicated in vitro by a series of 
studies that used either primary astrocytes derived from SOD1- 
overexpressing mouse models in coculture with either WT or mutant SOD1 
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murine motor neurons. This in vitro platform confirmed that astrocytes 
carrying mutant copies of SOD1 are toxic to the cocultured MNs 147. The 
same non-cell autonomous toxicity was observed independently in two 
studies that used human ES derived MNs cocultured with primary SOD1 
murine astrocytes 151,152.  
Further support to the idea of an astrocyte involvement in ALS comes also 
from an increasing body of pathological studies on post-mortem patient 
material. Several studies have reported findings suggesting that an 
underlying astroglial pathology is not limited to SOD1 cases but is also a 
common theme in other/unrelated cases of ALS. One examples of this is the 
presence of gliosis in ALS patients observed in ventral horns of the spinal 
cord, extending beyond the regions of MN loss153,154. Furthermore in some 
animal models astrogliosis develops at pre-clinical stages of the disease, 
prior to any MN loss, suggesting that gliosis might not be exclusively a 
secondary reparative response155.  
Collectively these studies highlight the need to better understand the nature 
of astroglial involvement in ALS. However, as previously observed in this 
section, fALS cased –on which models the totality of this cell-autonomy 
studies are based- cannot be classified as a TDP proteinopathy, while that is 
the case for all other case of ALS and for half of the FTLD cases. For this 
reason it is of extreme importance to clarify whether the reported SOD1 
astrocytes non –cell autonomous toxicity mechanism is present also in TDP 
proteinopathies. 
1.5) Induced pluripotent Stem Cells and in vitro modelling 
The lack of appropriate treatments for ALS is a reflection of the lack of 
understanding of its pathological mechanisms and molecular causes. As 
seen in the previous sections of this literature review, a number of models 
have been established to study ALS and TDP proteinopathies, and although 
they will continue to produce key insights into the disease mechanism, they 
present also several limitations. The most obvious of such problems is that 
most models are based on the overexpression of either human or murine 
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mutant versions of the disease protein, and most of them present levels of 
expression several times higher than the biological levels present in the 
patients. Moreover, although a major causative protein has been identified, 
for most cases the disease present as a sporadic form, probably determined 
by a combination of toxic insults and genetic background prone to 
vulnerability (both of which are at present beyond the level of 
understanding available for ALS). Also, the pathology observed in animal 
models is sometimes considerably different from what observed in patients 
(see TDP Proteinopathies Models). 
Human cellular models of diseases could potentially overcome some of 
these limitations, and an important step in this direction has been the 
introduction of embryonic stem cells based models, as described for SOD1- 
in vitro models 151,152. 
Human embryonic stem cells are isolated from the inner cells mass of 
blastocyst stage embryos which can be further differentiated into all three 
germ layers (ectoderm, mesoderm, and endoderm) 156. Embryonic stem cell 
based approaches to obtain human cells in vitro have been successfully 
established in the last decade, to the point that at present a wide variety of 
developmentally relevant paradigms can be applied to hESC cultures to 
generate specific human cell types. As a particular example, a number of 
studies reported successful generation of human MNs in vitro starting from 
hESCs157-160. 
Although hESCs provide a source of human cellular material to perform 
neurodevelopmental and neurofunctional studies, to establish a model of  a 
dominant genetic disorder it is still necessary to perform genetic 
modifications or rely on overexpression techniques, as most of the 
commonly available hESC lines do not have disease specific mutations. 
To derive disease-specific hESCs lines, there are essentially two 
conventional methods: 
• Rederivation by isolating of single blastomere from morula stage 
embryos which are entered into pre-implantation genetic diagnostic 
program  
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• Derivation of hESCs by somatic cell nuclear transfer (SCNT) [7].  
The first option present both practical problems (availability and cost of 
screening) and in some cases legal and ethical issues 161. 
The second alternative is an based on the nucleus from the somatic donor 
cells transplanted into the enucleated oocytes by micromanipulator162. 
However, the success rate of hESC establishment from SCNT is 
considerably low and technically demanding.  
In 2007 Takahashi et al. published a new methodology (i.e. reprogramming) 
that allowed to overcome these issues. This study described hoe pluripotent 
cells could be derived from somatic cells by the forcing the expression of 
key pluripotent transcription factors identified in hESCs (OCT4, c-MYC, 
SOX2, and KLF4); these “reprogrammed” cells were named induced 
pluripotent stem cells (iPSCs) 163 164. The advantage of iPSC cells over other 
in vitro approaches is that the reprogrammed cells present the same genetic 
alterations present in the original somatic cells, including obviously the 
dominant genetic mutations, but –even more importantly- also including the 
genetic background on which the inherited disease develop, open the door to 
the possibility of “patient-specific disease modelling”. 
In general, human iPSCs and ESCs display several similar properties, such 
as their morphology, self-renewal, differentiation capacity, cell surface 
antigens, and gene expression profile 165 Both show high expression of 
telomerase reverse transcriptase  as well as the stage specific embryonic 
antigens (SSEAs), as SSEA-3, SSEA-4, TRA-1-60and TRA-1-81. More 
importantly iPSCs could be differentiated into all three germ layers, 
following the same protocols used to differentiated hESCs. 
Importantly, new methodologies have been published, allowing to produce 
iPSC lines from not just fibroblasts but also a wide variety of other somatic 
cell types, such as mesenchymal stem cells, umbilical cord blood, and T-cell 
lymphocyte.  
For diseases such as ALS, the reprogramming of somatic cells from nervous 
disorder patients provides a unique opportunity to generate disease-
harbouring pluripotent cells that can be differentiated into neural cells for 
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studying disease development, shed light on specific molecular mechanisms 
and investigate their involvement in disease pathogenesis.  
Several in vitro disease models based on patient-derived iPSC lines have 
been successfully established in the last years and some of them have been 
hugely influential in understanding the molecular mechanisms of the 
modelled disease. In particular iPSC-based models have been established 
not only for monogenic disease such as HD166, familial dysautonomia 167, 
spinal muscular atrophy (SMA) 168, but also for multifactorial disorders 




Aims of the Project 
Aim I:  
The first aim of this project is to establish a patient-derived iPSC based 
platform to study the consequences of TDP proteinopathies-causing 
mutations on motor neurones and astrocytes. To accomplish this specific 
protocols will be optimised to generate functional populations of astrocytes 
and motor neurones, and the consequences of TDP-43 mutations will 
addressed by biochemical, molecular and survival studies.  
   
Aim II:  
Use the established platform to answer the question of cell autonomy in 
TDP-43 proteinopathy. In particular, the experiments will be focused on:  
• Determining whether the TDP-43 mutation causes cell-autonomous 
toxicity in motor neurones. 
• Determining whether the TDP-43 mutation causes cell-autonomous 
toxicity in astrocytes populations. 
• Determining whether the TDP-43 mutation carrying astrocytes exert 
a non-cell autonomous toxic effect on motor neurones, affecting 






Chapter 2: Materials and Methods 
2.1) Generation and Characterisation of iPSC Lines 
2.1.1) Reprogramming 
Fibroblasts from a normal male (56 y old; CRL- 2465; ATCC), a normal 
female (40 y old; CRL-2524; ATCC), and from a 56-y-old male carrying 
the M337V TDP-43 mutation were reprogrammed using integrating 
retroviral vectors encoding for Sox2, Oct4, c-Myc and Klf-4 as previously 
described172.  
From the reprogramming experiments, four iPSC lines were generated: two 
independent clonal lines derived from the patient with the M337V TDP-43 
mutation [M337V-1 and M337V-2], one line from the age-matched male 
control fibroblast [CTRL-1] and one from the age-matched female control 
fibroblasts [CTRL-2].  
2.1.2) Assay for Teratoma Formation.  
To perform the teratoma formation experiments, iPSC were harvested, 
washed once with DMEM/F12, and mixed with Matrigel (BD Biosciences). 
A total of 106 cells were injected intra musculus into immune-compromised 
NSG mice. Teratomas formation was confirmed within 6 to 8 weeks post 
injection. Paraffin fixed sections were stained with Masson trichromatic for 
histological determinations. 
2.1.3) PCR and Quantitative PCR (qPCR).  
Cells were harvested at confluence using Accutase (Sigma) and RNA was 
isolated from the samples with RNeasy kit (Qiagen) following the 
manufacturer’s instructions. DNA contaminations were removed by the 
treatment with DNA-Free (Ambion). cDNA synthesis was performed by 
using 1 µg of total RNA with the First Strand cDNA Synthesis Kit (Roche) 
or the DyNAmo cDNA Synthesis Kit (New England Biolabs) in a 20- to 25-
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µL volume. Real-time qPCR reactions were set up in triplicates with the 
Brilliant II SYBR Green QPCR Master Mix (Stratagene) or Applied 
Biosystems TaqMan Assays and run on an iCycler System (Bio-Rad). 
Primer sequences are provided in Primers Table. 
2.1.4) Bisulfite Sequencing.  
Bisulfite genomic DNA sample treatment and processing were performed as 
previously described173 with a primer pair designed to target bp 2136 to 
1721 of the Oct4 promoter (forward: 5′-
GGATGTTATTAAGATGAAGATAGTTGG- 3′; reverse: 5′-
CCTAAACTCCCCTTCAAAATCTATT-3′). Bisulfite conversion 
efficiency of non-CpG cytosines ranged from 85% to 99% for all individual 
clones for each sample. 
2.1.5) iPSC Culturing: 
Once established the iPSC lines were propagated as colonies on a layer of 
irradiated mouse fibroblasts, and passage 1:3 when confluent using the 
enzyme Collagenase I (R&D). Feeder based iPSC cultures were maintained 
for up to passage 60 in vitro and samples were cryopreserved regularly. 
Pluripotent colonies on feeders were cultured with KSR-F10 Medium.  
Before starting any experiment, iPSC lines were transited from feeder 
culture conditions to feeder free cultures, by plating the colonies on 
Matrigel coated plates and maintaining them in mTSER 1 medium (Stem 
Cell Technologies). 
2.2) Generation and Characterisation of Motor Neurones from iPSC 
Lines 
2.2.1) Neural Conversion 
Feeder free cultures were used for neural conversion protocol 4 to 6 days 
after passaging. Neural conversion of iPSC lines was obtained by dual 
SMAD inhibition, as described by Chambers and collaborators1, 
36  
supplementing CDM medium174 with N-acetyl cysteine (NAC, Sigma) 
1mM, SB431542 (Tocris) 10 µM and Dorsomorphin (Tocris) 2 µM. During 
neural conversion the medium was changed every 48h, and the treatment 
was prolonged for 6-7 days.  After the end of the neural conversion phase 
the clusters of newly formed NSCs were lifted with mechanical dissociation 
coupled with collagenase treatment, and then cultured in suspension in 
CDM for 24 hours. The NSCs clusters were then plated on laminin coated 
plates in NSCR Base medium supplemented with 5 ng/mL FGF2, changing 
the medium every 48 hours for 4-5 days, until neural rosettes structures 
formed. Neural rosettes were then manually dissociated using a 19G needle 
and used for the patterning phase.  
2.2.2) MNs induction Protocol: 
After enzymatic dissociation, neurospheres were formed and caudalised in 
suspension in Phase II Medium for 7–12 days, according to the iPSC Line. 
For the monolayer based MN differentiation caudalised neurospheres were 
then dissociated with Accutase (Sigma) and plated down on coverslips 
coated with laminin (Sigma) and fibronectin (Sigma) in Phase III Medium. 
to generate MN precursors. Replated MN precursors were switched to MN 
Maturation medium and cultured for 3–6 wk. For the sphere based MN 
differentiation caudalised neurospheres were then cultured in Phase III 
Medium for 7-9 days and finally switched to MN Maturation medium for 2-
4 weeks before checking the HB9 induction with immunostaining. 
Dissociation of neurospheres after the maturation phase was performed 
using Papain Dissociation System (Worthington Biochemical). For each 
experiment a sample containing 5-20 spheres (according to experiment 
type) was taken from the original culture. Each sample was washed three 
times in D-PBS (Life Technologies) before being treated with 500 µL of 
Papain/DNAseI dissociation solution (reconstituted in HBSS according to 
manufactured instructions) for 1 hour at 37º C. After a successful 
dissociation treatment with papain, the neurospheres appeared less compact 
and with a visibly increased size (more noticeable with larger diameter 
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neurospheres). Single cells suspensions were obtained by pipetting 10-20 
times the papain-treated neurospheres with a p1000 tip. The cell suspension 
was then pellet at 1.2 rcf for 3 minutes, and the pellets re-suspended in 300 
µL of Inhibitor/DNAseI solution (reconstituted in HBSS according to 
manufactured instructions). To eliminate the remaining debris and un-
dissociated neurospheres the cell suspensions were carefully layered on top 
of 1 mL of undiluted Ovomucoid inhibitor Solution (reconstituted in HBSS 
according to manufactured instructions). After 5 minutes incubation at room 
temperature the debris and neurospheres precipitate to the bottom of the 
tube, while the single cells remain in the top layer, which can be collected 
and then centrifuged at 1.2 rcf for 3 minutes. The single cells can then be re-
suspended in MN Maturation Medium and plated according to experimental 
needs. 
2.2.3) Electrophysiology  
Whole cell patch-clamp recordings were made at room temperature using an 
Axopatch-1C amplifier. Coverslips containing iPSC-derived neurons are 
transferred to a recording chamber perfused with an acsf containing: 152 
NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 10 glucose pH 7.3 (320–330 mOsm). 
Patch pipettes were filled with an internal solution containing (in mM): 155 
K-gluconate, 2 MgCl2, 10 Na-HEPES, 10 Na-PiCreatine, 2 Mg2-ATP and 
0.3 Na3-GTP, pH 7.3 (300 mOsm). 
For the recording of whole-cell AMPA- and NMDA-evoked currents the 
external solution was supplemented with picrotoxin (50 µM) and strychnine 
(20 µM). Whole cells currents were recorded in voltage clamp in response 
to bath application of NMDA(100uM) and Glycine (50uM), AMPA 
(50uM) and GABA(100uM). 
Spontaneous  excitatory post synaptic currents (EPSCs) in voltage-
clamp where induced by application of the GABA receptor antagonist 
Picrotoxin(50uM) along with the potassium channel blocker 4-AP. This 
spontaneous activity was recorded in (1mM) Mg2+ and was blocked the 
AMPA receptor antagonist CNQX(5uM).  
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2.2.4) Neuromuscular Junction Assay: 
Mouse myoblast line C2C12 was cultures in DMEM 4.5 Glucose (GIBCO) 
supplemented with 20% FBS (Hyclone - Thermo Scientific) and 1% P/S 
(GIBCO). Once the culture reached ≅70 % density the medium was 
changed to DMED 4.5 Glucose supplemented with 2% Horse Serum 
(Invitrogen), 1% GlutaMax (GIBCO) and 1% P/S (GIBCO). Neurospheres 
at the end of the patterning phase were seeded on the C2C12 after observing 
fused myofibers (3-5 days from medium change). For the visualisation of 
the acetylcholine receptors clustering we use α-Bungarotoxin conjugated 
with Alexa 555 (Invitrogen) at a concentration of 1:500, during the staining 
procedure described above. 
2.3) Generation and Characterisation of Astrocytes from iPSC Lines.  
2.3.1) EL Conversion protocol Protocol: 
Generation of neurospheres from iPSC lines and their patterning to acquire 
motor neuron progenitor identity were performed as described above. The 
patterned neurospheres for the EL conversion were collected from cultures 
that have been maintained for 2 weeks in maturation phase of the MN 
induction protocol. The selected neurospheres were mechanically chopped 
at the beginning of the enrichment phase and cultured in NSCR EL20 
medium for 2–4 weeks (depending on the size of the chopped spheres). 
After enrichment, the spheres were then propagated in NSCR EF20 medium 
and passaged mechanically by chopping them every 2 weeks. After the EL 
conversion the neurospheres were maintained in cultures for up to 20 
months and used to establish monolayer progenitors cultures.  
Samples from each iPSC lines used in this study containing ≃100	    EL 
converted neurospheres were taken for cryopreservation after the 
establishment of the cultures and then regularly every 6 months. Each 
sample was re-suspended in NSCR base medium containing 10% DMSO 
(Sigma) and then stored within a iso-pentane based cryopreservation unit at 
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-80º C overnight, to be then transported to the main liquid nitrogen tanks for 
long-term cryopreservation. 
2.3.2) Generation of Astrocyte Progenitors Cells (APCs) cultures: 
Monolayer APCs cultures were obtained by dissociating the EL converted 
spheres with the Papain Dissociation System (Worthington Biochemical). 
For each experiment a sample containing 10-30 spheres (according to the 
size) was taken from the original culture. Each sample was washed three 
times in D-PBS (Life Technologies) before being treated with 500 µL of 
Papain/DNAseI dissociation solution (reconstituted in HBSS according to 
manufactured instructions) for 1 hour at 37º C. After a successful 
dissociation treatment with papain, the neurospheres appeared less compact 
and with a visibly increased size (more noticeable with larger diameter 
neurospheres). Single cells suspensions were obtained by pipetting 10-20 
times the papain-treated neurospheres with a p1000 tip. The cell suspension 
was then pellet at 1.2 rcf for 3 minutes, and the pellets re-suspended in 300 
µL of Inhibitor/DNAseI solution (reconstituted in HBSS according to 
manufactured instructions). To eliminate the remaining debris and un-
dissociated neurospheres the cell suspensions were carefully layered on top 
of 1 mL of undiluted Ovomucoid inhibitor Solution (reconstituted in HBSS 
according to manufactured instructions). After 5 minutes incubation at room 
temperature the debris and neurospheres precipitate to the bottom of the 
tube, while the single cells remain in the top layer, which can be collected 
and then centrifuged at 1.2 rcf for 3 minutes. The single cells can then be re-
suspended in NSCR base medium to be counted and plated on Matrigel (BD 
Biosciences, 1:80 dilution)-coated plates at a density of 104 cells/cm2. These 
cultures usually reach confluence within a week and are considered the 
initial passage for the APC monolayers. 
The monolayer APC cultures were propagated in NSCR EF20 medium and 
passaged when confluent using Accutase (Sigma) [split ratio 1:2-1:3].  
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2.3.3) Astrocyte Generation: 
To obtain differentiated astrocytes from APC monolayers, confluent 
cultures were passaged 1:3 as described above on a Matrigel coated plate 
and the day after their medium was changed to AstroMED medium 
containing 10 ng/mL CNTF (R&D). The differentiating cells were 
maintained for 14 days with 75% medium change every 48 hours. Once 
differentiated, astrocytes were detached and re-plated on a suitable 
substrate/plate according to the experimental needs. 
2.3.4) Astrocytes Functional Characterisation: 
 
Glutamate Uptake Assay 
Differentiated astrocytes were plated on Matrigel-coated 96-well plates at a 
density of 2x104 cells per well and cultured in AstroMED-CNTF for an 
additional 7 days. During the assay, astrocytes were exposed to phenol free 
HBSS (Invitrogen) containing 100 µM L-Glu; samples from the cultures 
were taken after 30, 60 and 120 minutes. The concentrations of L-Glu in the 
samples were determined using the Amplite Fluorimetric Glutamic Acid 
Assay Kit (ATT Bioquest), following the manufacture’s instructions.  
Fluorescence intensity was then measured on a FluoSTAR Optima plate 
Reader (BMG Labtech).  
As negative controls for the assay L-Glu HBSS supplemented with 2 mM  
L-trans-pyrrolidine-2,4-dicarboxylic acid (Sigma) or 100 µM L-Glu HBSS 
without sodium (Biosera) were used, both were assayed at 120 min.  
To obtain an indirect estimate of number of cells per well CyQuant Cell 
Proliferation Assay (Invitrogen) was used as indicated by the manufacturer, 
and the quantification of fluorescent signal was performed on FluoSTAR 
Optima plate Reader (BMG Labtech). The raw CyQuant data were 
processed by subtracting the background calculated on an empty plate with 
the same coating as the plates used in the glutamate uptake assay. The data 
were then normalized by the CyQuant value of CTRL-1 iPSC-derived 
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astrocytes. The processed CyQuant data were used to normalize the 
glutamate uptake assay data.  
Data obtained during the Glutamate uptake assay were analysed with the 1-
way Anova and Bonferroni post-test or with 2-way Anova. Results from the 
mutant lines (M337V-1 and M337V-2) and from the control lines (CTRL-1 
and CTRL-2) were pooled together to be presented in the figures.  
 
Synaptogenesis Assay 
For quantification of synapse formation, differentiating neurons derived 
from Control iPSC and hESC (H9) were plated either in isolation (as 
described above for MN cultures) or on a layer of iPSC-derived 
differentiated astrocytes. The coculture were maintained for 3 weeks  in the 
same medium used for isolated neuronal cultures (NSCR Neurons or MNs 
Maturation Med) and then analysed by immunostaining for synaptic 
proteins [Synapsin I (SynI) in the preliminary experiment, SynaptophysisnI 
(PSY) and PSD-95 in the following experiment] and the neuronal marker β-
3 tubulin. The average number of SynI+ or PSY+/PSD-95+ positive puncta 
per 30 µm axonal segment was calculated on five different fields for every 
condition, analysing three biological replicates. The average number of 
puncta in equivalent isolated cultures of neurons was used as a normalizer. 
Results from the mutant lines (M337V-1 and M337V-2) and from the 
control lines (CTRL-1 and CTRL-2) were pooled to be presented in the 
figures, and analysed using 1-way Anova with Bonferroni post-test. 
 
Calcium Waves. 
Differentiated astrocytes cultures were incubated in HBSS containing 5 µM 
Fluo-4AM dye (Invitrogen) for 1 h at 37ºC according to manufacturer 
instructions. Cultures were then washed three times in HBSS solution and 
left for an additional 30 minutes at 37ºC to allow complete de-esterification 
of the dye. At this point, 50 µM 2-APB (Calbiochem) was added to the 
negative control. For mechanical stimulation, a suspension of 200-µm 
diameter glass beads in HBSS was applied to the cells during imaging. 
42  
ATP-evoked calcium responses were obtained by local application of a 
5mM ATP solution (Sigma). Imaging was performed at 1fps on a Zeiss 
Axiovision microscope with incubation chamber at 37ºC. 
2.4) TDP-43 transfections and over-expression analysis in astrocytes 
2.4.1) Transfections 
For this experiments 2 weeks old differentiated astrocytes cultures were 
plated in a 96-well Matrigel coated plate, at a density of 3x104 cells/well and 
then transfected with pGW1-eGFP and either pGW1-WTTDP43:mApple 
pGW1-M337VTDP43:mApple, using LIPO-2000 (Invitrogen) transfecting 
reagents. Transfections were performed using 0.5 µL of LIPO-2000 reagent 
for every transfected well, and 0.5 µg DNA per plasmid per well. Astrocytes 
were incubated with the transfecting reagents and DNA for 45 minutes at 
37ºC and then their medium was changed to fresh AstroMED-CNTF.  
2.4.2) Imaging 
Live-Imaging started 24 hours after transfection, on a Zeiss Axiovision 
microscope with incubation chamber at 37ºC.  
2.4.3) Expression Levels Analysis 
Images of transfected astrocytes were analysed with ImageJ64 and original 
ImageJ plug-ins written in Jython. The eGFP images were used to determine 
a ROI around the astrocytes to be analysed; the same ROIs were then used 
to calculate area, raw integrated density (RawInt) and background levels on 
both eGFP and TDP43:mApple images. Relative TDP43:mApple 
expression levels were calculated by normalizing background-subtracted 
RawInt of the red channel to that of the green channel. Arbitrary expression 
units (x) were derived by normalizing the relative expression level of each 
cell to the average value for each group (WT and M337V). These arbitrary 
units were used to stratify the transfected astrocytes into six groups with 
increasing relative expression (A= below 0.65x, B=between 0.66x and 
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0.81x, C=between 0.82x and 0.97x, D=between 0.98x and 1.14x, 
E=between 1.15x and 1.30x, F=above 1.30x). The astrocytes were scored 
using the following criteria: cells with TDP43:mApple localized in the 
nucleus were assigned to the nuclear group; cells that presented 
TDP43:mApple in both nucleus and cytoplasm or cytoplasm alone were 
assigned to the cytoplasmatic group.  
 
2.5) Astrocytes-Motor Neurones Cocultures 
For cocultures experiments 2 weeks old neurospheres from the maturation 
phase were dissociated using papain (as described for MNs) and plated on a 
layer of differentiated astrocytes at a density of 7.5x104 cells per well of a 
96 well plate. Astrocytes for the cocultures were plated on Matrigel coated 
96 well plates after differentiation at a density of 2.5x104 cells per well of a 
96 well plate. The cocultures were maintained in MN Maturation Medium. 
2.6) Molecular Analysis in differentiated cultures 
2.6.1) Quantitative RT-PCR 
Differentiated cultures were detached using Accutase (Sigma), and RNA 
was isolated using the RNeasy kit (Qiagen), following the manufacturer’s 
instructions. The Turbo DNA-Free kit (Invitrogen) was used to eliminate 
genomic DNA contaminations. Synthesis of cDNA was performed using 0.5 
μg of total RNA with the DyNAmo cDNA Synthesis Kit (Thermo 
Scientific) in a 20μL volume. Real-time qPCR reactions were performed in 
triplicate using the DyNAmo Flash SYBR Green qPCR kit (Thermo 
Scientific) and examined on a CFX96 System (Bio-Rad). Relative 
expression levels were calculated by the 2DDCt method with β-actin as the 
reference gene. 
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2.6.2) Western Blots 
Differentiated cultures (at the end of the maturation phase for MNs and after 
14 days of differentiation for astrocytes) were harvested using Accutase and 
lysed in cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
Triton x-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA). To 
isolate the detergent-soluble fraction the lysates were centrifuged at 15,700 
× g for 30 minutes at 4°C and the supernatant was collected. Subsequently, 
the detergent-insoluble fraction on the remaining part of the samples was 
extracted using an equal volume of urea buffer {7 M urea, 2 M thiourea, 4% 
(wt/vol) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS), 30 mM Tris (pH 8.5), after an additional RIPA buffer wash to 
minimize the carryover contamination from the soluble fraction. To 
eliminate genomic DNA samples were sonicated three times for 10 seconds 
in a water bath, and centrifuged again at 100,000 × g for 30 min at 22°C. 
Fresh protease inhibitors [complete Mini (Roche) and 1 mM PMSF] were 
added to all buffers. Soluble protein concentrations were determined by a 
BCA protein assay (Pierce). 12% SDS/PAGE gels were loaded with 15 μg 
of protein for each sample on transferred after complete resolution on PVDF 
membranes. For the insoluble fraction, an equivalent sample volume was 
analysed. The PVDF membranes were blocked in Western Blocker Solution 
(Sigma) and incubated in primary antibody overnight at 4°C. Proteins were 
detected with horseradish peroxidase–conjugated secondary antibodies, and 
blots were developed with Amersham ECL Plus and Hyperfilm (GE 
Healthcare). Semiquantitative densitometric analysis of western blots was 
performed with ImageJ, using β-actin as a loading control for the soluble 
fraction and Ponceau S staining for the detergent-resistant fraction. 
2.6.3) Immunofluorescence and Densitometry Analysis 
Cultures were fixed for immune-labelling with 2% paraformaldehyde, and 
then permeabilised with 0.2% Triton X-100 (Sigma) at room temperature, 
and blocked in 3% goat serum (DAKO). Incubation with primary and 
secondary (Alexa Fluor dyes; Invitrogen) antibodies was performed at room 
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temperature for 1 hour and 30 minutes respectively, with three PBS washes 
between each phase. The nuclei were counterstained with DAPI (Sigma) 
after the secondary antibody incubation. Images were acquired using either 
a Zeiss Observer microscope or a Zeiss LSM 780 microscope laser-aided 
confocal microscope (both running ZEN vers. 1.4, Zeiss), according to the 
experimental needs.  
Densitometric analysis on TDP-43 astrocytes immunostaining 
immunostaining was performed using ImageJ64 (vers. 1.4.4.0): the DAPI 
channel was converted into a thresholded binary mask from which regions 
of interests (ROIs) were defined, and nuclear TDP-43 signals were 
measured in these ROIs. Cytoplasmic TDP-43 signals were measured by 
subtracting the binary mask from the TDP-43 channel, and the average 
signal intensity normalized by the number of astrocytes on the field.  
Densitometric analysis on TDP-43 in MNs cocultures with astrocytes was 
performed using the same software packages described above. ROIs were 
designed around SMI-32+ neurons that resided in a field with minimal 
presence of GFAP+ astrocytic protrusion within the focal plane considered, 
and then used to measure TDP-43 signal intensity. Results are presented as 
normalized on the same genotypes neurons cocultured on WT astrocytes. 
2.7) Survival Analysis by longitudinal microscopy  
2.7.1) Transfections 
MNs Transfections. 
Neurospheres were patterned to MN identity using the sphere-based 
protocol described above. Samples for the survival analysis were collected 
from the main neurospheres cultures after 2-4 weeks in the MN Maturation 
phase. Dissociation was performed using Papain Dissociation Kit 
(Worthington) as described above; after obtaining a single cell suspension 
we performed electroporation using the NEON electroporation system 
(Invitrogen). Electroporation were performed using three 1300 mV pulses, 
each 10 ms in length.  Electro orated cells were then plated at a density of 
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75x10^3 per well in a 96 well plate coated with poly-Ornithine and 
Laminin. To identify the MNs for survival analysis a reported plasmid 
expressing eGFP under the control of HB9 promotorial element was used 
(developed in Steve Goldmann Lab and kindly donated175). 
 
Astrocytes Transfections. 
Differentiated astrocytes were plated in a 96-well Matrigel coated plate, at a 
density of 3x104 cells/well and then transfected with pGW1-mApple, using 
LIPO-2000 (Invitrogen) transfecting reagents. Transfections were 
performed using 0.5 µL of LIPO-2000 reagent for every transfected well, 
and 0.5 µg DNA per plasmid per well. Astrocytes were incubated with the 
transfecting reagents and DNA for 45 minutes at 37ºC and then their 
medium was changed to fresh AstroMED-CNTF.  
2.7.2) Imaging Set-up 
Live-Imaging started on the cultures 24 hours after the transfections, and 
was performed daily for consecutive days. At the first time-point for each 
plate, the central position within the analysed wells was identified and saved 
within a virtual reference frame based on a physical feature of the plate 
(generally one of the markings), adopted as point of origin. This allowed to 
re-image every day the exact same position within the transfected wells. 
 
All imaging necessary for the survival analysis experiment was performed 
either on a Zeiss Axiovision microscope at the MRC Centre for 
Regenerative Medicine in Edinburgh, or on a custom robotic microscope 
system (described in Barmada, S.J. et al. Journal of Neuroscience 2010) at 
the Gladstone Institute, San Francisco CA. 
2.7.3) Data Analysis 
The images acquired during the survival analysis experiments were 
analysed using ImageJ built-in cell counter macros and original programs 
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written with MatLab. Cell death was determined by cell membrane rupture, 
blebbing, or loss of GFP fluorescence. 
The data collected for survival analysis was analysed using R software 
(www.r-project.org) and the freely available survival analysis scripts library 
associated. 
The Kaplan-Meier (KM) estimator was used to establish the survival in the 
different groups (as called by the survfit() function) and then cumulative 
risk of death curves were plotted (based on the KM fit, as called by the 
survfit() function parameter fun="cumhaz") to analyse the difference in 
survival between the various lines. Statistical significance of differences 
between groups was determined with log-rank test. Cox proportional 
hazards analysis was used to determine the influence of the M337V iPSC 
background on the risk of death of Motor neurons and astrocytes in culture. 
Results were pooled together using a unified analysis ( Simple Survival) 
when coming from the same batches of transfections/electroporation; 
otherwise, experiments performed in different days with different reagents 
batches were analysed using stratified analysis ( Stratified Survival). 
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2.8) Cell Culture Media 
NSCR Base Medium: AdDMEM/F12 with 1% N2 supplement and 0.1% 
B27 Supplement, 1% nonessential amino acids, 1% penicillin/streptomycin, 
1% GlutaMAX solution (all from Invitrogen) 
NSCR EF20 Medium: NSCR Base Medium supplemented with 20 ng/mL 
FGF-2 (PeproTech) and 20 ng/mL EGF (R&D Systems).  
NSCR EL20 Medium: NSCR Base Medium supplemented with 20 ng/mL 
LIF (Sigma) and 20 ng/mL EGF (R&D Systems).  
AstroMED-CNTF: Neurobasal with 0.2% B27 Supplement, 1% nonessential 
amino acids, 1% penicillin/streptomycin, 1% GlutaMAX solution (all from 
Invitrogen), 10 ng/mL CNTF (R&D Systems).  
NSCR Neuron Medium: AdDMEM/F12 with 1% N2 supplement and 0.5% 
B27 Supplement, 1% nonessential amino acids, 1% penicillin/streptomycin, 
0.5% GlutaMAX solution (all from Invitrogen), 0.1 µM retinoic acid (R&D 
Systems); 20 ng/mL BDNF (R&D Systems) and 20 ng/mL GDNF (R&D 
Systems) were added after the first week of differentiation.  
Phase I Medium: CDM medium174 supplemented with N-acetyl cysteine 
(NAC, Sigma) 1mM, SB431542 (Tocris) 10 µM and Dorsomorphin (Tocris) 
2 µM. 
Phase II Medium: NSCR Base Medium supplemented with 0.1 µM retinoic 
acid and 5 ng/mL FGF2. 
Phase III Medium: NSCR Base Medium supplemented with 0.1 µM retinoic 
acid, 1 µM purmorphamine (Calbiochem) and 5 ng/mL FGF2. 
MN Maturation Medium: NSCR Base Medium supplemented with 0.01 µM 
retinoic acid (R&D Systems), 0.1 µM purmorphamine (Calbiochem), 20 














Antibody Host Company Dilution 
TDP-43 C-Term Rabbit (poly) Cell Signalling 1:100 
TDP-43 mono Mouse (mono) Abnova 1:500 
SMI-32 Mouse (mono) Covance 1:1000 
ChAT Goat     (poly) Millipore 1:350 
β-3 Tub  Mouse (mono) Sigma 1:1000 
HB9  Mouse (mono) DHSB 1:250 
Olig2 Rabbit (poly) Millipore 1:300 
Pax6  Mouse (mono) DHSB 1:250 
Sox2  Mouse (mono) Millipore 1:250 
Sox1  Rabbit (poly) Millipore 1:200 
Nestin  Mouse (mono) Millipore 1:500 
Synapsin I  Mouse (mono) Millipore 1:250 
Vimentin  Mouse (mono) Millipore 1:500 
 NFIA Rabbit (poly) Abcam 1:250 
GFAP  Rabbit (poly) DAKO 1:500 
 GFAP-cy3  Mouse (mono) Sigma 1:500 
 S100B  Rabbit (poly) DAKO 1:500 
EAAT1  Rabbit (poly) Novus 1:200 
 PSD-95  Rabbit (poly) Cell Signalling 1:200 































































































2.11) R Analysis Commands 
 
Command Function Procedure 
library(survival)	   Load the survival 
library 
General 
source("{file	  path}")	   Load the survival 
source database 
General 





Analyse the data 
associating the time 
and occurrence of a 
binary event, based 
on groups 
Simple Survival 
kmfit.by.group	  <-­‐	  survfit(Surv(time,	  
as.logical(event))	  ~	  group,	  data=test.data)	  
Fit the K-M model by 
group 
Simple Survival 
lrtest	  <-­‐	  survdiff(Surv(time,	  as.logical(event))	  ~	  
group,	  data=test.data)	  
Defines the terms for 
the likelihood ratio 
(LR) test by group 
Simple Survival 
lrtest	   Show the LR test 
results, indicating 
groups used and n. 
numbers 
Simple Survival 
plot(kmfit.by.group,	  fun="cumhaz",	  main="{title	  
of	  the	  graph}",	  xlab="{axis	  title}",	  ylab="{axis	  
title}",	  col=c("{color1}",	  "{color2}"	  ...),	  lty=c({line	  
type1},	  {line	  type2}...))	  
Plots the cumulative 
hazard curves by 
applying the Kaplan-





"{group2}"	  ...),	  col=c("{color1}",	  "{color2}"	  ...),	  
lty=c({line	  type1},	  {line	  type2}...))	  
Add a legend to the 
Graph: 
Simple Survival 
coxfit	  <-­‐	  coxph(Surv(time,	  as.logical(event))	  ~	  
group	  ,	  data=test.data)	  
Statistical Analysis 
with the Cox 
Proportional model 
Simple Survival 









Analyse the data 
associating the time 
and occurrence of a 
binary event, based 
on groups but 
stratified by a 
variable (ex. Date) 
Stratified Survival 
 
kmfit.by.group	  <-­‐	  survfit(Surv(time,	  
as.logical(event))	  ~	  group	  +strata(expt),	  
data=test.data)	  
Fit the K-M model by 




coxfit	  <-­‐	  coxph(Surv(time,	  as.logical(event))	  ~	  
group	  +strata(expt),	  data=test.data)	  
	  
Statistical Analysis 










plot(survfit(coxfit),	  fun="cumhaz",	  main="{title	  
of	  the	  graph}",	  xlab="{axis	  title}",	  ylab="{axis	  
title}",	  col=c("{color1}",	  "{color2}"	  ...),	  lty=c({line	  
type1},	  {line	  type2}...))	  
Plots the cumulative 
hazard curves 
extrapolated by the 
Cox Proportional 










Chapter 3: Generation of Motor Neurones and Astrocytes 
from iPSC Lines 
3.1) Characterisation and Validation of the iPSC lines 
 
At the beginning of this project, a number of pluripotent cell lines cultures 
had already been established (all listed in Table 2). The iPSC lines were 
generated in George Q. Daley’s lab in 2009 using a 4 factor reprogramming 
strategy (Oct-4, Sox2, Klf4 and c-Myc). Lines M337V-1 and M337V-2 
represent two clonal lines generated from fALS patient derived fibroblasts 
carrying the M337V mutation on TARDBP. Lines CTRL-1 and CTRL-2 
were generated from male and female control fibroblasts respectively, and 
they represent the major controls used in this project. As an additional 
control for the behaviour of iPSC lines and their derivatives, cultures from 
human embryonic stem cells (hESC), H9 and Shef-4 were established and 
used in several optimization experiments.  
The purpose of this initial stage was to determine whether the iPSC lines 
were completely reprogrammed and therefore constituted a suitable source 
of materials for this project. The iPSC lines used in this study were 
validated using a set of established criteria including expression profile of 
pluripotency markers, efficiency of reprogramming, karyotype analysis and 
stability over long-term culture. M337V and CTRL lines were maintained in 
culture for over 40 passages on both MEF feeders or as feeder free culture 
(Fig. 1B & C) and demonstrated long-term culture stability. They also 
presented a normal 46 XY karyotype (Fig. 1D, karyotype analysis 
performed by J. Fletcher, in Ian Wilmot’s lab) and them retained the 
expression of pluripotency markers such as OCT4, TRA1-60 and SOX2 
(Fig 1E & 1F). The fALS iPSC and control lines were regularly genotyped 
by direct sequencing of single nucleotide change causing the M337V 
switch, in order exclude cross contamination between mutant and wild-type 
cultures at the pluripotent stage (Fig. 1G). To assess the efficiency of the 
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reprogramming process on the iPSC lines, bisulphite sequencing of one 
fragment of OCT4 promoter was undertaken (Fig. 1H, bisulphite 
sequencing performed by Dr. B.Bilican), which revealed a methylation 
pattern similar to established human ES lines. 
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Figure 1. Establishment of iPSCs from patient fibroblasts. (A) Primary dermal 
fibroblast cultures were established from a punch biopsy belonging to a fALS TDP-43 ALS 
patient. (B) Cultures formed tightly packed human ES-like colonies after lentiviral 
reprogramming with OCT4, SOX2, KLF4, and c-MYC, when plated on a layer of MEF. 
(C) Reprogrammed colonies remained pluripotent and self-renewing when cultured in 
feeder-free conditions. (D) Reprogrammed iPSC presented a normal karyotype [46 XY, 
representative image from M337V-1 shown]. (E-F) Immunohistochemical characterization 
of feeder-free patient iPSCs for the pluripotency markers OCT4, Tra-1-60, and SOX2. (G) 
Direct sequencing confirmed the M337V mutation in TDP-43 in patient-derived iPSCs. (H) 
Bisulphite sequencing analysis of the OCT4 promoter in M337V iPSCs and hESC line H9s.  
All results are from M337V iPSC clone 2 (M337V-2) and are representative of what iPSC 





All iPSC lines used in this study showed silencing of the exogenous 
reprogramming factors and activation of endogenous OCT4, SOX2, c-Myc 
and KLF4 (Fig. 2A, assay performed by Dr. G.Sullivan); moreover, they 
also had comparable total expression levels of OCT4, SOX2, c-MYC, and 
KLF-4 as verified by qPCR with probes specific for endogenous and 
exogenous reprogramming factors (Fig. 2B). The ability of these lines to 
generate all three germ layers was further assessed by performing a teratoma 




Table 1:  
Pluripotent Cell Lines used in this Study 






















XX Control fibroblasts none 
H9 (WA09) Normal 
(46) 















Figure 2. Validation of patient-derived iPSCs. (A) RT-PCR analysis showing the 
activation of endogenous loci and silencing of transgenic expression of the four 
reprogramming factors [OCT4, SOX2, KLF4, and c-MYC] in M337V-2 and control iPSCs. 
(B) Quantitative RT-PCR (qRT-PCR) analysis of total expression levels of NANOG in 
M337V and WT iPSCs and hESC lines H1, Shef4, and Shef6. Values are mean ± SEM. (C) 
After transplantation, all iPSCs generated teratomas displaying immature/mature neural 
tissue (ectoderm), chondrocytes (endoderm), and gut and sebaceous gland (mesoderm). 







3.2) Generation of Motor Neurones from iPSC Lines 
 
To establish a motor neurone (MN) generation protocol we started from 
recapitulating the developmental process that leads in vivo to MN 
specification 176,177, taking as example already published protocols for the 
generation of human spinal neurons 157,158,178. 
 
The protocol established for MN specification and differentiation (Fig. 3) 
encompasses three general phases that mimic the in vivo developmental 
process. Over a period of 6-12 weeks this protocol generates functional 
MNs from iPSC cells, passing through:  
(1) Neural conversion of iPSCs, resulting in neural stem cells (NSCs) 
populations. 
(2) Patterning phase that specifies the correct positional identity in NSCs, 
converting them to regionalised motor neuron progenitors (pMN). 
(3) Maturation phase that allows the regionalised progenitors to 
differentiate into mature MNs.  
  
60  
Figure 3: Motor Neurons Generation Protocol.  The protocol established for the 
generation of MNs from iPSC lines is composed of three independent phases that 
recapitulate the developmental processes taking place in vivo. The first phase consists of 
the neural conversion of pluripotent cells by dual smad inhibition, prolonged for the first 
week of treatment, followed by a patterning phase with retinoid signalling and hedgehog 
signalling for 2 weeks. The final step of the protocol consists of a maturation phase, in 
which a supportive medium with neurotrophic factors and without mitogens allows the 









3.2.1) Neural Conversion 
As previously shown in several developmental studies based in Xenopus 
embryos and in mice 179-182, the BMP pathway inhibition plays an important 
role in neural fate determination and it has been already used to promote the 
conversion of cultured pluripotent cells to neural progenitors 183. To 
develop the neural conversion phase for this protocol the dual SMAD 
signalling inhibition methodology, as published by Chambers and co-
workers in 2009184 was taken as a starting point and optimised. To begin the 
neural conversion phase feeder free iPSC or hESC cultures were exposed to 
a chemically defined medium (CDM) containing SB431542, a compound 
that inhibits the Active/TGFβ pathways, and dorsomorphine, an analogue of 
Noggin, to inhibit BMP signalling (Phase I Medium; see M&M). Half of the 
medium was replaced every 48 hours for a period of 7 days. During this 
conversion phase pluripotent cell colonies change their attachment 
properties, as they shift their identity towards the neural lineage, and can be 
easily detached as small clumps after seven days of dual SMAD inhibition 
by treatment with collagenase. The spheroids obtained by lifting the 
colonies are cultured in suspension overnight in CDM and plated the 
following day on laminin. Once plated on laminin, the neurospheres were 
left in culture for a period of 3 - 5 days in FGF2 containing medium, until 
they formed recognisable “neural rosettes” (Fig. 4A), organised structures 
formed by a high concentration of neuroepithelial precursors, positive for 
the human early neuroepithelium marker Pax6 (Fig. 4B-C). These neural 
rosettes were manually isolated from the rest of the plated neurosphere-
colony and then cultured in suspension to form new neurospheres. The 
efficiency of neural conversion was calculated by staining selected 
neurospheres for the neural progenitor cytoskeletal filament Nestin and the 
transcription factor Sox1 (Fig. 4C & 4D); both M337V and Control iPSC 
lines presented a high (90-95%) neural conversion efficiency, showing a 
behaviour similar to the hESC line H9 (Fig. 4E).   
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Figure 4: Neural Conversion Efficiency. (A) When played on laminin at the end of the 
neuralisation protocol, colonies formed tridimensionally coherent structures known as 
“neural rosettes”. (B-C) Neural rosette from iPSC lines present a high concentration of 
Pax6+ cells within the radially organized structures, as expected from previous reports. [B 
shows representative rosette from Control iPSC line, C shows representative rosette from 
M337V Lines]. (D-E) After rosettes selection cells were stained for Nestin (green) and 
Sox1 (red) to determine the efficiency of neural induction/selection; representative fields at 
both 63x (D) and 20x (E) magnification are shown from M337V iPSC-derived 
neurospheres. (F) Quantification of 5 independent fields for each line after neural 
induction; percentage of double labelling was comparable between the three cell lines used 










3.2.2) Patterning and Induction of Motor Neurones progenitors 
 
Following neuralisation neural stem cells (NSCs) formed tight clusters of 
cells. Importantly, at this stage of the process, the clusters of NSCs have a 
poor attachment to the substrate compared to the original iPSC colonies. 
Taking advantage of this variability in attachment the clusters of NSCs were 
detached from the plate using a combination of enzymatic and mechanical 
dissociation treatment. The clusters were then cultured in suspension 
overnight to form neurospheres, which are then taken through the patterning 
phase to specify a regional identity suitable for the generation of MNs. MNs 
arise from the pMN domain in the spinal cord, which represents the second 
most ventral population of the spinal cord (Fig. 5A) after the p3 
interneurons progenitors domain. For this reason the principal signals 
needed for the specification of the pMN identity are retinoic acid (RA), 
whose gradient determines the antero-posterior identity in the neural tube, 
and sonic hedgehog (SHH) signalling generated from the floor plate, the 
gradient of which determines the acquisition of ventral identities (Fig. 5B).   
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Figure 5: Schematic representation of the developing neural tube. (A) Spinal cord 
positional identities are established during the elongation of the neural tube, thanks to a 
gradient of retinoic acid (RA), which influence the expression of the Hox positional 
identity genes. Spinal cord progenitors are specified posteriorly to the hindbrain, from r7 
downwards, and are therefore characterised by the expression of the Hox4 family. (B) The 
roof plate (RP) and floor plate (FP) in the developing neural tube are the sources of BMP 
and Hedgehog signalling, determinants for dorso-ventral identity specification. The pMN 
domain represents the second most ventral progenitor population of the spinal cord, after 







In order to mimic the patterning of the neural tube in vivo the regional 
specification phase of the neurospheres was decided trough a caudalisation 
phase (first 7-9 days) in which the neurospheres are exposed to retinoic acid 
to acquire a caudal identity, and a second phase in which puromorphamine 
(an analogue of Sonic Hedgehog) is introduced in the culture to induce 
ventralisation.  
Readouts for determining the efficiency of pMN specification included 
expression analysis for the homeobox gene HoxB4 (Fig. 6A), expressed 
from rhombomere 7 to more caudal portions of the neural tube, were Pax6 
and Olig2, two factors expressed in the pMN that are necessary for MN 
progenitor specification 185.  
All lines exposed to the patterning protocol homogeneously expressed 
HoxB4 (Fig. 6A), indicating that exposure to RA efficiently induced the 
specification of caudal identity. Both M337V and control iPSC lines 
responded to the patterning phase with comparable efficiency, and their 
performance was similar to he’s cells exposed to the same protocol. In 
particular, no significant difference was observed in the percentage of cells 
expressing Pax6 or Sox2, a neural progenitor marker at the end of the 
patterning phase (Fig. 6B-D). Moreover, all lines showed comparable levels 
of Olig2 induction, as measured with double immunolabelling with 
antibodies against Nestin and Olig2 (Fig. 6E & 7F). Patterning of the 
neurospheres resulted in the induction of an Olig2+/Nestin+ pMN progenitor 




Figure 6: Generation of Motor Neuron Progenitors. (A) At the end of the casualization 
phase, after exposure to RA, the neural progenitors in culture exhibited a uniform 
expression of the positional identity gene HoxB4. (B) Representative image of 
immunostaining for Pax6 and Sox2 from M337V iPSC lines. (C) Quantification of cells 
positive for the neural stem cell marker Sox2 after the patterning phase showed that all 
lines present a comparable induction efficiency [M337V 79.45% ± 2.9 SEM; CTRL 
65.69% ± 6.5 SEM; hESC (H9) 78.40% ± 2. SEM] (D) Quantification of cells positive for 
Pax6 after the patterning phase showed that iPSC lines present a comparable induction 
efficiency, although there is a difference in induction efficiency when compared to he’s 
cells [M337V 52.38% ± 2.03 SEM; CTRL 51.65% ± 4.06 SEM; hESC (H9) 67.68% ± 
23.35]. (E) Representative image of immunostaining fro the pMN domain marker Olig2 
from M337V iPSC lines. (F) Quantification of cells positive for Olig2 after the patterning 
phase showed that all lines used present an equivalent induction of pMN identity in culture 







3.2.3) Establishment of pMN Maturation Protocol in both neurospheres 
and monolayer 
 
The neurosphere-based system described so far has many practical 
advantages: it is a robust and scalable system and allows for a easy 
transportation of the cellular material even over long distances. However, 
the maturation of the specified MNs in the neurospheres present specific 
challenges related to the inaccessibility of most cell bodies and in general 
the difficulty in assessing the cellular morphology. In particular, assessment 
by immunocytochemistry and immunofluorescence becomes particularly 
challenging when MNs are differentiated within the neurospheres, and this 
can result in an unreliable quantification of the protocol’s efficiency. For 
this reasons the maturation phase of the MN protocol was optimised using 
both a neurosphere-based system and a transition to a monolayer culture. 
After the patterning phase the pMN Olig2/Nestin progenitors can be taken 
further into the differentiation protocol by plating them on 
laminin/fibronectin186 coated coverslips for the maturation phase. The 
differentiation of the progenitors was induced by removing mitogens (FGF2 
in particular) from the culture media, which results in the neuroblasts 
exiting the cell cycle and starting to generate post-mitotic neurons, as 
demonstrated by the extending neurites on the surface of the coverslips (Fig. 
7A). The vast majority of neuroblasts and maturing neurons tend to remain 
within the neurosphere (Fig. 7B), which makes extremely difficult to study 
the behaviour and localisation of TDP-43 in the neurons, since almost all 
cell bodies reside inside the sphere.  
To overcome this problem a protocol to enzymatically dissociate the 
patterned neurospheres was established and optimised. After the regional 
specification the neurospheres were dissociated using Accutase, and the 
resulting progenitors were plated as a monolayer at high density (Fig. 7C). 
The differentiation in this monolayer cultures was induced using the same 
mitogen free medium used in the neurosphere-based protocol. The 
monolayer culture was permissive for MN specification and maturation, as 
demonstrated by the differentiation of plated progenitors into Isl1+ neurons 
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(Fig. 7D) and allowed analysis of cell bodies as well as identification of 
each cell’s neurites and axon. 
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Figure 7: Comparison between standard sphere-based and monolayer MN maturation 
protocol . Plating neurospheres at the end of the patterning phase (A) results in enhanced 
neurites outgrowth but limited migration of the cell bodies out of the sphere (B); the 
monolayer patterning/maturation protocol (C) allows to analyse the ultrastructure of motor 








3.2.4) Motor neurones maturation phase 
 
Patterned MN progenitors were plated on laminin/fibronectin-coated 
coverslips for a period of 3-6 weeks to differentiate into motor neurons. To 
allow the development of MNs, the culture medium was modified by 
withdrawing mitogens (FGF2 in particular) and supplementing it with 
supportive factors (in particular ascorbic acid and forskolin 187), NAC188, 
neurotrophic factors GDNF and BDNF. Initial stages of MN differentiation 
in culture were assessed by co-immunolabelling using antibodies against the 
transcription factor HB9 (Mnr2) that can be used as a post-mitotic MN 
marker189, and βIII tubulin (Fig. 8A) or co-labelling with Hb9 and SMI-32 
(an antibody directed against a non-phosphorylated epitope of neurofilament 
heavy chains used to identify mature motor neurons in the spinal cord190) 
later on during MN maturation (Fig. 8B). We then wanted to measure the 
efficiency of MN generation in order to exclude differences in the way the 
iPSC TDP M337V line and the control line responded to the protocol (Fig. 
8C): quantification of the percentage of cells that expressed HB9 over three 
independent differentiation experiments revealed that the M337V mutation 
does not determine a difference in the MN generation efficiency in vitro.  
At the end of the maturation phase expression of ChAT (choline 
acetyltransferase) a marker of cholinergic neurons, (Fig 8D), and synapsin I 
(Fig. 8E) was observed, indicating that both iPSC lines can generate 
cultures with a functional profile comparable with that of mature MNs in 
response to the same protocol.   
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Figure 8: Maturation of iPSC-derived Motor Neuron in vitro. (A) After 4-6 weeks in 
culture the patterned neural progenitors give rise to MNs positive for the specific Marker 
HB9. (B) As maturation proceeds MNs in culture acquire co-positivity for HB9 and the 
neurofilament marker SMI-32, used in vivo to identify  spinal MNs (C) Quantification of 
neurons positive for the MN specific marker HB9 after the maturation phase showed that 
the iPSC lines present a comparable MN induction efficiency [ M337V 79.45% ± 2.9 SEM; 
CTRL 65.69% ± 6.5 SEM; hESC (H9) 78.40% ± 2.] (D) Quantification of cells positive for 
Pax6 after the patterning phase showed that iPSC lines present a comparable induction 
efficiency, although there is a difference in induction efficiency when compared to he’s 
cells [M337V 50.72% ± 6.36 SEM; CTRL 53.17% ± 10.56 SEM]. (E) Representative 
image of immunostaining fro the MN functional marker Chat from M337V iPSC lines, 
showing that maturation of MNs in vitro proceeded towards the expression of more mature 






3.2.5) Electrophysiology and NMJ Assay 
 
In order to be able to properly model the pathology of ALS in vitro the MNs 
generated with this protocol need not only to stain for pMN specific markers 
but also to have measurable functional properties comparable to in vivo 
MNs. We decided to concentrate our functional characterization on their 
ability to form neuromuscular junctions (NMJs) in vitro and on their 
electrophysiological properties.  In order to asses whether the iPSC-derived 
MNs lines are capable of forming NMJ in vitro an assay established to test 
their ability to form putative neuromuscular contact points when cocultured 
with fused murine myofibers191. To perform this assay differentiating 
precursors (before the HB9 expression could be detected in the culture) 
were plated on a layer of already fused C2C12 cells, and kept in culture 
using the MN maturation medium for a period of 1-2 weeks. The readout of 
this experiment was detection of α1 nicotinic acetylcholine receptor 
clustering on the myofibers, a typical phenomenon observed in vivo at the 
contact points between axonal growth cones and skeletal myofibers, using 
Alexa-555 conjugated α-Bungarotoxin, which is a specific inhibitor of 
nicotinic acetylcholine receptors. Both iPSC lines were able to generate 
NMJ-like structures during this assay (Fig. 9A). Furthermore the 
electrophysiological activity of functional motor neurons was indicated by 
repetitive firing of action potentials and receptor responsiveness, (Fig. 9C 
performed by Clare Puddifoot in David Wyllie’s lab). Whole-cell patch-
clamp recordings of ChAT+ TDP-43 M337V iPSC-derived MNs 
demonstrated tetrodotoxin-sensitive, repetitive firing of action potentials 
(Fig. 9D). Furthermore, in 10-week old cultures, spontaneous excitatory 
post-synaptic currents were also observed (Fig. 9E). Currents evoked in 
response to bath application of NMDA, AMPA and GABA suggested the 
expression of the two glutamatergic excitatory neurotransmitter receptors as 
well as the GABAA receptor (Fig. 9F&G). These results are consistent with 
the functional maturation profile of hESC- and iPSC-derived neurons and 
indicate that M337V iPSC-derived MNs are electrophysiologically active. 
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Figure 9: Functional Characterisation of iPSC-derived Motor Neuron in vitro. (A) 
Representative image of cocultures of maturing MNs differentiating murine myofibers 
(derived from C2C12 line), stained for SMI-32 and the nicotinic receptor antagonist α-
Bungarotoxin. At the point of contact between MN neurites and fused myofibers it is 
possible to observe clustering of the nicotinic receptors. (B) Representative image of MN 
used for electrophysiological recordings, filled with LucY+ dye during the recordings and 
post-stained with the MN marker Chat (C-D) Current–clamp traces showed tetrodotoxin-
sensitive action potentials in response to injection of depolarizing current in M337V (C) 
and WT (D) MNs. (E) Sample traces of spontaneous miniature EPSCs recorded from an 
M337V culture. All miniature EPSC events were blocked with CNQX. (F) (E) Examples of 
whole-cell currents recorded from ChAT+ M337V iPSC-derived MNs in response to bath 
application of NMDA (100 µM) plus glycine (50 µM), AMPA (50 µM), or GABA (100 


















3.3) Generation of Astrocytes from iPSC Lines 
In order to study the effect of M337V mutation on the astrocytes and in turn 
the role of mutations on the disease phenotype, it was necessary to optimize 
a scalable protocol to efficiently specify glial phenotypes in our cultures. 
Moreover, in order to asses whether the presence of the mutation had any 
functional consequences on the astrocytes – and in turn on the disease 
phenotype - the glial populations used in this part of the study needed to 
present a functional profile comparable to in vivo astrocytes. 
As discussed previously (see Introduction, chapter on Gliogenesis) the 
mammalian central nervous system develops in a precisely organized 
temporal and spatial sequence of events. Early neural progenitors are 
incapable of generating astrocytes, and gliogenic potential is acquired over 
time during development at the expense of the ability to give rise to neurons.  
In recent years a number of different protocols have been developed to 
generate astrocytes from human pluripotent cells, trying to reproduce this 
neuronal- to glial- fate specification potency switch with different 
approaches124,192-194. These methodologies differ in degrees of efficiency, 
purity and functional characterization of the differentiated cells, but can be 
divided into two main categories based on the approach used to induce the 
gliogenic switch: 
• Some methodologies rely on the use of serum in the culture media to 
induce astroglial specification in the cultured progenitors. The use of 
animal serum (normally festal calf serum, FCS) and TGF-β has been 
historically very widely used in the differentiation and culture of 
astroglial cells in vitro 195, given their ability to induce the expression of 
astrocytes lineage specific markers in cultured neural progenitors196. This 
approach has been used in a recently published iPSC-disease modelling 
study for Huntington’s Disease (HD) 192. The downside of using serum-
containing media is the fact that serum itself is a non-chemically defined 
xenon component, and it presents issue in terms of possibilities of 
translation and reproducibility. 
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• Protocols that rely on prolonged time in culture to achieve the gliogenic 
potential switch in vitro. As described previously (see Introduction, 
chapter on Gliogenesis) a number of studies reported that cultured neural 
progenitors do not give rise to significant number of astrocytes within the 
first weeks of culture 120,121,193. It is known that prolonged propagation of 
neural progenitors in vitro leads to decreased neurogenic potential and 
progressively increasing ability to differentiate into GFAP+ cells, and 
several groups have taken advantage of this mechanism to generate 
astrocytes from human progenitors124,193,194. The use of this particular 
approach has a limitation in that the efficiency of astrocytes 
differentiation and the purity of the culture are dependent on time spent 
in culture. Emdad and colleagues reported that in a adherent NPCs 
system, by 5 weeks there is a significant number of cells expressing 
GFAP (≃70%), but at the same time a consistent number of cells still 
express neuronal markers (TuJ1, ≃40%)193. Similar results were obtained 
with suspension NPC cultures in the Zhang lab, but they were also able 
to obtain efficiently highly enriched astroglial cultures by prolonging the 
time in culture from 90 to 180 days124. 
To fulfil the aims of this project one needs to be able to obtain highly 
enriched astroglial populations from iPSC-derived NPCs in a chemically 
defined culture environment. However, at the same time we sought to 
decrease the time needed to specify the astroglial lineage in vitro. Moreover, 
we wanted to be able to produce astrocytes populations from the same 
progenitors used to generate our MN cultures, in order to be able to compare 
directly the different phenotypes in the two cell types without any bias due 
to differences in the neural conversion or patterning phase. 
To accomplish this, it was necessary to optimize a methodology that relies 
on the application of pro-gliogenic signals during propagation of suspended 
NPCs cultures to accelerate the neurogenic-gliogenic switch.  
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3.3.1) Optimization of gliogenic conversion phase 
 
The optimization of the NPC gliogenic conversion phase started by 
examining the prolonged propagation based protocols described in the 
previous section, focusing on which elements could be manipulated to 
accelerate and enhance the acquisition of glial fate specification potency. 
Generally proliferation and propagation of NPC in vitro is maintained by 
FGF2 and EGF, for both monolayer NPC cultures120-123 and neurospheres124-
126.  
As see in the introduction, responsiveness of neural precursors to either 
FGF2 or EGF is directly linked to their gliogenic potential. Moreover, 
several studies have convincingly demonstrated that activation of JAK-
STAT pathways by members of the IL-6 family plays a key role in 
determine the acquisition on neurogenic potential, indicating LIF as one of 
the most important pro-gliogenic factors in vivo as well as in cultured 
progenitors (see Introduction, chapter on Gliogenesis). 
Interestingly, it has been also demonstrated that it is the activity of EGFR 
that control the competence of NPC to interpret LIF signalling as an 
astroglial-fate inducer in vivo108. 
Against this background it was decided to modify the classical prolonged 
culture approach to specify glial identities in vitro by withdrawing FGF2 
and culturing the cells in the presence of EGF and LIF. The aim of this 
culture modification is to obtain a reliable –and short timed- “conversion 
phase” in which the population of cultured NPC homogeneously shifts its 
identity towards astroglial fate. 
To test the validity of this approach, it was first tested on hESC derived 
NPCs. 
H9-derived neurospheres where derived as in the previous sections of this 
chapter. After the neural conversion phase, samples were divided into two 
different populations: one propagated in FGF2 and EGF containing medium 
(EF), the other to be expanded in EGF and LIF containing medium (EL). 
The identity of the NPC in the neurospheres from the different groups was 
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assessed by plating them on Matrigel-coated plates and performing 
immunostaining for NESTIN and GFAP after 24 to 48 hours (according to 
attachment efficiency). After 2 weeks of treatment the EL population 
already presented a noticeable increase in the amount of GFAP+ cells and 
processes migrating out of the landed neurospheres (Fig 10 A&B). 
At this point, a quantification of the number of spheres presenting the 
majority of cells positive for GFAP or Nestin was performed within the 
samples, in order to assess whether the treatment was having a positive 
effect not only on a single-spheres basis but also on a population level, 
independent of inter-spheres variation in size and composition. The results 
show that the EL treatment does not affect the expression of NESTIN in the 
spheres population after either 1 week or 2 weeks of treatment (Fig. 10C). 
However, the EL treatment combined with propagation had a significant 
effect in increasing the amount of GFAP+ cells in the neurospheres over the 
course of 2 weeks, compared to equivalent cultured propagated in EF (Fig. 
10D). The EL treatment was then tested on unpatterned iPSC-derived 
neurospheres, showing that by 4 weeks in EL propagation all neurospheres 
in the culture (regardless of their size) homogeneously expressed GFAP. 
The EL conversion test was carried out on both M337V and CTRL iPSC 
derived neurospheres, obtaining similar results (Fig. 10 E&F). 
These results demonstrate that it is possible to increase the rate of gliogenic 
switch in cultured NPC by withdrawing FGF signalling and actively 
supporting the process with co-application EGF and LIF. Neurospheres that 
have been trough the EL-based conversion are then labelled as 
‘astrospheres.’ The next necessary step for this protocol was a suitable 
neurosphere dissociation system, to obtain single cells population to plate 
for following differentiation and analysis. The dissociation system was 
optimized starting from a commercially available kit designed to obtain 
viable populations of single cells from rodent brain explants, based on the 
combined action of Papain and DNAseI (Papain Dissociation Kit, see 
Materials & Methods).   
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After optimization of volumes and enzymes concentration, with this 
particular enzymatic approach it was possible to successfully dissociate the 
neurospheres after 4 weeks of propagation in EL conditions, obtaining a 
viable population of single cells to be plated in monolayer for differentiation 
and characterization. 
The differentiation potential of the EL neurospheres-derived monolayer 
cultures was then tested by withdrawal of mitogens and application of 
factors known to promote astroglial differentiation in NPCs, in particular: 
ciliary neurotrophic factor (CNTF), bone morphogenic protein-4 (BMP4), 
LIF, co-application of BMP4 and LIF and a basal medium containing only 
general cell supportive factors (as B27 supplement) 107,197,198 (Fig. 10G). 
Interestingly, all conditions tested gave rise to high percentages of GFAP+ 
cells within the differentiated population. The application of pro-gliogenic 
factors increases the efficiency of differentiation (61% ± 7.63 SEM in B27 
only, compared to the average effect of all the pro-gliogenic factors 
combined of 87.5% ± 6.17 SEM). Moreover, amongst the different factors 
tested, CNTF was the most effective at promoting the induction of GFAP+ 
cells after 14 days of differentiation compared to the others (CNTF 89.3% ± 
2.7 SEM, BMP4 85.3% ± 7.3 SEM, LIF 88.7% ± 5.02 SEM, BMP4/LIF 
86.6% ± 9.6 SEM). Also, CNTF treated cultures gave rise to 
homogeneously GFAP+ monolayer on Matrigel coated plates after 14 days, 
without displaying any overgrowth of the cultured cells or any attachment 
problems. Other pro-gliogenic factors tested (particularly BMP4/LIF 
combination) were less reliable in terms of maintaining a perfectly attached 
monolayer of cells at the end of the differentiation. 
 
Given that the aim of this part of the project is to model the glial counterpart 
of the already generated spinal MNs, the following part of the project was 
focused on the generation astrocytes populations using this methodology 
starting from neurospheres that have been through the MN patterning phase 




Figure 10: Optimization of Glial conversion phase in vitro. (A-B) he’s-derived 
neurospheres were cultured for 2 weeks with either EGF/LIF medium (EL) or EGF/FGF2 
medium (EF), and then plated on Matrigel to perform immunostaining for GFAP and 
Nestin. (C) Immunofluorescence profiling of the plated neurospheres populations based on 
the diffusion of Nestin positivity within the spheres  shows that at both time-point 
considered the EL and EF population are equivalent. [EF week1 97.55% ± 1.41 SEM; EF 
week2 93.23% ± 1.41 SEM; EL week1 89.90% ± 4.25 SEM; EL week2 96.15% ± 3.85 
SEM;] (D) Immunofluorescence profiling of the plated neurospheres populations based on 
the diffusion of GFAP positivity within the spheres  shows that at both time-point 
considered the EL population presented a significantly increased number of spheres 
homogeneously positive for GFAP+, compared to the EF population [EF week1 19.05% ± 
4.22 SEM; EF week2 36.95% ± 1.75 SEM; EL week1 74.13% ± 6.69 SEM; EL week2 
94.60% ± 3.19 SEM; *** for p<0,001, 2-way ANOVA]. (E-F) After 4 weeks of EL 
conversion treatment both Control (E) and M337V (F) iPSC-derived neurospheres 
presented diffuse and homogeneous positivity for GFAP within the spheres. (G) 
Quantification of GFAP+ cells after single cells dissociation and 14 days differentiation 
with different morphogens [CNTF 89.3% ± 2.7 SEM, BMP4 85.3% ± 7.3 SEM, LIF 88.7% 







3.3.2) Generation of astrocytes from patterned iPSC-derived NPCs 
 
Building on the results presented on the previous paragraph a time-efficient 
and scalable “conversion phase” based on the EL protocol was optimized to 
be used specifically on iPSC-derived MN patterned neurospheres (see MN 
protocol above) (Fig.11A). 
Neurospheres from two clones of the TDP-43 M337V iPSC line and two 
control (CTRL) iPSC lines were used for this phase of the project. 
Immediately after the end of their MN maturation phase, the neurospheres 
were mechanically chopped to expand their numbers and then switched to 
their EL-based conversion phase for a period of 4 to 6 weeks (depending on 
lines, spheres size, etc.). To maximize the number of astrospheres after the 
EL conversion, cultures were then switched back to EGF- and FGF2-
containing expansion medium. Once a suitable number of astrospheres from 
each iPSC line was obtained they were dissociated to generate monolayer 
cultures for differentiation and characterization.  
The resulting populations were positive for vimentin and nuclear factor 1A 
(NFIA), two markers of astrocyte progenitor cells (APCs) 199,200(Fig. 11B), 
and could be propagated as a monolayer culture with EGF and FGF2 for 
several passaged in culture.  
Consistent with what has been described for APCs in vivo and in vitro, less 
than 30% of cells in early passage APC cultures were positive for the 
astrocytic marker glial fibrillary acidic protein (GFAP) during proliferation. 
However, subsequent differentiation over 14 days in the presence of CNTF 
increased the proportion of GFAP positive cells to over 90% (Fig. 11C).   
Consistent with the results obtained from the optimization of the EL 
conversion phase, after two weeks of differentiation the vast majority of the 
cells co-expressed the astrocytic markers GFAP and S100β (Fig. 11D). 
Moreover, less than 2% of cells were positive for the neuronal marker βIII 
tubulin (Fig. 11D&E), confirming the efficiency of this protocol in 
generating highly enriched APC populations.  
The efficiency of astrocytes generation between M337V and CTRL iPSC 
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lines was compared, to determine whether the mutation has any effects on 
gliogenic fate specification. No difference was observed in the efficiency of 





Figure 11 Generation of astrocytes from iPSC lines. (A) iPSC-derived neurospheres 
were enriched for APCs by culturing in EGF/LIF-containing medium for 2–4 weeks and 
then expanded in EGF/FGF2-containing medium. To obtain monolayer cultures, enriched 
neurospheres were dissociated using papain and differentiated with CNTF. (B) APCs in 
monolayer cultures maintained a homogenous identity and morphology, featuring a high 
percentage of cells positive for the glial progenitors markers Vimentin [85.6% ± 2.9 SEM] 
and NFIA [79.8% ± 1.9 SEM] (scale bar = 100 µm). (C) APC present 24.6%± 2.61 SEM 
cells positive for GFAP during proliferation in EGF and FGF2; this percentage increases 
rapidly during the first 7 days of CNTF differentiation [84.9%± 0.53 SEM] reaching a peak 
after 14 days [90.8% ± 1.13 SEM] (D) Differentiation of monolayer APCs for 14 days in 
CNTF results in a population of astrocytes positive for GFAP [90.6% ± 0.7 SEM] and 
S100β [91.9% ± 1.9 SEM] (panels represent the same field, scale bar = 25 µm). A few 
neurons were found in the differentiated cultures [1.7% ±0.4 SEM]. (E) Representative 
field for a differentiated iPSC-derived astrocytes after 14 days of CNTF differentiation, 
labelled for GFAP (red) and TuJ1 (green), showing that the protocol gives rise to highly 
enriched astrocytes cultures. (F) M337V and control iPSC lines showed comparable 
numbers of GFAP-positive cells post-differentiation [M337V 92.25% ±0.97; WT 91.36% 





3.3.3) Functional Characterization of iPSC-derived Astrocytes 
 
In order to successfully model the astroglial component of TDP-43 fALS, it 
is of utmost importance that the cells generated to perform the modelling 
experiments not only present an expression profile compatible with bona 
fide astrocytes, but they also an appropriate functional profile. We decided 
to test our GFAP+/S100β+ cells for three distinct functional properties: 
• Ability to uptake L-Glutamate  
• Ability to promote Synapses formation 
• Ability to propagate Calcium Waves 
 
Glutamate Uptake Assay: 
The Glutamate uptake assay is based on measuring the concentration of a 
known solution of L-glutamate added to the culture medium in which the 
astrocytes are cultured, repeating the measurements at regular intervals (Fig. 
12A). The detection system used is an enzymatic reaction that couples the 
interaction between L-glutamic acid and NADP to produce NADPH, which 
is specifically recognized by a fluorescent NADPH sensor and recycled 
back to NADP. A red florescence signal proportional to the amount 
NADPH produced is generated during the reaction and measured with an 
automated plate reader. 
We first tested whether the differentiated astrocytes expressed members the 
metabotropic glutamate transporters (EAAT) family. Differentiated 
astrocytes derived from both genetic backgrounds were positive for the 
metabotropic glutamate transporter EAAT1 (Fig. 12B).  
Moreover, the astrocytes generated through the optimized protocol were 
able to uptake L-Glutamate from the medium in a time-dependent fashion 
(Fig. 12C). L-Glutamate uptake was blocked by the glutamate transporter 
inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC) or by removing 
sodium from the medium, consistent with the action of EAAT1.  
Interestingly no significant difference was detected in the l-glutamate 
clearance rate between M337V and CTRL iPSC-derived astrocytes (Fig. 12 
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D , CTRL 0.447µM/min ± 0.4 SEM; M337V 0.428µM/min ± 0.7 SEM)   or 
in the total amount of L-glutamate cleared from the medium after the 
experiment with or without EAAT-inhibition (Fig.12E).  
Taken together these results suggests that the astrocytes generated from 
either mutant or wild-type iPSC lines with this novel protocol display the 
ability to successfully clear excesses of excitatory amino acids from the 
culture. Implications are that the presence of the M337V mutation does not 
seem to have a detrimental effect on this particular astrocyte function, or at 




Figure 12: Functional characterization of iPSC-derived astrocytes I (Glutamate 
Uptake). (A) Schematic representation of L-glutamate uptake assay on iPSC-derived 
astrocytes. (B) Representative field of immunolabelling for glutamate transporter EAAT-1 
and GFAP in differentiated iPSC-derived astrocytes cultures (panels represent the same 
field, scale bar = 100 µm). (C) L-Glutamate uptake assay on iPSC-derived astrocytes: 
iPSC-derived astrocytes cleared L-glutamate in a time-dependent fashion (*** for p<0.01, 
1-way ANOVA). The uptake was abolished by either the absence of sodium or the presence 
of 2 mM PDC [both negative controls were run for 120 min]. (D) M337V iPSC-derived 
astrocytes did not show a significant difference in glutamate clearance rate, compared to 
control astrocytes (1-way ANOVA, p>0.05 for all times considered). (E) Glutamate uptake 
fold increase: M337V and CTRL astrocytes are able to clear over 75% of L-glutamate from 
the medium in 120 min, and uptake is inhibited equally by PDC. No significant difference 







To measure the ability of the iPSC-derived astrocytes to promote the 
formation of synapses, we devised a simple assay on coculturing 
differentiating neurons on a monolayer of astrocytes for three weeks and 
quantifying the number of vesicle positive for synaptic components in the 
neurites of the patterned neurons (Fig. 13A).  
An initial test, modelled on the data presented by Krencik and colleagues 124, 
was performed using neurons derived from  hESC-derived (H9) adherent 
neural progenitors patterned to obtain a ventral-spinal cord identity 120. At 
first the experiment was focused on confirming that iPSC-derived astrocytes 
behaved similarly to hESC-derived astrocytes in their ability to promote 
synaptic puncta formation, the differentiating neurons were plated either in 
isolation or in coculture with H9 astrocytes and control iPSC-derived 
astrocytes. After three weeks the cultures were analysed by immunostaining 
for the pre-synaptic vesicle marker Synapsin I [SYN] (Fig. 13B), and the 
average number of SYN+ puncta per neurite was quantified. Results show 
that both hESC- and iPSC-derived were equally able to upregulate by 2-fold 
the number of synaptic puncta compared to isolated neuronal cultures 
(Neurons 1.00 ± 0.08 SEM, Coculture hESC 2.48 ± 0.36 SEM, Coculture 
WT 2.15 ± 0.11)(Fig. 13C). Moreover, in a separate replicate of this 
experiment it was possible to prove that M337V iPSC-derived astrocytes 
performed similarly to control astrocytes in this particular assay (Fig. 13D).  
These initial experiments provide evidence that the ability to promote 
synapses formation does not seem to be impaired by the M337V mutation in 
astrocytes. To be able to draw a definitive conclusion on the synaptogenesis 
ability of the iPSC-derived astrocytes it was necessary to measure not only 
their ability to promote the formation of synaptic puncta [defined by 
immunostaining for a pre-synaptic markers, such as SYN] but also the 
ability to promote the formation of mature synapses, defined as co-
localisation of pre- and post-synaptic markers in the cocultured neurons. 
For this reason astrocytes from either control or mutant iPSC lines were 
cocultured with differentiating control iPSC-derived ventral-spinal cord 
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patterned neurons for a period of three weeks. Cultures where then stained 
with antibodies against the presynaptic protein Synaptophysin I (PSY) and 
the post-synaptic protein PSD-95, in order to quantify the number of mature 
synapses in coculture conditions compared with the same neurons plated in 
isolation (Fig. 13E). Our results showed that mutant astrocytes promoted 
the formation of PSY+/PSD-95+ mature synapses similarly to control 
astrocytes (Fig. 13F). Moreover, replicates of the synaptogenesis assay 
performed using equivalent neurons derived from the M337V iPSC lines 
revealed that mutant astrocytes perform similarly to control in promoting 
formation of synapses, regardless of the genotype of the cocultured neurons 
(Fig. 13G). 
In conclusion, the results presented in this section suggest that the presence 
of the M337V mutation in astrocytes does not affect negatively their ability 




Figure 13: Functional characterization of iPSC-derived astrocytes I (Synaptogenesis). 
(A) Schematic representation of Synaptogenesis assay on iPSC-derived astrocytes. (B) 
Representative field of immunolabelling for GFAP and Synapsin I in cocultures between 
iPSC-derived astrocytes cultures and differentiating patterned neurons (panel on top 
represent isolated neuronal, cultures, panel at the bottom represent neurons cocultured with 
astrocytes). (C) iPSC-derived astrocytes presented a behaviour comparable to hESC (H9) 
derived astrocytes, and significantly promoted formation of synaptic puncta [Neurons 1.00 
± 0.08 SEM, Coculture hESC 2.48 ± 0.36 SEM, Coculture WT 2.15 ± 0.11; *** p<0.01, 1-
way ANOVA]. The increase in synaptogenesis was measured by scoring the average 
number of SYN+ puncta in 30-µm neurite segments. (D) Both genotypes of iPSC-derived 
astrocytes were equally able to promote formation of synaptic puncta (quantification as 
described in C) [Coculture M337V 1.91 ± 0.08 SEM; Coculture WT 2.134 ± 0.12 SEM; 
Neurons 1.000 ± 0.09 SEM]. (E) Representative immunofluorescence panels from 
synaptogenesis assay; image shows representative neurite segment used for analysis, 
stained with TuJ1 (blue), PSY (red) and PSD-95 (green), scale bar=15 µm. (F) iPSC-
derived astrocytes significantly promoted formation of mature synapses when cocultured 
with differentiating neurons (*** p<0.01, 1-way ANOVA). The increase in synaptogenesis 
was measured by scoring the number of PSY+/PSD-95+ puncta in 30-µm neurite segments. 
[Coculture M337V 2.351 ±0.17 SEM; Coculture WT 2.595 ±0.12 SEM; Neurons 1.000 ± 
0.08 SEM]. No significant difference was observed in the behaviour of M337V or CTRL 
iPSC-derived astrocytes. (G) Synaptogenesis assay with M337V or WT patterned neurons 
revealed that astrocyte promotion of synapse formation was independent from the genotype 
of cocultured neurons, and that M337V astrocytes do not exert a negative effect on synaptic 
formation, even to mutant neurons. [M337V Neurons on WT Astro 0.897 ±0.04 SEM; 
M337V Neurons on M337V Astro 0.980 ±0.03 SEM; WT Neurons on WT Astro 
0.996±0.01 SEM; WT Neurons on M337V Astro 1.007 ±0.02 SEM]. 
Data presented in this figure represent the average of three independent experiments, each 
with two clones of M337V (M337V-1 & M337V-2) iPSC and two independent CTRL lines 







Calcium Waves Assay: 
 
Astrocytes are able to respond to a variety of stimuli (mechanical, electrical 
and chemical) by increasing the free intracellular concentration of 
calcium201,202. This rapid increase in calcium can rapidly spread from one 
stimulated cell to the neighbouring astrocytes, in a directional fashion, thus 
creating a “wave” of synchronous responses.  
It is possible to visualize the uncomplexed cytoplasmic calcium ions in 
astrocytes by using a fluorescent dye that reacts to their presence. The Fura 
class dyes in particular203, are a family of polyamino-carboxylic acids with 
can be used as ratiometric fluorescent dyes, thanks to their ability to bind 
uncomplexed calcium. Moreover, it is possible to convert Fura compounds 
to acetoxymethyl esters (AM) versions, to grant them the ability to pass the 
cell membrane, which greatly simplify the experimental design of this assay. 
For these experiments a commercially available membrane permeable dye, 
Fura-4AM was used. Astrocytes for these calcium waves tests were 
differentiated in CNTF for 14 days and then plated on matrigel-coated 6well 
plates. Before the experiment, astrocytes cultures were loaded with Fura-
4AM in a HBSS solution. 
The first test was focused on the ability of the iPSC-derived astrocytes to 
propagate intercellular calcium waves upon mechanical stimulation. To 
generate obtain a focal stimulation a glass micro-beads with a diameter of 
200µm was dropped on the astrocytes within the field of illumination (Fig. 
14A). Both genotypes astrocytes exhibited the potential to propagate 
calcium waves from the area of stimulation to neighbouring cells in a time 
dependent fashion (Fig. 14B, Supplementary Video 1).  
One of the mechanism that astrocytes use to propagate the intracellular 
increase of calcium is the release of ATP, which in turn activates IP3 
pathway in neighbouring cells allowing them to both release calcium from 
intracellular depots and release ATP in the extracellular space to support the 
spread of calcium response 204,205. For this reasons it was also necessary to 
test whether iPSC-derived astrocytes were able to respond predictably to 
ATP focal application. For this reason the experiment previously described 
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was repeated, substituting the mechanical stimulus with the local application 
of a concentrated ATP solution (Fig. 14C). Again, calcium waves were 
elicited upon ATP stimulation (Fig. 14D, Supplementary Video 2), in both 
M337V and Control iPSC-derived cultures. This ATP-evoked increase in 
cytosolic calcium was abolished by application of 2-APB, an inhibitor of 

























Figure 14: Functional characterization of iPSC-derived astrocytes I (Calcium Waves). 
(A) Schematic representation of Calcium Waves mechanical stimulation on iPSC-derived 
astrocytes. (B) Representative time-lapse images (extracted from Supplementary Video 1) 
showing that iPSC-derived astrocytes are able to generate intercellular calcium waves upon 
mechanical stimulation. Annotations represent time in seconds from stimulus application. 
(C) Schematic representation of Calcium Waves ATP stimulation on iPSC-derived 
astrocytes. (D) Local application of ATP was able to promote increase in intracellular 
calcium in iPSC-derived astrocytes, consistently whit what described for calcium waves in 
vivo. (E) ATP-evoked increase in calcium concentration was abolished in the presence of 










The first and most important step of an in vitro disease-modelling project is 
the ability to generate reliably the appropriate cellular types.  
The results presented in this chapter show by transporting developmental 
biology observation in vitro it has been possible to optimise two protocols 
that give rise reliably and efficiently to motor neurones and astrocytes 
starting from patient-derived iPSC lines. Moreover we have been able to 
functionally characterise the differentiated cells and prove that they present 
a functional profile comparable to what is described for their in vivo 
counterparts.  
Interestingly no significant difference was observed in the functional profile 
of either motor neurones or astrocytes derived from the M337V iPSC lines 
compared to Control iPSC, indicating that the presence of the mutation does 
not per se affect negatively the generation of functional neurones or glia. 
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Chapter 4: Phenotype Analysis in isolated cultures 
 
As described in the introduction chapters, TDP-43 is the major component 
of the ubiquitinated protein aggregates found in ALS and FTLD 
pathological human samples. During the development of these pathologies, 
TDP-43 presents specific changes in localisation and biochemical profile, 
that constitute the typical phenotype described for TDP-proteinopathies206. 
In particular TDP-43 localisation is drastically changed during pathology. 
While normally this protein resides mainly in the nucleus, shuttling 
transitorily to the cytoplasm to mediate aspects of RNA metabolism15,28, in 
pathological samples TDP-43 is accumulated in the cytoplasm, sometimes 
with complete depletion of the nuclear TDP pool in affected neurons. Also, 
TDP-43 aggregates are observable during the pathology in the cytoplasm. 
From a biochemical point of view, TDP-43 during the disease frequently 
accumulates in the detergent resistant fraction, presenting also cleavage into 
35 and 25 kDa fragments and phosphorylation61,206. These changes in TDP-
43 biochemistry and localisation constitute a “pathological signature” of 
TDP proteinopathies. 
 After the protocols to generate functional MNs and astrocytes from iPSC 
lines, presented in Chapter3, were tested and optimised, we proceeded to 
analyse the localisation and biochemical signature of TDP-43 in the 
differentiated cells in isolation, in order to determine whether the iPSC-
based model reproduces the described disease phenotype. 
 
4.1) Expression and Biochemistry of TDP-43 in iPSC-derived Motor 
Neurones 
Before analysing the biochemical profile of TDP-43 in differentiated MN 
cultures, it was necessary to determine whether the expression levels of its 
mRNA, TARDBP gene, were significantly modified in the M337V genetic 
background. 
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For this reason the gene expression levels of TDP-43 in the MN cultures 
was analysed. Quantitative RT-PCR on RNA extracted from mature cultures 
revealed that expression levels of TARDBP, or HDAC6 (a transcriptional 
target of TDP-43 itself 85) do not vary significantly between the M337V and 
Control iPSC-derived MNs (Fig. 15 A-B, performed by Dr. B. Bilican). 
Furthermore, even though there was some clonal variation between M337V-
1 and M337V-2, there was not a detectable significant difference on average 
in the expression levels of MNs specific transcripts such as HB9 and ChAT 
(Fig. 15 C-D, performed by Dr. B. Bilican).  
Having established that TDP-43 expression does not significantly vary 
between M337V and Control MNs, we next analysed the biochemical 
profile of this protein in differentiated cultures. Immunoblot analysis on 
samples extracted from ChAT+ MN cultures revealed that M337V iPSC 
derived cultures appear to present an accumulation of TDP-43 full length in 
both the soluble (Fig. 15 E, performed by Dr. B. Bilican) and detergent 
resistant (Fig. 15 F, performed by Dr. B. Bilican) fractions. We then 
quantified the difference between the two clones of the mutant line and 
Control-1 by the Semi-quantitative densitometric analysis on the 
immunoblots bands, revealing a three to four-fold increase in soluble TDP-
43 and a 1.5 fold increase in detergent-resistant TDP-43 (Fig. 15 G-H, 
performed by Dr. B. Bilican). 
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Figure 15: Expression and Biochemistry of TDP-43 in iPSC-derived Motor Neurones. 
(A-D) qRT-PCR analysis of TARDBP, histone deacetylase 6 (HDAC6), HB9, and ChAT 
expression in MN-containing neuronal cultures (n = 3). (E-F) Western blot analysis of 
soluble (E) and detergent resistant (F) TDP-43 in M337V-1, M337V-2, and Cont-2 MN-
containing cultures. Three independent extractions are shown for each cell line. β3-Tubulin 
was the loading control for soluble fractions (E), and Ponceau S reversible membrane 
staining was the loading control for detergent-resistant fractions (F). (G) Semi-quantitative 
analyses of band signal intensity for soluble TDP-43 Immunoblot analysis. Levels of 
soluble TDP-43 normalized to β3-tubulin, Cont-2 set to 1: M337V-1 = 3.67 ± 0.58; 
M337V-2 = 4.54 ± 0.01; Cont-2 = 1.0 ± 0.24. M337V-1 vs. M337V-2, n.s.; M337V-1 vs. 
Cont-2, P = 0.013; M337V-2 vs. Cont-2, P < 0.001, n = 3 in- dependent extractions. (H) 
Semi-quantitative analyses of band signal intensity for detergent resistant TDP-43 
immunoblot analysis. Levels of detergent-resistant TDP-43 normalized to Ponceau S, Cont-
2 set to 1: M337V-1 = 1.52 ± 0.08; M337V-2= 1.67 ± 0.10; Cont-2 = 1.0 ± 0.16. M337V-1 
vs. M337V-2, not significant; M337V-1 vs. Cont- 2, P = 0.04; M337V-2 vs. Cont-2, P < 







4.2) Localisation of TDP-43 in iPSC-derived Motor Neurones 
In order to analyse the behaviour and localisation of TDP-43 in 
differentiated iPSC-derived MNs several different commercially available 
antibodies directed against different epitopes of TDP-43 were screened. As 
described before, the normal TDP-43 localisation in neurons is 
predominantly nuclear, with some discrete small foci of accumulation in the 
cytoplasm and -especially- in neurites, in response to neuronal activity40. A 
panel of 4 antibodies with different specificity for different forms of TDP-
43 (nominally the full length 43 kDa form, the 25 and 35 kDa degradation 
cleavage products) was optimised, based on commercially available 
antibodies used in previous publications. The immunostainings were 
performed on fixed MN cultures at the end of their maturation phase, after 
the expression of SMI-32 and Chat. All antibodies tested were able to detect 
TDP-43 in fixed cultures, although with deferent degree of signal strength 
and specificity (Fig. 16 A-D). After these batch testing phase, a Rabbit 
polyclonal antibody raised against the full-length protein was selected, due 
to its intense signal in the immunofluorescence set up used, specificity of 
the recognition to the antigen and practicality of use in double 
immunostaining set ups with the antibodies tested during the optimization of 
the protocols. Using this antibody we did not observe any abnormality in the 
localisation of TDP-43 in MNs generated from the M337V iPSC line (Fig. 
16E) at the end of the maturation protocol compared with Control iPSC-
derived MNs. 
Interestingly, we observed that strongly SMI-32 positive cells in the MN 
culture seemed to have an increased amount of nuclear TDP-43 compared to 
SMI-32 negative neurons (Fig. 16F). Densitometric quantification of TDP-
43 immunostaining revealed that SMI-32+ presents an average 20% increase 
in the amount of nuclear TDP-43 (SMI-32+ 1.236 ± 0.07, SMI-32- 1.032 ± 
0.05, p<0,05) (Fig. 16G). Despite this difference, we were unable to detect 
any increase in the nuclear TDP-43 densitometry comparing M337V and 
Control SMI-32+ cells (Fig. 16H). 
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Figure 16: Localisation of TDP-43 in iPSC-derived Motor Neurones. (A-D) 
Optimisation of four different TDP-43 antibodies in mature Control iPSC-derived MNs 
(identified by Chat and SMI32 co-positivity): A’ and B‘) two  polyclonal antibodies target 
to the n-terminal portion of the protein; C’) a polyclonal antibody targeted to the c-terminal 
portion of the protein; D’) a monoclonal antibody generated by immunization against the 
full length recombinant TDP-43. All antibodies show a predominantly nuclear localization 
in neurons, with absence of discrete aggregates of large size. (E) TDP-43 staining on M37V 
iPSC-derived MNs does not reveal substantial mislocalisation or aggregation (F) 
Immunofluorescence analysis of nuclear TDP-43 in SMI-32+ and SM-I32− cells. (G) 
Densitometric quantification of nuclear TDP-43 in SMI-32+ and SMI-32- neurons 
[p<0,001 n=30 cells per group over 3 independent fields]. (H) Densitometric analysis of 
nuclear TDP-43 in SMI-32+ and SMI-32− cells. No significant difference between M337V 









4.3) Expression and Biochemistry of TDP-43 in iPSC-Astrocytes 
As the M337V iPSC-derived MNs demonstrated a tendency to accumulate 
TDP-43 in both soluble and detergent resistant fractions without a 
corresponding increase in TARDBP mRNA expression, it was of particular 
interest to clarify whether the astrocytes displayed the same biochemical 
phenotype. 
Using quantitative RT-PCR analysis we determined that mutation-carrying 
astrocytes do not present an increased expression of TARDBP mRNA, nor 
they display any significant difference in the expression of TDP-43 
downstream target HDAC6 (Fig. 17A, top panels performed by Dr. B. 
Bilican). Moreover, as for the MNs expression analysis we also wanted to 
check that generally the expression profile was not altered by the M337V 
mutation. For this reason we performed quantitative RT-PCR analysis on 
two astrocyte specific transcripts, S100β and GFAP, but we could not detect 
any difference in their expression levels comparing M337V and Control 
iPSC-derived astrocytes (Fig. 17A, bottom panels performed by Dr. B. 
Bilican). 
We then proceeded to analyse the TDP-43 protein levels in iPSC-derived 
astrocytes; immunoblot analysis revealed that mutation carrying astroglial 
cultures present a increase in soluble TDP-43 levels, without the 
corresponding increase in detergent resistant levels observed in the MNs 
(Fig. 17B performed by Dr. B. Bilican). This increase in soluble TDP-43 
was quantified to be 2-fold compared to control astrocytes, with semi-
quantitative densitometric analysis of three independent protein extractions 




Figure 17: Expression and Biochemistry of TDP-43 in iPSC-Astrocytes. (A) qRT-PCR 
expression analysis of iPSC-derived astrocytes shows no significant difference [p>0.05 for 
all pairs, unpaired t-test] in mRNA levels of TARDBP, HDAC6, S100β or GFAP; results 
are presented as expression fold increase normalized to M337V-1. (B) Representative 
western blot from soluble and detergent resistant TDP-43 analysis of M337V-1, M337V-2, 
and CTRL-1 astrocytes. (C) Semiquantitative analyses of soluble TDP-43 band signal 
intensity was accomplished using ImageJ on three independent extractions [M337V-1 
1.993 ±0.38 SEM, M337V-2 1.917± 0.37 SEM, CTRL-1 1.107 ±0.26 SEM, p=0.003, 







4.4) Localisation of TDP-43 in iPSC-Astrocytes 
The next step in the project was to study the localisation of TDP-43 in 
iPSC-derived astrocytes. For this purpose, sub-confluent astrocytes 
monolayer cultures differentiated from APCs in CNTF for 14 days were 
immuno-labelled with antibodies against GFAP and TDP-43 and then 
imaged with a confocal microscope. High-resolution images were then used 
to perform densitometric analysis with ImageJ. In order to be able to 
determine any changes in TDP-43 localisation, single astrocytes within the 
fields of view were manually analysed by first determining and delimitating 
the nuclear and cytoplasmic regions of each cell using DAPI and FAP 
respectively, and then measuring the density of TDP-43 fluorescent signal 
from these regions (Fig. 18A). The densitometric analysis was performed on 
25 astrocytes per field, using a total of 12 different fields for every iPSC 
lines, over four different biological replicates. This quantification revealed 
that astrocytes derived from the mutant iPSC line present a 2-fold increase 
in the amount of cytoplasmic TDP-43 compared to control astrocytes (Fig. 
18 B-D). Interestingly nuclear TDP-43 levels appear to remain unchanged 




Figure 18: Localisation of TDP-43 in iPSC-Astrocytes. (A) Example of region-based 
densitometric TDP-43 analysis in astrocytes. Nuclear region was manually drawn based on 
DAPI, cytoplasmic region was manually drawn based on GFAP. (B-C) Representative 
confocal images of TDP-43/GFAP immunolabelling used for densitometric analysis. (D) 
Densitometric quantification of TDP-43 localization by confocal microscopy showing a 
significant increase of cytoplasmic TDP-43 in M337V astrocytes. [M337V nuclear 1.088 ± 
0.091 SEM, cytoplasmic 1.806 ± 0.127 SEM; CTRL nuclear 1.006 ± 0.049 SEM, 
cytoplasmic 1.009 ± 0.050 SEM. Results are presented as densitometric signal fold increase 






4.5) Ectopic TDP-43 expression in iPSC-Astrocytes 
The results presented in the previous sections of this chapter indicate that 
the M337V TDP-43 mutation in astrocytes determines increased levels of 
soluble full length TDP-43, and that this accumulation of protein is mainly 
localised in the cytoplasm. These findings represent a strong indication of a 
TDP-43 phenotype in our vitro system, in particular it must be highlighted 
that this is the first comprehensive in vitro fALS study to look at TDP-43 in 
isolated patient-derived astrocytes. For this reason it is of the utmost 
importance to determine that the cytoplasmic accumulation of TDP-43 is 
really due to the presence of the M337V mutation, rather than ascribable to 
an in vitro artefact. Also, the experiments presented so far do clearly 
demonstrate that the accumulation observed is a direct effect of the presence 
of the mutation on TDP-43, or part of a secondary mechanism due to 
differences in the genetic background. 
To clarify this point we choose to analyse exogenous TDP-43 expressed in 
Control-iPSC derived astrocytes, in order to eliminate any differences due 
to the genetic background of the iPSC lines and focus on the effect of the 
M337V mutation on TDP-43 localisation.  
Control iPSC-derived astrocytes were first co-transfected with a plasmid 
encoding either WT or M337V TDP-43 fused to mApple, under the control 
of a constitutive promoter, and a plasmid constitutively expressing eGFP 
(Fig. 19A). Transient transfection leads to different expression levels within 
the population, and in the case of TDP-43 exogenous expression this is 
accompanied by a diverse range of localisation within the same transfected 
populations. In particular, some astrocytes would present a mostly nuclear 
localisation of the ectopic TDP-43 (Fig. 19A, top panel), while other 
equally fluorescent cells would display high levels of cytoplasmic ectopic 
TDP-43 (Fig. 19A, bottom panel). The transfected populations were then 
analysed to determine the relative expression levels of exogenous TDP-43, 
in order to subdivide the population in groups. The intensity of the 
constitutively expressed eGFP was used as a normaliser of the densitometric 
measurement on the exogenous TDP-43 signal. The normalised exogenous 
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TDP-43 signal quantification was then used to arbitrarily divide the 
transfected population into 5 different expression groups (A to F) from low 
to high relative expression of exogenous TDP-43 (Fig. 19B). 
Within the different expression groups, the localization of exogenous TDP-
43 was then analysed. Astrocytes with prominent nuclear localization of 
transfected WT or M337V TDP43-mApple were grouped and compared to 
astrocytes with nuclear-and-cytoplasmic or exclusively cytoplasmic 
fluorescence. Interestingly, these results showed a strong influence of 
expression levels on TDP-43 localization. Elevated expression levels were 
directly related to cytoplasmic mislocalisation of TDP-43 (Fig 19C), as it 
has been previously reported70. However, while WT TDP-43 displayed a 
dynamic range of localization correlating with expression levels, M337V 
TDP-43 showed an inherent bias towards cytoplasmic localization (Fig 
19D).  Notably, this effect was particularly evident when the low expression 
levels groups from the WT and M337Vtransfected population were 
compared directly (Fig. 19E). 
These results confirm that the observed changes in localization of TDP-43 
in iPSC-derived astrocytes are in fact due to the presence of the M337V 
mutation on TARDBP, which causes localisation bias towards the 





Figure 19: Ectopic TDP-43 expression in iPSC-Astrocytes. (A) Representative images of 
cytoplasmic and nuclear-only TDP43:mApple-transfected astrocytes showing the criteria 
for inclusion of astrocytes in either cytoplasmic [top panels] or nuclear [bottom panels]. (B) 
Stratification of TDP-43:mApple-expressing astrocytes into six groups based on their 
relative expression levels; groups A–F contain astrocytes with progressively increasing 
exogenous TDP-43 expression levels. (C) Analysis of exogenous WT TDP-43 localization 
on stratified relative expression groups. The localization of WT TDP-43 was significantly 
related to relative expression levels (Nuclear vs Cytoplasmic TDP-43: A=n.s., B=n.s., 
C=n.s., D=p<0.05, E=p<0.01, F=p<0.001). Data pooled from three independent 
experiments (D) Analysis of exogenous M337 TDP-43 localization on stratified relative 
expression groups. M337V TDP-43 remained localized mainly to the cytoplasm regardless 
of expression level (nuclear vs cytoplasmic TDP-43: A–F=p<0.001). Data pooled from 
three independent experiments. (E) Comparison of ectopic TDP-43 localization in 
astrocytes from the lowest relative expression level groups [group A in panels d and e]. At 
low expression levels 73.6%± 3.31 of astrocytes from the TDP43M337V:mApple group 
present mainly or exclusively cytoplasmic localization of the protein, compared to 







TDP-43 profiling in iPSC-derived differentiated cells revealed that this 
platform reproduces key feature of the pathological signature described of 
TDP proteinopathies. In particular we were able to detect accumulation of 
both soluble and detergent resistant TDP-43 in mature MNs-containing 
cultures, despite the expression levels of TARDBP appear to be unchanged 
in the M337V iPSC-derived cultures compared to controls. Interestingly, 
also in astrocytes TDP-43 protein levels were increased in the mutation 
carrying cultures without any significant changes to the mRNA expression 
levels. These results suggest that the differences in protein levels observed 
in both neurons and glia arise from a post-translational mechanism, rather 
than increased abundance of the transcript. Moreover, the mutant protein 
does not seem to interfere with the auto-regulatory feedback mechanism 
proposed for TDP-43 control of mRNA levels 29,42. Of relevance is that 
possible to detect a difference in the way MNs and astrocytes process the 
mutant protein: while in MN cultures both soluble and detergent resistant 
are significantly increased, in astrocytes the detergent resistant levels are 
unchanged. This could underline a fundamental difference in the way these 
cell types manage the accumulation of M337V TDP-43. 
In terms of TDP-43 localisation, although biochemically M337V MN 
cultures present a significant difference compared to controls, we did not 
observed overt mislocalisation of the protein in iPSC-derived MNs. This 
could be due to the age of the MN cultures, as most of the evidences for 
accumulation and aggregation come from post-mortem sample analysis.  
Interestingly however, it was possible to determine with the experiments 
reported in this section, that the M337V mutation causes cytoplasmic 
accumulation of the protein in astrocytes. Moreover, this cytoplasmic 
accumulation is a direct consequence of a localisation bias caused by the 




Chapter 5: Survival Analysis in isolated cultures 
5.1) Introduction to in vitro Survival Analysis in iPSC-derived cultures 
 
As discussed in the previous chapters, part of the phenotype described for 
TDP proteinopathies, and ALS in particular, is the mislocalisation and 
aggregation of TDP-43 in the cytoplasm of MNs and glial cells.  
Although the exact molecular mechanism responsible for this pathology is 
still not clear, what causes the disease’s symptoms is ultimately the specific 
death of MNs. Also, it has been shown in several in vitro and in vivo 
systems that expression of mutant TDP-43 is in itself toxic to 
neurons67,70,207. 
For this reason, one of the most important aspects to verify in establishing a 
patient iPSC-derived model for ALS is whether there is a survival 
difference between mutation carrying and control cells.  
However, in trying to determine a survival difference between iPSC-derived 
cultures one encounters several specific problems, mainly related to the 
intrinsic heterogeneity of the culture itself. In particular, one of the major 
problems is that the efficiency of differentiation into the particular cell type 
of interest (in this case MNs) is generally less than 100% (see Results 
Chapter 1), determining that the cultures analysed are always a mixture of 
the cell type of interests with other neuronal, glial or other unrelated cell 
types. For this reason, it is generally more difficult to rely on unbiased 
population based assays (like general LHD-release based population 
assays), and one need to specifically identify the cell type of interest, for 
example by staining several replicates for MN-specific protein HB9 and 
determining the exact percentage of MNs in the culture over time. 
This methodology however can present an additional challenge, determined 
by the fact that stem cells and progenitor differentiation in vitro is not 
perfectly synchronized, especially when considering relatively short periods 
of time (i.e. weeks)208. In the specific example of staining several replicates 
of MN cultures at time 0 and two weeks later to determine HB9+ cells 
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survival over time, in an unsynchronized culture MN-progenitors would be 
differentiating at different speed, determining “newly-born” HB9+ cells in 
between the beginning of the experiment and the final time-point. Therefore 
part of (if not all) the percentage of MNs lost to problems in cell survival 
during the experiment would be masked by the generation of new neurons 
from the asynchronous progenitors. This in turns means that only a 
relatively large toxic effect can be observed with such experiments. To 
perform survival analysis in our iPSC-derived cultures we collaborated with 
the Finkbeiner lab, at the Gladstone Institute in San Francisco: between 
2005 and 2009 they established a technique to perform high-content 
screening based on a automated microscope system209,210. This technique 
was initially optimized on primary neuronal cultures and successfully used 
to create in vitro models of protein toxicity and aggregation for ALS and 
Huntington’s Disease70,211,212.  
This methodology is based on transfecting the population of interest with a 
cellular fluorescent reporter, identifying the positive cells after transfection 
and then following them over time using an automated microscope (Fig. 
20A). Using this method it is possible to follow the survival of the single 
cells within the population rather than the population as a whole, using the 
same survival analysis equations used in drug screenings213,214 and register 
also very small effects on survival and relative risk of cell death. To perform 
this particular survival analysis on our iPSC-derived cultures it was 
necessary to first optimise a protocol to insert fluorescent reporters in the 
iPSC-derived cultures. For the MN survival analysis we used a HB9-eGFP 
reporter originally generated in the Goldman lab175. An electroporation 
based transfection was optimised in order to introduce the reporter into 
maturing iPSC-derived MNs and then confirmed the identity of the eGFP 
positive cells with immunostaining for MN-specific markers (Fig. 20B).   
While the MNs cultures are heterogeneous (see Results Chapter 2.1.2) the 
differentiated astrocytes cultures derived from iPSC lines with the protocol 
described above (see Results Chapter 2.1.3) are highly enriched in 
GFAP+/S100β+ cells (>90%). Therefore it was possible to perform the 
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experiment by using a plasmid encoding for a fluorescent protein driven by 
a constitutive promoter (Fig. 20C); as an additional control for the astrocyte 
survival analysis cultures were analysed by immunostaining at the end of 
the experiment to confirm that the majority of cells expressed the astrocyte 




Figure 20: Survival Analysis on iPSC-derived cultures using automated longitudinal 
microscopy. (A) Schematic representation of in vitro High Content Screening experiment 
using automated longitudinal microscopy. (B) Representative images of  co-
immunolabelling of HB9-eGFP+ transfected cells and motor neuronal markers, to confirm 
the identity of the transfected cells. (C) Representative images of pGW1-mApple 
transfected astrocytes cultures (on the right) at the beginning of a survival experiment, and 





5.2) Survival Analysis in iPSC-derived MNs 
To study the survival analysis in M337V iPSC-derived MNs neurospheres 
based cultures (see Results Chapter 1.2.3) four weeks into their maturation 
phase where dissociated to single cells suspension and then transfected with 
the HB9-eGFP reporter plasmid using a NEON electroporation system, and 
then plated on a 96-well plate. The automated imaging started 24 hours after 
transfection and proceeded for 10 days at regular daily intervals. Images 
were then assembled into time-lapses and analysed to determine survival for 
every transfected neuron. In particular, the time of cell death for all 
transfected cells within the fields of analysis was determined applying the 
criteria previously described by Arrasate and colleagues209 (Fig. 21A), and 
the data was then used to determine the risk of death for the MNs 
populations derived from the different iPSC lines and plot cumulative risk 
curves (Fig. 21B).  Interestingly, results showed that under basal conditions, 
the cumulative risk curves for the two clones of the M337V line were 
clustering together at significantly higher cumulative risk levels compared 
to both control iPSC lines. Moreover, MNs derived from both clones of the 
mutant iPSC lines presented over two fold-increase in cumulative Hazard 
Ratio (cHR) compared to MNs derived from CTRL-1 iPSC line (Fig. 21C). 
Given that the two lines for each genotype were presenting very similar 
behaviour in this highly sensitive analysis of cumulative risk of death and 
cHR, it was possible to cluster the different genotype together, averaging 
the contribution to survival of the different iPSC lines (Fig. 21D). The 
analysis of cHR by genotype revealed that the presence of the M337V 
mutation in mature MNs confer a 2.65 fold increase in the relative risk of 
death (cHR M337V 2.6516, cHR CTRL 1; p=2x10-16) compared to Control 
MNs under basal conditions. 
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Figure 21: Survival Analysis of iPSC-derived MNs. (A) Representative images from a 
typical survival analysis of HB9:EGFP-expressing MNs; cell fate was followed over 10 
days, and cell death was determined by loss of fluorescence or dissolution of the cell itself 
(note as one of the astrocytes [red arrow] survives for the whole experiment, while in the 
same field, another cell [blue arrow] displays morphologic changes and disappears). (B) 
Real-time survival analysis of M337V-1, M337V-2, CTRL-1 and CTRL-2 iPSC-derived 
MNs under basal conditions. (C) Comparison between cumulative Hazard ratios between 
M337V-1, M337V-2 and CTRL-2 iPSC-derived MNs compared to CTRL-1 derived MNs. 
[CTRL-1 as HR=1; CTRL-2 HR=0,7262; M337V-1 HR=2,1942; M337V-2 HR=2,3231, 
for M337V-1 and M337V-2 vs. CTRL-1 p<0,001]. (D) Real-time survival analysis of MN 
cultures clustered by genotype, p<0.001. 




5.3) Survival Analysis in iPSC-derived Astrocytes 
After having established that the M337V mutation confers an intrinsic 
increased risk of death to MNs, we wanted to verify whether the same toxic 
effect could be found in astrocytes carrying the mutation. For this purpose 
differentiated iPSC-derived astroglial cultures were transfected using a 
plasmid expressing the fluorescent protein mApple under the control of a 
constitutive viral promoter (CMV); these cultures were then imaged every 
24 hours for 10 days with automated longitudinal microscopy.  As for the 
MN survival analysis the time of cell death was determined for all 
transfected cells within the fields of analysis (Fig. 22A) and then used to 
plot cumulative risk curves for astrocytes derived from the different iPSC 
lines (Fig. 22B).  Similarly to what observed for the survival analysis in MN 
cultures, the cumulative risk of astrocytes derived from the two clones of 
the M337V line clustered together at significantly higher cumulative risk 
levels compared to both control iPSC lines. Cumulative Hazard Ratio (cHR) 
analysis between astrocytes derived from the different iPSC lines revealed 
that both M337V iPSC clones present over two fold-increased risk of death 
compared with astrocytes derived from CTRL-1 iPSCs (Fig. 21C). Finally, 
the analysis of cumulative hazard in astrocytes cultures clustered by 
genotype revealed a 2.5-fold greater risk of death associated with the TDP-
43 M337V mutation in comparison with controls under basal conditions 
(cHR M337V 2.6516, cHR CTRL 1; p=2x10-16) (Fig. 21D), similarly to 




Figure 22: Survival Analysis of iPSC-derived Astrocytes. (A) Representative images 
from a typical survival analysis of EGFP-expressing astrocytes; cell fate was followed over 
10 days, and cell death was determined by loss of fluorescence or dissolution of the cell 
itself (note as one of the astrocytes [red arrow] survives for the whole experiment, while in 
the same field, another cell [blue arrow] displays morphologic changes at 97 h and 
disappears by 140 h). (B) Real-time survival analysis of M337V-1, M337V-2, CTRL-1 and 
CTRL-2 iPSC-derived astrocytes cultures under basal conditions. (C) Comparison between 
cumulative Hazard ratios between M337V-1, M337V-2 and CTRL-2 iPSC-derived 
Astrocytes compared to CTRL-1 derived MNs. [CTRL-1 as HR=1; CTRL-2 HR=0,8503; 
M337V-1 HR=2,0733; M337V-2 HR=2,3796, for M337V-1 and M337V-2 vs. CTRL-1 
p<0,001]. (D) Real-time survival analysis of MN cultures clustered by genotype, p<0.001. 





5.4) Dissection of M337V toxicity mechanism by drug screening 
 
Having established that the presence of the M337V mutation confers an 
intrinsic toxicity under basal conditions in both MNs and astrocytes 
demonstrates that the iPSC-based platform to model fALS does not only 
recapitulate the molecular phenotypes (as accumulation of TDP-43 and 
cytoplasmic mislocalisation) as demonstrated in Chapter 2, but it also 
present a measurable survival difference between mutant carrying and 
control cells. This is a particularly interesting aspect of the in vitro 
phenotype because having a measurable difference in survival allows in 
principle to use the automated microscopy set up to test potentially 
modifying disease compounds. This approach can therefore be used both as 
a proof of principle for drug testing strategies but also to try to dissect the 
toxicity mechanism by using already established compounds that affects 
specific cellular pathways. In particular we used specific compounds to 
elucidate whether the toxicity observed in M337V carrying cells could be 
recued (and if so to what degree) by acting specifically on caspase-mediated 
apoptosis and autophagy. 
 
5.4.1) Apoptosis and M337V Toxicity 
To determine if the observed cell death is due to increased apoptosis, we 
evaluated the effect of an already established pan-caspase inhibitor, QVD-
oph215, on the risk of death of M337V astrocytes, as measured by automated 
longitudinal microscopy. Treatment with the pan-caspase inhibitor 
successfully decreased the overall cumulative hazard of both M337V and 
control astroglial cultures (Fig. 23A). In particular, QVD-treated control 
astrocytes showed a cHR of 0.33 (p = 5.07 x 10-11, log-rank test) compared 
to the vehicle-treated group. On the M337V background, QVD-treatment 
similarly produced a significantly decrease in cHR, which passed from 2.66 
in the vehicle-treated group (p = 8.13*10-12, log-rank test, compared with 
vehicle-treated CTRL astrocytes) to 0.72 in the QVD-treated group (p = 
0.0145, log-rank test, compared with vehicle-treated CTRL astrocytes. 
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Therefore the presence of a non-reversible caspase inhibitor decreased the 
risk of death over threefold in both genotypes. However, when the M337V 
and WT QVD-treated groups were compared directly, the M337V 
astrocytes still displayed a significantly greater hazard ratio than WT 
astrocytes (2.19, p = 2.32 x 10-7, log-rank test)(Fig. 23B). The comparison 
of hazard ratios between M337V and control astrocytes with QVD or 
vehicle-only treatment revealed that caspase inhibition did decrease the 
overall toxicity observed in astrocytes cultures but in fact failed to 
significantly lower the observed mutant TDP43-specific toxicity (Fig. 23C).   
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Figure 23: Caspase-independent toxicity of M337V TDP-43 in Astrocytes. (A) Real-
time survival analysis of M337V and control iPSC-derived astrocytes in the presence of 10 
µM QVD-oph. The inhibition of caspase activation reduces the risk of death in M337V and 
control astrocytes (with CTRL+vehicle as a reference, HR for M337V+vehicle 2.61, 
p=8.13x10-12; HR for M337V+QVD 0.72, p=0.0145; HR for CTRL+QVD 0.33, 
p=5.07x10-11). (B) Direct comparison of QVD-treated M337V and Control iPSC-derived 
astrocytes (C) Comparison between cumulative hazard ratio of M337V astrocytes in QVD-
treated and vehicle–treated groups. [Vehicle treated M337V vs CTRL astrocytes 
cHR=2.60; QVD-treated M337V vs. CTRL astrocytes cHR=2.20. The error bars represent 
95% confidence intervals]. 
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5.4.2) Autophagy and M337V Toxicity 
Autophagy is one of the major cellular recycling pathways. Used to remove 
long-lived proteins, aggregates and organelles, it involves sequestration of 
material inside double-membrane vesicles called autophagosomes, which 
fuse to lysosomes in order to degrade vesicle contents 216. Autophagic 
recycling has been recently shown to be very important for neuronal 
survival, as mice deficient in autophagy spontaneously develop 
neurodegeneration with age217. Deficient autophagic clearance might be one 
of the causes of accumulation of misfolded proteins that potentially leads to 
neurodegenerative proteinopathies218. More importantly, it has been shown 
that autophagy plays a role in TDP-43 accumulation and toxicity 219 and 
more recently autophagy inducers have been shown to ameliorate the 
phenotype of a TDP-43 proteinopathy model 220.  
Tsvetkov and colleagues from Steve Finkbeiner group, have characterised 
the function of a library of FDA-approved compound based on their affinity 
with a known Akt inhibitor, 10-[4-(N-diethylamino)butyl]-2-
chlorophenoxazine (10-NCP) 221. In particular they demonstrated that the 
use of these compounds can significantly decrease the cumulative risk of 
death measured by automated longitudinal microscopy in an in vitro 
primary model of Huntington’s disease. 
Thanks to an on-going collaboration, it was possible to test the effect of 
some of these compounds on the M337V TDP-43 toxicity observed in both 
MNs and astrocytes. In particular, three compounds were selected: 10-NCP, 
together with two already characterised compounds from this library, 
already in use as neuropsychiatric drugs, Fluphenazine (FPZ), and Methyl-
Trimeprazine (MTM) (Fig. 24A). 
Treatment of M337V-derived MN cultures with these three compound 
revealed that while 10-NCP and MTM failed to significantly decrease the 
cumulative risk of death compared to control MNs, in contrast FPZ had a 
significant effect and partially recued the toxicity observed (Fig. 24B). 
Interestingly, when this approach was performed on Control iPSC-derived 
MNs both FDA-approved drugs demonstrated the ability to increase the 
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cumulative risk of death, as a side effect. In particular, while 10-NCP did 
not seems to have a significant effect on the control MNs, MTM increased 
their cHR to 1.49 (p=0.005) and FPZ had a particularly marked toxic effect, 
rising the cHR to 1.76 (p=0.0002)(Fig. 24C). 
The effect of these three compounds on TDP-43 toxicity was then tested in 
iPSC-derived astrocytes cultures. Interestingly, all compounds seemed to 
have a more powerful effect and homogeneous behaviour in astrocytes, 
compared to what observed in MNs. In fact, all three compounds were able 
to positively affect the TDP-43 toxicity observed in M337V iPSC-derived 
astrocytes (M337V vehicle cHR as baseline; M337V FPZ cHR=0.66, 
p=0.0013; M337V 10-NCP cHR=0.61, p=0.0006; M337V MTM cHR=0.61, 
p=0.00025) (Fig. 24D), while they did not have any negative effect on the 
cumulative risk of death observed in control astrocytes populations (CTRL 
vehicle cHR as baseline; CTRL FPZ cHR=1.18, p=0.22; CTRL 10-NCP 
cHR=1.12, p=0.48; CTRL MTM cHR=1.06, p=0.67) (Fig. 24E). 
The data obtained from the autophagy inducers was then analysed by 
combining effect of the three treatments and factoring the different 
genotypes, in both MNs and astrocytes. In general, Autophagy inducers 
were not able to rescue the toxicity observed in mutation carrying cells, 
reducing the cHR registered for M337V MNs and collapsing the cumulative 
risk curve to the baseline. They did however have a negative effect on the 
overall survival of the control MNs cultures (Fig. 24F). On the contrary, in 
astrocytes the autophagy inducers were able to significantly reduce the 
cumulative risk in the mutation carrying cells without having an overall 
negative effect on the control iPSC-derived astrocytes (Fig. 24G). The 
rescue of autophagy inducers was however incomplete even in astrocytes, as 
the cHR of the M337V-treated group was reduced compared to the M337V 
vehicle treated group, but still significantly higher than the vehicle treated 
Control astrocytes (M337V vehicle cHR=2.53, p=2.55x10-11; M337V 
ATPhGYi cHR=1.56, p=0.000313; CTRL vehicle as 1).  
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Figure 24: M337V toxicity is partially rescued by Autophagy inducers compounds. 
(A) Formula structures of the three autophagy inducers used in these experiments. (B) 
Real-time survival analysis of M337V iPSC-derived MN in the presence of autophagy 
inducers. (with vehicle as a reference, FPZ cHR=0.79, p=0.028; MTM cHR=0.96, p=0.691; 
10-NCP cHR=0.86, p=0.17). (C) Real-time survival analysis of CTRL iPSC-derived MN in 
the presence of autophagy inducers. (with vehicle as a reference, FPZ cHR=1.76, p=0.0001; 
MTM cHR=1.49, p=0.0056; 10-NCP cHR=1.28, p=0.108). (D) Real-time survival analysis 
of M337V iPSC-derived Astrocytes in the presence of autophagy inducers. (with vehicle as 
a reference, FPZ cHR=0.66, p=0.0013; MTM cHR=0.61, p=0.0003; 10-NCP cHR=0.61, 
p=0.0006). (E) Real-time survival analysis of CTRL iPSC-derived Astrocytes in the 
presence of autophagy inducers. (with vehicle as a reference, FPZ cHR=1.18, p=0.218; 
MTM cHR=1.06, p=0.673; 10-NCP cHR=1.26, p=0.474). (F) Analysis of cumulative plots 
combining the effect of autophagy inducers (ATPhGYi) on the different genotypes of MNs 
(with CTRL-vehicle as a reference, M337V vehicle cHR=2.01, p=1.08x10-16; CTRL 
ATPhGYi cHR=1.50, p=0.00146; M337V ATPhGYi cHR=1.74, p=1.09x10-05). (G) 
Analysis of cumulative plots combining the effect of autophagy inducers (ATPhGYi) on 
the different genotypes of MNs (with CTRL-vehicle as a reference, M337V vehicle 
cHR=2.53, p=2.55x10-11; CTRL ATPhGYi cHR=1.13, p=0.307; M337V ATPhGYi 







The experiments presented in this chapter show that in the iPSC-based 
model established for this project it is possible to detect a survival 
difference between in both MNs and astrocytes, when comparing M337V 
and control genotypes under basal conditions. 
In ALS, the most relevant pathological phenomenon is arguably the loss of 
MNs that determines the symptoms in the first place. For this reason the 
ability to reproduce this selective vulnerability in vitro is of great 
importance, not only because it allows to study the mechanism of such 
toxicity but it also offers a clinically relevant measurable outcome for 
disease modifying compound screening. 
Interestingly, a similar toxicity under basal conditions was observed also in 
highly enriched astrocytes cultures. Although several in vitro models have 
shown that mutant TDP-43 can be toxic in several different systems (from 
immortalized cell lines to primary cultures), this study demonstrates for the 
first time that TDP-43 can exert a direct toxicity in astrocytes. These 
findings represent the first report of cell-autonomous astrocyte toxicity in a 
mutant iPSC line and would be compatible with the idea that, at least 
initially or in part, reactive astrogliosis observed in ALS might not be 
simply a response to neuronal injury but a consequence of direct mutation-
mediated astrocyte toxicity.  
One of the key aims of establishing a reliable in vitro model for ALS is the 
elucidation of the pathways involved in the specific loss of cells observed in 
the patients, and ultimately the possibility to test different therapeutic 
strategies directly on patient derived material.  
In this context, we were able to prove that the difference in survival between 
mutant and control astrocytes was not abolished by QVD-treatment, which 
suggests that the M337V TDP-43 toxicity in astrocytes can be attributed 
largely to caspase-independent mechanisms. 
Moreover, treatment with autophagy inducers was partially able to 
ameliorate the survival of both M337V MNs and astrocytes, despite these 
drugs showed the tendency to increase the cumulative risk of death in 
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control MNs. This is potentially an important results, because together with 
recently published work on a TDP-43 animal model220, highlights the 
potential role of autophagy in ALS pathogenesis, and with it the possibility 








Chapter 6: Survival Analysis in isolated cultures 
 
Mutations on SOD1 were the first genetic causes of ALS to be discovered, 
therefore most research efforts in the last years have been focused on 
mtSOD1-fALS models. However, thanks to recent discovery of other 
genetic variants linked to fALS (such as TDP-43, FUS, C9ORF17) 5,15,22 we 
have now a better understanding of contribution of other genes in this 
disease. Of particular importance was the discovery that nearly all cases of 
ALS (as well ad half of the total number of cases for FTLD) present a 
pathological signature compatible with a TDP proteinopathy222. The only 
notable exceptions to this observation are those fALS cases determined by 
mutations on SOD1 which count for a minority all fALS cases. This suggest 
that the most influential model for ALS research in the last 25 years might 
not be the one from which we can draw conclusions applicable to the 
majority of cases. 
For these reasons it is of crucial importance to understand whether the same 
characteristics of SOD1 ALS pathology apply to TDP-43 proteinopathies. 
One finding of particular relevance that the field gained from the study of 
SOD1 fALS models is that this form of the disease can be regarded partially 
as a non-cell autonomous neurodegenerative disorder (NCA-ND). 
In fact, both in vitro and in vivo models convincingly demonstrated that 
astrocytes carrying SOD1 mutations mediate, at least in part, disease 
progression in SOD1 fALS147,150-152. Understanding whether the TDP-43 
mutation carrying astrocytes have a comparable neurotoxic effect is thus of 
great interest.  
Results presented in previous chapters showed that the M337V mutation 
impairs survival in isolated cultured under basal conditions (see Chapter 3) 
and increase TDP-43 levels. The same analytic approach was then used to 
examine the survival and morphology of MNs cocultured with either 
M337V or control astrocytes. 
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6.1) Analysis of TDP-43 in MN-Astrocytes cocultures 
 
To study the effect of mutation carrying astrocytes on TDP-43 levels a 
physical coculture system was established starting from the differentiated 
iPSC cultures optimized so far. Astrocytes monolayers for the cocultures 
were prepared by differentiating APCs cultures for 14 days in the presence 
of CNTF (as described in Chapter 1.X) and then plated on a matrigel coated 
microscopy grade culture-chamber slide, to favour the long-term attachment 
of the astrocytes without compromising the imaging quality. Astrocyte 
cultures were maintained on the chamber slide for a period of three days 
before plating the neurons. 
Motor neurons for the cocultures were generated from both genotypes of 
iPSC lines as described in the previous chapters from neurospheres. After 
two weeks in their maturation phase, patterned neurospheres were 
dissociated to single cells using papain and then plated on top of either 
M337V or Control iPSC-derived astrocyte culture previously prepared. The 
cocultures were maintained for a period of three weeks and then fixed for 
analysis. 
Immuno-staining for both MN and astrocytes markers was performed (SMI-
32 and GFAP) to confer the identity of the cells to be analysed, in addition 
to TDP-43 staining to compare the protein levels between different cultures 
(Fig. 25A). The immune-labelled cultures were imaged with a confocal 
microscope in order to be able to focus the analysis on the MN TDP-43 (on 
top), restricting the influence of the astrocyte TDP-43 signal (coming from 
the monolayer at the interface with the culture slide). Moreover, the MNs to 
be analysed were selected based on the possibility to single out their signal 
from the underneath astrocytes: in particular the criterium was a minimal 
presence of GFAP signal within the space occupied by the analysed MNs, 
within a imaging section of 1 A.U. {calculated on the TDP-43 staining, 
since the fluorochrome used has the longest wave-length compared to the 
others}. Selected MNs were manually analysed by drawing regions of 
interests based on SMI-32 staining. The TDP-43 signal from within the 
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region of interest was then measured. Quantification of the densitometric 
analysis revealed that TDP-43 levels fluctuate between the different 
genotypes and cocultures conditions, but no significant difference was 




Figure 25: TDP-43 analysis in MNs-Astrocytes coculture. (A) Representative 
immunostaining image for 3-week old MN-Astrocytes cocultures, labelled with antibodies 
against SMI-32, GFAP and TDP43. (B) Densitometric quantification of TDP-43 signal by 
confocal microscopy comparing MNs from both Control and M337V iPSC lines plated on 
either genotype of astrocytes for 5 weeks. [M337V MNs on M337V Astro 1.166 ± 1.2 
SEM, M337V MNs on CTRL Astro 1.000 ± 0.07 SEM; CTRL MNs on M337V Astro 
0.951 ±  0.07 SEM, CTRL MNs on CTRL Astro 1.00 ± 0.2 SEM. Results are presented as 
densitometric signal fold increase normalized to the same genotype of MNs plated on 




6.2) Morphological Analysis in MN-Astrocytes cocultures 
 
 
Astrocytes-neuronal interactions are fundamental to many different key 
processes in neuronal development and maturation. Among others, one of 
the key roles played by astrocytes is the regulation of neurite growth. 
Astrocytes are able to promote neurite growth by providing various 
diffusible and non-diffusible cues 223,224. In contrast, reactive astrocytes 
around sites of neurodegeneration or injuries generally produce growth-
inhibitory extracellular matrix (ECM) proteins suppressing the extension of 
regenerating axons 225. In the context of NCA-ND, and ALS in particular, 
the measurement of neurites length has been used as a parameter of neural 
health and development, when cocultured with mutation carrying astrocytes, 
(e.g. mutant SOD1 fALS primary astrocytes) 226. 
One practical obstacle to a reliable measurement of neurite outgrowth in 
complex cultures such as iPSC-derived MNs is the difficulty in 
distinguishing reliably the different cell’s neurites with immunostaining (for 
reference see Fig. 25 A, panel SMI-32). To overcome this obstacle it is 
possible to use fluorescent reporters instead of immunolabelling to identify 
the cells to analyse. The non-complete efficiency of the transfection process 
insures that virtually all neurons expressing the fluorescent reporter will not 
be overlapping, or in the immediate vicinity of another transfected cell, 
allowing to reliably assign each neurite to the correct neurons and to 
measure their length. 
To asses whether iPSC-derived mutation carrying astrocytes present an 
impaired capability to promote neurite outgrowth, Control and M337V 
iPSC-derived MNs (derived as described in Chapter 1) were transfected 
with the pHB9:eGFP fluorescent reporter (as described in Chapter 3) and 
then plated on astrocytes monolayer derived from either genotypes iPSC 
lines. The cocultures were maintained for a period of three weeks post 
plating and then imaged with automated live microscopy (Fig. 26 A). 
Images of HB9:eGFP+ cells were then analysed using the NeuronJ software 
package 227,228 by tracing the length of the visible neurites. The 
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quantification of the average neurite length was then compared for the 
different coculture conditions. Results from this experiment revealed that 
M337V astrocytes do not seem to present an impairment in their ability to 
promote neurites outgrowth, independently from the genotype of the 




Figure 26: TDP-43 analysis in MNs-Astrocytes coculture. (A) Representative 
immunostaining image for 3-week old MN-Astrocytes cocultures, expressing the MN 
specific reporter HB9::eGFP. (B) Quantification of average neurite length comparing MNs 
from both Control and M337V iPSC lines plated on either genotype of astrocytes for 3 
weeks. Measure are presented in n. of pixels [M337V MNs on M337V Astro 242.9 ± 13.75 
SEM, M337V MNs on CTRL Astro 231.4 ± 12.7 SEM; CTRL MNs on M337V Astro 





6.3) Survival Analysis in MN-Astrocytes cocultures 
 
To determine whether, as demonstrated in vitro and in vivo for SOD1 fALS, 
TDP-43 mutation carrying astrocytes are negatively affecting the survival of 
MNs, survival analysis of astrocytes-MNs coculture was undertaken using 
the longitudinal microscopy approach adopted for the analysis of isolated 
cultures. Control and mutant iPSC-derived neurospheres were dissociated 
and transfected with the HB9::eGFP reporter at the end of the MN induction 
protocol, after two weeks of culture in their maturation phase  (as described 
in Chapter 3). Transfected MNs were then plated on a monolayer of 
differentiated astrocytes derived from either the mutant or control iPSC line. 
The coculture was imaged with automated longitudinal microscopy every 
24 hours for 10 days to perform survival analysis.  
The effect of control and mutant astrocyte background on the survival of 
Control MN cultures was tested first. Results of this comparison revealed 
that cumulative risk of death of wild-type MNs cultured on mutant 
astrocytes was not significantly different from that of WT MNs cultured on 
WT astrocytes, suggesting that mutant astrocytes do exert a significant toxic 
effect to wild-type MNs (Fig. 27 A). 
Subsequently, the survival of mutant M337V MNs in coculture with 
astrocytes was determined. Similarly to what observed for Control iPSC-
derived MNs, mutation-carrying astrocytes did not exert non-cell-
autonomous toxic effects MNs carrying the M337V TDP-43 mutation (Fig. 
27 B).  
As an internal control for these experiments the MNs populations from 
wither genotype were also plated in isolation and analysed in parallel. This 
experiment confirmed that the M337V MNs used in the coculture 
experiments presented greater cell-autonomous vulnerability than healthy or 
control MNs as shown before (see Chapter 3.2) (Fig. 27 C). 
Interestingly, when cocultured with astrocytes of either genotype, the cell-
autonomous vulnerability previously observed in isolated mutant MNs was 
no longer evident (Fig. 27 D). These results suggest that, independently 
from the genetic background of the astrocytes, coculture conditions rescue 
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the survival difference associated with the TDP-43 M337V mutation in 
motor neuronal cultures and –importantly- that TDP-43 mutant astrocytes 
do not exert an in vitro toxic effect on neurons. 
The lack of a significant non-cell autonomous toxic effect was also 
reproduced when the same experiments were repeated using a pan neuronal 
MAP2::mApple reporter instead of the MN specific HB9::eGFP. In 
particular, as shown for the MNs, both wild-type and M337V MAP2 
positive neurons did show decreased viability when cocultured with TDP-43 
mutation carrying astrocytes (Fig. 28 A-B), nor they presented any 
difference in viability when compared directly (Fig. 28 C). 
The results obtained from these coculture survival experiments suggests that 
–contrary to what observed for SOD1 astrocytes- TDP-43 mutation carrying 
astroglia are not toxic to MNs. Given the important implications of these 
observation, it was of utmost importance to be able to confirm that the 
absence of significant non-cell autonomous effects did not represent merely 
a false negative result, originated by the inadequacy of the detection system 
used. 
To answer this particular concern, the same longitudinal microscopy 
approach was used to determine the survival of iPSC-derived MNs 
cocultured with primary murine astrocytes overexpressing the G93A mutant 
human SOD1. A number of in vitro experiments have convincingly 
demonstrated that mutant SOD1 astrocytes are toxic to cocultured MNs 
147,151,152, and for this reason this particular experiment represent a ideal 
“positive control” to determine the reliability of the previous observations. 
Indeed the results showed clearly that –as previously reported- MNs plated 
on mutant SOD1 overexpressing astrocytes present a significantly increased 
risk of death compared to MNs cocultured with wild-type SOD1 astrocytes 
(Fig 28 D). This result confirms that the longitudinal live microscopy based 
survival analysis adopted for the coculture experiments is capable of 
detecting non-cell autonomous effects determined by astrocytes on MNs, 
supporting the idea that the absence of a increased toxicity in MNs cultured 
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with M337V iPSC-derived astrocytes is due to a difference in pathogenic 
mechanism between SOD1 fALS and TDP-43 fALS. 
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Figure 27: TDP-43 analysis in MNs-Astrocytes coculture I. (A) Real-time survival 
analysis of Control iPSC-derived MNs plated on either M337V or control iPSC-derived 
astrocytes. Mutant astrocytes are not toxic to cocultured WT MNs (with WT MNs on WT 
astrocytes as a reference, HR for WT MNs on M337V astrocytes 0.98, p=0.68).  (B Real-
time survival analysis of M337V iPSC-derived MNs plated on either M337V or control 
iPSC-derived astrocytes. Mutant astrocytes are not toxic to cocultured WT MNs (with WT 
MNs on WT astrocytes as a reference, HR for WT MNs on M337V astrocytes 0.83, p=0.2).  
(C) Real-time survival analysis of MNs cultured in isolation (n=3), demonstrating cell-
autonomous toxicity of mutant TDP43 (with WT as a reference, HR for M337V 2.02, p 
8.91x10-7) (D) Longitudinal analysis of both genotypes of MNs plated on either Control or 
M337V astrocytes. Both Control and M337V astrocytes improved the survival of Control 
MNs. M337 astrocytes had no detectable toxicity to cocultured MNs. All graph represent 







Figure 28: TDP-43 analysis in MNs-Astrocytes coculture II. (A) Real-time survival 
analysis of Control iPSC-derived MAP2+ cells plated on either M337V or control iPSC-
derived astrocytes. Mutant astrocytes are not toxic to cocultured neurons (with Control 
Neurons on WT astrocytes as a reference, HR for WT Neurons on M337V astrocytes 1.08, 
p=0.58).  (B Real-time survival analysis of M337V iPSC-derived MAP2+ cells plated on 
either M337V or control iPSC-derived astrocytes. Mutant astrocytes are not toxic to 
cocultured M337V Neurons (with M337V Neurons on WT astrocytes as a reference, HR 
for M337V Neurons on M337V astrocytes 1.079 , p=0.57).  (C) Longitudinal analysis of 
both genotypes of MAP2+ neurons plated on either WT or M337V astrocytes. (D) Real-
time survival analysis of WT MNs cultured on a layer of murine primary astrocytes 
overexpressing either WT human SOD1 or mutant human SOD1 (n=3), demonstrating non-
cell autonomous toxicity of mutant SOD1 astrocytes (with WT SOD1 Astrocytes coculture 









Recent in vitro and in vivo experiments convincingly demonstrated that in 
SOD1 fALS models astrocytes mediate, at least in part, disease progression 
147,150-152. However, observations from SOD1 models might not be directly 
applicable to all ALS cases. In fact, the most common pathological features 
amongst ALS cases is TDP-43 pathology, which is notably absent from 
SOD1 fALS cases 5. Understanding whether the TDP-43 mutation carrying 
astrocytes can determine a non-cell autonomous neurotoxic effect is thus of 
great interest.  
The results presented in this chapter address the question of non-cell 
autonomy in the iPSC based platform, using both molecular techniques and 
longitudinal analysis.    
In particular, no difference was detected by immune-labelling densitometric 
analysis in the TDP-43 levels between MNs of either genotypes plated on 
the M337V astrocytes compared equivalent cocultures with the control 
astrocytes. This method of analysis gives a reliable comparison between the 
different groups, but it is not as powerful as the biochemical analysis by 
immunoblotting used to determine the levels of TDP-43 in isolated cultures. 
It has not been possible to undertake immunoblotting analysis in the 
cocultures due to the lack of an optimized protocol to separate the MN 
component from the astrocytes monolayer at the time of sample harvesting. 
This could be solve in future studies by optimizing a fluorescent cells 
sorting protocol coupled with HB9::eGFP reporter transfection. 
Astrocytes derived from the mutant iPSC line did not also show any 
significant differences in their ability to promote axonal outgrowth in MNs, 
when compared to wild-type astrocytes. 
Interestingly the survival of control MNs plated on mutant astrocytes and 
equivalent MNs cocultured with control astrocytes did not show any 
significant decreases in viability, suggesting that mutant astrocytes might 
not be contributing to the pathogenesis in the same way SOD1 mutant 
astrocyte do. Importantly, by using the same longitudinal microscopic based 
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methodology on a already established non-cell autonomous toxicity model 
(coculture with G93A SOD1 overexpressing astrocytes), it was possible to 
confirm the ability of this experimental system to address cellular autonomy 
in iPSC based cellular models as has previously been shown in xeno-
cultures.  
Together these findings suggest that the absence of non-cell autonomous 
astrocyte mediated toxicity under basal conditions of mutant TDP-43 
reflects underlying differences in pathogenic mechanism and warrant further 
studies using the platform described in this thesis to study sporadic and 
other familial ALS iPSC lines. 
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Chapter 7: Discussion and Future Work 
 
 
This study describes the establishment of a patient iPSC-based platform to 
model ALS in vitro. In particular, the final aim was to use the established 
system to address question of cell-autonomy and astrocyte-neuronal 
interactions in the context of TDP-43 fALS and TDP proteinopathies in 
general. To accomplish this goal, it was initially necessary to obtain suitable 
population of both motor neurones and astrocytes from the TDP-43 
mutation carrying iPSC lines and controls. 
7.1) Generation of Motor Neurones and Astrocytes from iPSC lines 
The protocol used to generate reliably population of MNs from the iPSC 
lines was optimised to mimic closely the different phases that in vivo 
specify the MN identity.  
The first step in CNS development during embryonic development is the 
generation of the neural tube, which entails the specification of the 
neuroepithelial identity from the previously pluripotent cells. This step was 
reproduced in vitro by applying the dual SMAD inhibition system184, which 
takes advantage of a small molecule inhibitors to selectively block the 
Activin/TGF-β (SB431542) and dorsomorphine, an analogue of BMP4 
inhibitor Noggin, to reproduce in the cultured pluripotent colonies the same 
neural specification effect that specifies the neuroepithelium in vivo. 
After the neural tube formation the regional identities are determined along 
the rostro-caudal axis first and then along the dorso-ventral axis. This dual 
stage patterning was reproduced in vitro by first treating the neural 
progenitors with retinoic acid to obtain a homogeneously caudalised 
population, and then exposing them an analogue of sonic hedgehog (SHH) 
to shift their expression profile towards a ventral identity. Importantly, in 
vivo as well as in the cultures, the generation of regionally specified 
progenitors able to give rise to specific neuronal populations is a process 
that takes places over a relatively long period of time. For this reason, 
separating the MN generation protocol into different phases offers an 
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additional practical advantage, besides mimicking closely the embryonic 
development: because every phase is separate, it has been possible to 
optimise every step separately to obtain a maximised efficiency (ex. 
maximum percentage of Nestin/Sox1 positive cells at the end of the 
neuralisation phase, maximised percentage of HoxB4 positive caudalised 
progenitors after retinoic acid treatment, etc.). 
The same strategy to mimic the in vivo neural development was adopted in 
the development of a protocol to generate astroglial cells from the iPSC 
lines. As seen in the Introduction, gliogenesis is a highly regulated process 
that occurs at a specific time during development; the astrocytes generation 
protocol was modelled to incorporate the same signalling that regulates the 
generation of astrocytes in the developing embryo. 
Moreover, as for the MN protocol, the generation of astrocytes was divided 
into two separate phases, to optimise separately the induction of astrocyte 
progenitors and the differentiation and maturation of these progenitors into 
functional astroglial.  
In the first phase of the protocol, pro-gliogenic signalling was used to 
generate enriched and scalable astroglial progenitors starting from patterned 
neural precursors (directly from the final phase of the MN protocol).  As 
previously demonstrated with several in vivo and in vitro experiments, the 
prolonged propagation of neural precursors in the presence of LIF and EGF 
but without FGF2 promotes glial commitment and expansion, resulting in 
efficient astrocyte progenitor cells (APC) fate specification 108,110,113,229. 
Optimisation of the mechanical chopping, culturing technique and the 
transition between neurospheres to monolayer cultures, allowed to obtain 
highly enriched APC cultures, featuring ≃ 80% cells co-positive for 
Vimentin and NFIA. The separation of this protocol into generation of 
APCs and differentiation of the progenitors into functional astrocytes offers 
practical advantages, as the APCs monolayer cultures can be propagated in 
the presence of FGF2 and EGF, allowing to significantly reduce the amount 
of starting material necessary for an experiment, but they can also be 
cryopreserved, allowing to perform experiments with the same batches of 
164  
cells over long periods of times. From the enriched APC cultures it was then 
possible to obtain high purity (>90%) populations of differentiated 
astrocytes, co-positive for GFAP and S100β. 
The protocol here described represent a considerable advancement 
compared to the already published methodologies to obtain astroglial from 
pluripotent cells, in particular in terms of time needed to complete the 
protocol. 
In particular, it has been reported by Krencik and co-workers that neural 
progenitors cultured in suspension in EGF and FGF2 for prolonged period 
of times (3-9 months) will progressively lose their neurogenic potential, 
while increasing their ability to generate functional astroglia 124, in a fashion 
similar to what happens in the nervous system during development, and 
leading to a highly enriched GFAP+/S100B+ population by day 180 in 
culture. The EGF-LIF conversion based protocol here described allows to 
obtain similarly enriched population of APCs starting from MN-generating 
neurospheres with a much shorter period of time needed for efficient glial 
specification of the culture (6 weeks to obtain APCs and 2 weeks to 
differentiate them into astrocytes). However, to properly compare the two 
protocols it needs to be noted that they present several differences: firstly, 
the methodology described by Krencik and colleagues has a shorter 
patterning phase compared to the MN-specific patterning protocol used 
here; secondly, in this study the APC-enrichment is started at a stage when 
the neurospheres have already undergone growth factors withdrawal, to 
generate MN cultures, which in turn can further help the process of 
astroglial fate specification 230.  
For the purposes of this study it was crucial to ensure that the astrocyte 
populations generated for the coculture studies were coming from a 
population of iPSC-derived neurospheres in which the TDP-43 M337V 
toxicity and miss-localization was already established and confirmed. The 
addition of pro-gliogenic signalling in culture –together with the 
propagation of the neurospheres- allowed a reduction in the time needed to 
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obtain an efficient switch between neuronal and astroglial differentiation 
potential in MN-patterned progenitors.  
Other published protocols obtain a high astrocytes yield from cultured 
neural progenitors, but in most cases they either make use of serum 
containing media192 or they present a high percentage of cells in culture that 
still express neuronal markers193. 
Conversely, the protocol optimized in this study allows to obtain highly 
enriched astrocytes population in a chemically defined environments, while 
at the same time minimizing the amount of neuronal cells present in the 
cultures. 
7.2) Functional Characterisation of iPSC-derived differentiated cultures 
Having a population of cells that reproduces in vitro the expression profile 
of a determined population in vivo is obviously the starting point for any 
disease modelling study. In the case of this study, specific marker 
combinations were used to identify the desired cell types as they arise in the 
culture: for MNs the markers used are HB9, SMI-32 and ChAT; for 
astrocytes the combination of GFAP and S100B indicate the desired 
astrocyte lineage. However, it is also obvious that the mere expression of 
proteins found in the desired cells –taken alone- does not constitute a solid 
base to validate hypothesis and test potential treatments. The neurons and 
astrocytes generated in vitro need to resemble their in vivo counterparts 
beyond the expression profile, and present comparable functional properties. 
To test the validity of the protocols optimised for this study, a battery of 
functional test for both iPSC-derived MNs and astrocytes was devised. 
 
MNs Functional Characterisation 
As a first functional assay for the MNs, electrophysiological 
characterisation was performed on 10-weeks old cultures. Whole-cell patch 
clamp recordings showed repetitive firing of action potentials, and 
spontaneous excitatory post-synaptic currents. Moreover, this 
characterisation revealed that at this stage MNs present functional NMDA, 
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AMPA and GABAA receptors. Taken together these results indicate that the 
maturation protocol allows the MNs to reach a developmental stage 
advanced enough to exhibit the basic neuronal functional properties, and to 
be considered electrophysiologically active. 
To further test their functionality, the iPSC-derived MNs were cocultured 
with differentiated murine myofibers, derived from C2C12 cells. 
The NMJ formation assay revealed that the iPSC-derived MNs have the 
potential of inducing the clustering of nicotinic receptors when making 
contact with a fused myofibers. This particular experiment represent the 
current standard for the field 191,194 but it present some limitations: 
particularly, because of the absence of a defined tri-dimensional 
environment the structure formed by he’s- or iPSC-derived MNs and 
differentiated C2C12 is very different from the NMJ described in vivo 231, 
and so far no long term study on these “putative” NMJ in vitro exists. 
Moreover, further issues might be raised by the difference of species 
between the MNs and the C2C12.  
However, the conclusion that can safely be drawn from such functional 
characterisation –limited as they are- is that at the end of the maturation 
protocol optimised, when cultured with an established model of myofibers 
in vitro, the iPSC-derived MNs have the potential of initiate the clustering 
of receptors on the muscle cells, which in itself represent the first step of the 
NMJ formation. More studies concerning the functional properties of these 
in vitro putative NMJs are necessary to fully elucidate the functional 
potential of iPSC-derived MNs. 
Overall, considered the results of these functional assays, it is possible to 
consider the iPSC-derived MNs used in these study as a suitable population 
to use in further mechanistic studies. 
Also, interestingly, in the functional studies undertaken, it was not possible 
to observe any difference in the behaviour of the TDP-43 mutation carrying 
MNs compared to the controls. These would suggest that the M337V 
mutation per se does not impair either the development of MNs or their 
maturation, nor it prevents them to acquire an electrophysiologically active 
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profile. It needs to be observed, however, that in most animal models 
degeneration and NMJ defects reported at early stages 232: these effects of 
the mutations might not be observed in this in vitro system due to the 
limitations of the NMJ formation assays, or to the limited time that the 
myofibers and MNs are actually kept in coculture. 
 
Astrocytes Functional Characterisation 
One of the aims of this project was to determine whether astrocytes carrying 
the M337V TDP-43 mutations are toxic to MNs similarly to what observed 
for SOD1 astrocytes. To evaluate the potential toxic effect it is necessary to 
account for gain of toxic effects as well as loss of support functions. 
For this reason it is extremely important that the astrocytes used in the study 
present a functional profile very close to what observed for astroglial in 
vivo. Moreover, a thorough functional characterisation is also necessary to 
prove that the novel protocol optimised in this study is effectively 
generating bona fide astroglial cells. 
The functional characterisation of the astrocytes used in this study was 
focused on determining their ability to uptake glutamate, promote 
synaptogenesis, and propagate intercellular calcium waves (ICW). 
The results of the glutamate uptakes assay revealed that the astrocytes 
generated with the EGF-LIF enrichment protocol are capable of clearing 
excesses of L-glutamate from the media in a time dependent fashion. 
Importantly, this uptake was abolished by both absence of sodium and 
application of a specific metabotropic amino acid transporter inhibitor 
(PDC), which indicates the uptake observed is dependent on the activity of 
EAAT1. Interestingly, the presence of the M337V mutation did not impair 
the glutamate clearance ability in the astrocytes cultures, having both 
mutant and control astrocytes performing similarly in terms of both rate of 
clearance and total amount of cleared glutamate. This is a particularly 
relevant point, as the impairment of glutamate clearance and consequent 
excitotoxicity are thought to play a key role in MN toxicity observe in 
models of SOD1 fALS. In particular, it has been previously shown that 
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MNs are particularly sensitive to excitotoxicity 233,234, and there are some 
evidences of increased plasmatic levels of glutamate and decreased 
expression of glutamate transporters in patient samples235.  
This particular experiment however, presents an intrinsic limitation due to 
the in vitro culture conditions: in the CNS most of the glutamate is cleared 
from the synaptic clefts by the activity of EAAT2, another astrocytes 
specific metabotropic transporter. In fact, it is mostly EAAT2 that is found 
down regulated in SOD1 fALS models and patient samples 236. However, 
while EAAT1 is expressed in astrocytes upon maturation, the expression of 
EAAT2 is regulated by neuronal activity, neuronal networks maturation and 
other soluble factors 237. It is therefore expressed at low levels in isolated 
astrocytes cultures, particularly in pure astrocytes populations differentiated 
in vitro. The results presented in this study indicate that M337V TDP-43 
does not impair the glutamate uptake mediated mostly by EAAT1, however 
future experiments will need to address the effect of this mutation on 
EAAT2 dependent glutamate uptake, by coculturing the developing 
astrocyte with neurons from an early stage or by inducing an higher 
expression of EAAT2 by other means (for example, the application of 
Ceftriaxone238). 
Besides the maintenance of the neuronal environment, another important 
function of astrocytes is to promote synapse formation and maintenance (see 
Introduction). The second functional assay performed on the iPSC-derived 
astrocytes addressed their ability of promoting the formation of mature 
synapses in cocultured neurons. The results of these tests revealed that the 
iPSC-derived astrocytes are able to increase the number of mature synapses 
formed by the cocultured neurons, compared with isolated neuronal 
cultures, but they also revealed that the presence of the M337V mutation did 
not impair this synaptogenesis ability. In fact both genotypes of astrocytes 
performed equally in terms of number of mature synaptic vesicles observed 
in the cocultured neurons.  
The IPSC-derived astrocytes were also able to generate and propagate ICW 
in response to soluble cues and mechanical stimuli. In the present study the 
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presence of ICWs was determined by a stimulation paradigm and following 
live imaging. Future studies will need to compare the speed of propagation 
and the number of cells involved in these calcium waves, and possibly 
compare directly the ICW generated by iPSC-derived astrocytes with those 
from primary astrocytes, in order to better characterise this particularly 
important feature of astroglial cells and its development in vitro. 
Taken together, the presence of ICW in in vitro generated astrocytes 
indicates, their ability to promote synaptogenesis and the glutamate uptake 
capacity demonstrate that the protocol optimised for this study not only 
produces GFAP and S100B positive cells that look like astrocytes, but in 
vitro functional astrocytes that can be effectively used to study and model 
the involvement of astroglial cells in disease pathogenesis and progression. 
7.3) Phenotypical characterisation of the iPSC-based TDP-43 model 
One of the most important aspects to consider in the establishment of a 
TDP-43 in vitro model is whether it recapitulates the aspects of the TDP-43 
pathology described in the disease. To investigate whether the iPSC-
platform recapitulates TDP-43 pathology, after the directed differentiation 
protocols for both MNs and astrocytes were optimised and validated, a 
battery of molecular and survival assays was undertaken. 
 
Modelling the MN Component of ALS with iPSC 
As seen in the Introduction chapters, TDP-43 proteinopathies and ALS in 
particular are characterised primarily by accumulation and mislocalisation 
of this protein, coupled with the specific loss of neurons (MNs in the case of 
ALS) that ultimately causes the symptoms.  
Interestingly, in this study MNs generated from patient-derived iPSC line 
carrying a pathogenic TDP-43 mutation recapitulate key aspects of TDP-43 
proteinopathies in vitro, including cell-autonomous neuronal degeneration 
and the accumulation of insoluble TDP-43.  
The fist molecular characterisation was focused on TDP-43 biochemistry; 
mutation-carrying MNs presented significantly higher levels of soluble and 
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detergent-resistant TDP-43. This result is particularly interesting 
considering that TDP-43 is intrinsically prone to aggregation, and it has 
been shown that ALS-linked mutations increase its toxicity and tendency to 
aggregate239 67. Previously, increased stability of mutant TDP-43 proteins 
had been reported only in isogenic transformed cell lines 240. 
Interestingly, although M337V MNs had increased TDP-43 levels compared 
to control neurons, they expressed equivalent levels of TARDBP mRNA. 
This would suggest that differences in TDP-43 protein levels result from a 
post-translational mechanism rather than from transcriptional differences. 
Moreover, the mutant TDP-43 in iPSC-derived MNs do not appear to 
interfere with the proposed autoregulatory feedback mechanism proposed 
for the control of TDP-43 mRNA levels29,42. One of the possibilities to 
explain this differences is that missense mutations in the C-terminal domain 
of the protein might inhibit the turnover of mutant TDP-43 or alternatively 
negatively effect protein quality control pathways. 
These biochemical studies are important as they recapitulate one of the key 
feature of the pathology, but they also present a limitation due to the starting 
cellular material. In fact, the samples used represent a mixed cultures 
containing up to 50% HB9 positive cells, mixed with other spinal cord 
patterned neuronal cell types as well as a small percentage of progenitors 
and glial cells. Further studies will need to confirm the biochemistry 
experiments performed on the mixed MN cultures, by using a purified 
population of spinal cord MNs. 
 
Besides the biochemical signature, one of the other important molecular 
features of TDP-43 proteinopathies is the mislocalisation of this protein 
from the nucleus to the cytoplasm. Despite the higher biochemically levels 
of TDP-43 observed in M337V neurons detected, it was not possible to 
detect a significant mislocalisation of TDP-43 immunostaining 
densitometric analysis. However, this analysis revealed that SMI-32+ 
neurons had higher levels of nuclear TDP-43 in vitro, indicating the 
possibility that TDP-43 protein levels can differ between neuronal subtypes. 
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Both M337V and Control iPSC-derived MNs presented a punctate TDP-43  
pattern compatible with the involvement of TDP-43 in nucleocytoplasmic 
shuttling of RNA, the association of TDP-43 with RNA granules in 
somatodendrites, and the presence of TDP-43 in the microsome fraction of 
brainstem samples, suggesting active transport of TDP-43 along the axons 
241 40,242.  
Ubiquitinated TDP-43 aggregates were not observed in the iPSC-derived 
MNs, despite being one of the most striking features of reported from the 
post-mortem samples. This could indicate, together with the absence of 
nuclear TDP-43 clearance, that these phenomena represent a later stage of 
the pathology, while the in vitro iPSC-derived MNs are representative of a 
much earlier time-point on the pathogenesis timeline. 
 
The presence of elevated TDP-43 protein levels in mutation carrying MNs 
is important evidence that the iPSC-based platform can be used as a model 
for this class of diseases. However, it is also equally important that the in 
vitro system recapitulates the event that is the direct cause of the disease in 
the patients, namely the loss of MNs. 
Several cellular and transgenic models of TDP-43 expression established 
that elevated levels of wild-type and mutant TDP-43 can be highly toxic 
243,244. Moreover, it has been shown that the levels of cytoplasmic, rather 
than nuclear, TDP-43 correlate with cellular toxicity 70.  
Importantly, this study has shown that the presence of the M337V TDP-43 
mutation significantly increased the risk of death of iPSC-derived MNs 
under basal conditions, as measured by longitudinal fluorescence live 
microscopy of MNs, suggesting an inherent cell-autonomous toxicity of the 
mutation in MNs.  
In summary, these findings show that patient-derived TDP-43 M337V 
neurons recapitulate key biochemical aspects of TDP-43 proteinopathies 
and provide evidence that the M337V mutation in TDP-43 is toxic to iPSC-
derived MNs.  
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Shortly after these results on the MN component of the iPSC-based platform 
were published245, another research group reported a study on iPSC-derived 
MNs generated from TDP-43 fALS patients246. Importantly, the results 
presented by Egawa and colleagues confirm most of the finding of the 
present study, particularly the fact that the mutation per se does not impair 
MN specification or differentiation, the presence of TDP-43 punctate 
cytoplasmic staining and the elevated protein levels found in both the 
soluble and insoluble fraction. There are however some differences in the 
results that are worth noticing. In particular, the Japanese study reported 
increased levels of Tardbp mRNA levels in the mutation carrying cells, and 
they also do not report a survival difference between M337V and Control 
MNs. 
The difference in the results regarding the TDP-43 expression levels 
between this study and the results published by Egawa and colleagues can 
be attributed to several different causes. First, for the present study one 
patient line carrying the M337V mutation was used, while the Japanese 
study uses three different lines carrying respectively a Q343R, a M337V 
and a G298S mutations. Egawa and co-workers report that the clones of the 
M337V line they analysed presented Tardbp mRNA equivalent to control 
MNs, while all other lines presented increased levels: future studies will 
need to address the levels of TDP-43 expression increasing the numbers of 
patients recruited for the iPSC generation, and the number of clones used 
for each line. Another difference between the two studies is the cellular 
samples used: while in this project a mixed MN-containing of spinal cord 
patterned cultures were used to determine the mRNA levels, in the study 
presented by Egawa et al. the MNs were purified with Fluorescence 
Activated Cell Sorting (FACS) and a HB9 fluorescent reporter. 
Egawa and co-workers also do not report an intrinsic toxicity in MNs as a 
consequence of the M337V mutation, while in this study we demonstrated 
that the cumulative risk of death in MNs significantly increases when the 
mutation is present. One probable explanation for this discrepancy is again 
to be found in the different set-ups used for the survival experiment. Egawa 
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and colleagues used a fluorescent based system (IN Cell Analyser 2000, 
from GE Healthcare) for the survival analysis, counting the number of HB9 
positive cells in the culture at different time-points: interestingly they 
observe a decreased in percentage of survival after 4 days, that is then 
absent from the later time points246. In the live imaging system used for the 
present study every MN is followed individually which allows a more 
precise estimation of the risk of death, compared with counting the total 
number of HB9::GFP positive cells at every time point. These differences in 
the techniques used for these experiments, together with the variation in the 
number of lines used can explain the differences in the reported results. 
 
Modelling the Astroglial Component of ALS with iPSC 
Having established that the iPSC-based platform can recapitulate key 
aspects of ALS pathology –at least for what concerns the MN component-, 
the same molecular phenotyping techniques were applied to population od 
M337V iPSC-derived astrocytes, to investigate TDP-43 localisation, 
accumulation and effects on survival in astrocytes. 
As shown for the MN populations, M337V expressing astrocytes displayed 
elevated levels of soluble TDP-43 protein, without presenting an associated 
increase in Tardbp mRNA.  
These results, together with the data from the MNs, further support the idea 
that the M337V mutation affects TDP-43 protein levels via a post-
translational mechanism.  
It is also of interest that in astrocytes as in MNs, TDP-43 does not seem to 
negatively auto-regulate its own mRNA, as reported in established stable 
lines 240. 
Conversely to what observed in the MN cultures derived from the same 
iPSC lines, mutant astrocytes do not show increased levels of detergent-
resistant TDP-43 levels together with the accumulation of the protein in the 
soluble fraction. The reasons for this difference in the behaviour of the 
mutant protein are unclear, but it would indicate a different cell-specific 
processing mechanism of protein accumulation.  
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Along with accumulation of soluble TDP-43, mutant astrocytes also 
displayed inherent mislocalisation of TDP-43 to the cytoplasm. 
Interestingly, the increased cytoplasmic TDP-43 levels were not 
accompanied by a corresponding depletion of nuclear TDP-43 levels, 
further supporting the idea that the additional TDP-43 is due to increased 
stability and/or slower clearance.  
It is interesting to notice that the loss of TDP-43 nuclear localization has 
been linked to neuronal degeneration in TDP-43 proteinopathies in animal 
models and cellular systems (see Introduction).  
Although cytoplasmic TDP-43 levels were increased, in the mutant 
astrocytes it was not possible to detect any TDP-43 aggregates, as described 
in some post-mortem patient samples (Glial Cytoplasmic Inclusion, GCI 247) 
As discussed for the MN data, the absence of TDP-43 inclusions and 
nuclear clearance in astrocytes further support the idea that these events 
occur at later stage in the pathology, in which case iPSC-platform would be 
more suitable to model the earlier stages of the disease development, 
offering an invaluable window on the pathogenic mechanisms of TDP 
proteinopathies. 
 
Survival analysis of M337V iPSC-derived astrocytes revealed that the 
presence of the mutation confers a significantly greater risk of death, when 
compared to Control iPSC-derived astrocytes under basal conditions. The 
increase in cumulative risk determined by the M337V mutation registered in 
astrocytes was of similar magnitude to that observed for MNs (HR for 
M337V Astrocytes is 2.5 compared to controls, while HR for M337V MNs 
is 2.65 compared to controls). 
This results represents the first report of cell-autonomous astrocyte toxicity 
in a mutant iPSC line, and they are consistent with the idea that, at least 
initially or in part, reactive astrogliosis observed in ALS might not be 
simply a secondary response to neuronal injury but a consequence of direct 
mutation-mediated astrocyte toxicity.  
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Taken together, these results show that mutation-carrying astrocytes present 
both a mislocalisation of TDP-43 and a cell-autonomous survival deficit 
analogous to what observed in MNs, but the results do not indicate whether 
these two events are linked by causality or if they both are a by-product of 
another pathological mechanism. Because it was possible to detect both the 
mislocalisation and the decreased survival in astrocytes, they offer the 
possibility to elucidate the link between these two phenomena.  
Barmada and colleagues showed using ectopic TDP-43 expression in 
primary rodent neuronal cultures that the localisation and expression levels 
of the protein are the parameters that mostly influence ectopic-TDP-43 
toxicity. 
Interestingly, the ectopic M337V and WT TDP-43 expression studies on 
isogenic control astrocytes reported here (see Results Chapter 2.5), 
demonstrate that the M337V mutation confers an inherent bias towards 
cytoplasmic localization. In turn, the observation that cytoplasmic 
localization is associated with an increased risk of death offers an 
interesting correlation between the increased cytoplasmic TDP-43 of iPSC-
derived astrocytes and their lower survival, compared to controls. These 
findings would support the idea that, as observed in primary neurons, the 
mutation influences TDP-43 localisation, and in turn this causes the 
observed toxicity. Importantly, these experiments involved isogenic human 
astrocytes, so the differences in mislocalisation and toxicity can be 
attributed specifically to the presence of a disease-associated mutation in 
TDP-43, and not to potential influences of differences in genetic 
background. Future studies will be necessary to elucidate the mechanism 
involved in the change of TDP-43 localisation caused by the mutation. As 
TDP-43 shuttles between the nucleus and cytoplasm regularly, one of the 
possible explanation would be that the mutation influences the protein 
ability to interact with the nuclear import mechanism, an hypothesis 
suggested by Nishimura and colleagues: their results show that the deletion 
of the nuclear localisation signal in TDP-43 causes accumulation of the 
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protein in the cytoplasm, and recapitulate to some extent other features of 
the pathology65. 
 
7.4) Drug Studies as a proof of principle 
The availability of a human iPSCs based model for TDP-43 proteinopathies 
that present a measurable phenotype, offers the opportunity to test battery of 
compounds directly on patient cells and measure their ability to modify the 
observed phenotype. This particular approach can be used to test potential 
disease-modifying drugs, but at the same time it offers the opportunity to 
gain insights on the molecular mechanisms behind the observed phenotype. 
In this study we identified a cell autonomous toxicity determined by the 
presence of the M337V mutation on both MNs and astrocytes. Importantly, 
the use of survival analysis by longitudinal microscopy allowed to have a 
precise measurement of the cellular toxicity, through the study of 
cumulative hazard ratios between the different groups. The same approach 
was adopted to establish two proof of principles drug studies, that both 
provided insights on the disease mechanism and indicated some possible 
therapeutic strategies.  
 
Apoptosis Involvement in M337V Toxicity 
The first proof-of-principle drug test performed addressed the question of 
caspases activation in the TDP-43 toxicity observed in astrocytes. 
The treatment of both mutant and control astrocytes with the pan-caspase 
inhibitor QVD resulted in a three- to fourfold improvement in cell survival 
on both genetic backgrounds, indicating that in the in vitro system, part of 
the cell death observed is due to apoptosis by caspases activation. It is 
interesting to notice that not only the mutant astrocytes but also the control 
populations presented a significant decrease in the basal levels of cell death 
registered, indicating that a degree of basal cell death is a feature of the in 
vitro system. 
177  
However, when the QVD-treated groups were compared directly, the 
M337V astrocytes still had a significantly increased risk of death compared 
to control astrocytes, as measured by Cox proportional hazards analysis. 
This result suggests that the difference in survival between M337V and 
control astrocytes can be largely attributed to caspase-independent 
mechanisms. Indirect support for this caspase-independent mechanism of 
toxicity in astrocytes is based on the absence of TDP-43 aggregates or 
significant increase of TDP-43 cleavage products in mutant astrocytes, both 
of which are associated with caspase activity248,249.  
 
Autophagy Involvement in M337V Toxicity 
The second proof-of-principle drug studies on the iPSC platform was 
performed in collaboration with Steven Finkbeiner’s lab, at the Gladstone 
Institute (San Francisco, CA), and was focused on testing the effect of a 
autophagy inducers compounds on the measured TDP-43 toxicity in both 
MNs and astrocytes. 
Autophagy has been indicated as an important pathway involved in TDP-43 
clearance and neurodegeneration in several studies219,250,251 
In particular, Wang and co-workers showed that rapamycin protects against 
TDP43-mediated neurodegeneration in transgenic mice expressing mutant 
(A315T) TDP43, confirming a beneficial effect for autophagic upregulation 
in an animal model of FTD. However, the potential of autophagy as a 
disease modifying pathway to be manipulated in therapeutic strategies has 
not be clearly proven, as conflicting evidences have been published. In 
particular, besides the work present by Wang et al., one other study has 
suggested that upregulation is beneficial in an animal model of ALS 252, 
while others have shown that autophagy can enhance neurodegeneration and 
muscle atrophy 253,254.  
The compounds tested in the present study (10-NCP, MTM, and FPZ) have 
been shown to determine a robust enhancement in autophagic flux even at 
low concentration. All three compounds have also being shown to 
significantly enhance the clearance of TDP-43 in primary neurons and 
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prevented cytoplasmic mislocalisation of TDP-43 (data not shown, 
Barmada et al. 2013 unpublished).  
In the iPSC-platform, treatment with autophagy inducers partially rescued 
the survival deficit of both M337V MNs and astrocytes, despite showing 
some tendency to increase the cumulative risk of death in control MNs. 
In particular, FPZ proved to be affective in decreasing the cumulative risk 
of death associated with the M337V mutation in MNs, but it also presented 
a side toxic effect on the control populations. In astrocytes, the induction of 
autophagy proved to be able to largely rescue the survival deficit in 
mutation carrying cells, without drastically increasing the risk of death in 
control population.  
Overall, these results indicate that there could be a beneficial effect in 
inducing autophagy in TDP43-proteinopathies, and indicate autophagic 
inducers could be a valid therapeutic option for ALS and other TDP-43 
proteinopathies. Clearly, this proof-of-principles study was conducted on a 
limited number of lines, all coming from the same TDP-43 fALS patient. 
The inducers will need to be tested a greater number of patient lines, and in 
particular the repertoire of iPSC will need to include several sporadic 
patient derived lines, to be able to evaluate the usefulness of this therapeutic 
approach on the vast majority of ALS cases. 
However, besides these limitations, there remains a critical need for 
effective treatments for ALS and TDP-43 proteinopathies in general. It 
needs to be considered that the clinical effectiveness of ALS therapies 
derived from animal models is undermined by several factors: inadequate 
pre-clinical testing, imprecise model systems, species specific differences or 
a combination of all the above contributes often to a high rate of failure 
255,256. Thus, more faithful model systems are required: iPSC–based systems 
and drug screening can potentially bridge the gap between animal models 
and the clinical application of novel therapies, provided that they accurately 
recapitulate the relevant mechanisms of disease.  
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7.5) Cocultures and Non-cell autonomy 
Recently, several in vitro and in vivo models have convincingly 
demonstrated that astrocytes are, at least in part, responsible for disease 
progression in SOD1 fALS 147,150-152. However, since SOD1 fALS cases -
unlike the great majority of sporadic and familial ALS cases- do not present 
the features of TDP-43 proteinopathies 5, understanding whether the TDP-
43 mutation carrying astrocytes have a similar non-cell autonomous 
neurotoxic effect is of great importance. Interestingly, this study has not 
only shown for the first time that the M337V mutation causes cell-
autonomous toxicity in MNs, but it also highlighted a previously 
unrecognised TDP-43 pathology in the mutation carrying astrocytes, 
indicating that the astroglial activation in fALS might have a more 
prominent role other than just a secondary response to neuronal death. On 
this background, the same longitudinal microscopy based survival analysis 
approach was applied to MN-astrocytes cocultures, to elucidate whether the 
astrocytes TDP pathology can indeed cause further MN death. 
Importantly, no significant difference was detected in the survival of control 
MNs plated on mutant astrocytes and equivalent MNs cocultured with 
control astrocytes, which would suggests the absence of a marked non-cell 
autonomous toxic effect.  
To exclude that this particular result was a false negative due to lack of 
sensitivity rather than an indication of a radical difference between SOD1 
and TDP-43 fALS, the same technical set up was tested using control iPSC-
derived MN cocultures on primary mouse astrocytes over-expressing either 
human wild-type SOD1 or G93A SOD1. These primary astrocytes cultures 
derived from transgenic mice have previously been used to determine that 
mutant SOD1 confers to astroglial cells the ability to initiate and accelerate 
the progression of neuronal toxicity147. Results of this experiments 
confirmed the ability of this experimental system to address cellular 
autonomy in iPSC based models as has previously been shown in xeno-
cultures, confirming in turn that the results obtained from the cocultures 
with M337V astrocytes do not represent a false negative. It has been shown 
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in SOD1 fALS rodent model that mutation-carrying astrocytes are 
responsible for the progression but not the onset of the symptoms. 
Therefore, one of the potential hypothesis proposed to explain the absence 
of a non-cell autonomous effects in the iPSC-based model is that as the 
effect exerted on control MNs might be too small to be detected, and that 
the M337V astrocytes would negatively influence the survival of mutation 
carrying MNs. 
However, when the experiment was performed with M337V MNs, the 
results indicated that M337V astrocytes not only did not decrease the 
survival of mutant neurons, coculture with either genotype of neurons 
actually rescued the survival deficit observed in isolated M337V MN 
cultures. As a control for this experiments the same MN populations used 
for the cocultures where also plated in isolation, where the M337V TDP-43 
specific cell autonomous toxicity was replicated. Although this results 
seems at first counterintuitive, considered that previously in this study a 
cell-autonomous TDP toxicity was discovered in the astrocytes, it needs to 
be considered that the presence of the M337V mutation did not impair any 
of the astrocytes functionalities measured. In this context, one of the 
possible explanations for rescued toxicity in coculture conditions is that a 
population of functional astrocytes (even if carrying a potentially toxic 
mutation) will generally increase the health of a neuronal culture, by 
regulating the extracellular environment, providing neurotrophins and 
mechanical support. In this scenario, one of the possible limitations of this 
survival analysis is the actual length of the analysis itself. It is possible that 
besides the initial increase in general health, over long periods of time 
(longer than the 248 hours used here) the mutation carrying astrocytes will 
be less efficient in maintaining MN survival, or they might provide a 
relatively small toxic insult that is not detectable over short periods of time 
but accumulates observed the curse of several weeks or months.  
It need to be observed however, that in the other coculture experiments 
performed (characterisation of synapses and synaptogenesis ability, 
morphological analysis in MN-astrocytes cocultures) it was not possible to 
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detect any difference in the performance of M337V astrocytes over controls, 
even if the coculture was protracted for 3 weeks. 
To solve this issues future survival analysis in cocultures will need to be 
optimised to be able to prologue the analysis over the course of several 
weeks. Also, to convincingly address this issue, future studies will focus on 
the transplantation of iPSC-derived astrocytes in vivo, using fALS rodent 
models. 
Notwithstanding the necessity of further validation this results in other 
patient derived iPSC-lines and animal models, they suggest a potential 
radical difference in the consequence of astroglial-neuronal interaction, at 
least when modelled under basal conditions in vitro, between SOD1 and 
TDP-43 fALS.  
Interestingly, it has been recently shown that astrocytes derived from post-
mortem sporadic ALS and SOD1 fALS patient material have a non-cell-
autonomous toxic effect on mouse ES–derived MNs, indicating that the 
concept of astrocyte-mediated toxicity could be extended to sporadic motor 
neuron disease 226. Again, this further support the need to expand the 
experiments presented here to include more independently derive iPSC-lines 
representative of both fALS and sporadic cases. 
However, it need to be considered also that reactive astrogliosis is defined 
by a number of phenotypic changes in astrocytes 257 and the extent of 
mechanistic overlap between the SOD1 fALS and sALS astroglia mediated 
motor neuron toxicity have not been addressed, and remains to be 
independently confirmed.  
It is also important to note that at present no group reported non-cell 
autonomous toxicity of SOD1 fALS or sporadic ALS iPSC-derived 
astrocytes. One potential explanation is that generating astrocytes in vitro 
from iPSCs in the absence of degenerating neurons does recapitulate the 
entirety of the pathogenic mechanisms, due to the lack of some of the as yet 
uncharacterized, mutation-specific or more general reactive properties of in 
vivo astroglia.  
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Nevertheless, the platform described here is ideal to study both the reactive 
properties of in vitro generated astrocytes and the potential differences 
between astrocytes generated from sporadic and other fALS iPSC lines. 
 
 
7.6) Conclusion and Ongoing Work 
Although this study was limited to a single patient line with sub-clones and 
controls, it demonstrate the utility of patient-specific iPSC lines in 
modelling the molecular pathogenesis of adult neurodegenerative and their 
potential as a platform to test novel therapeutic approaches. 
The iPSC-based platform established can be further expanded and improved 
by including more fALS and sporadic patient-derive lines, but its usefulness 
can also be increased by performing more detailed molecular some of which 
are currently ongoing. 
In particular, a collaboration is currently ongoing with Tom Maniatis lab at 
Columbia University (NY), to study the consequences of M337V TDP-43 
mutation on the expression profile and splicing of both MN and astrocytes, 
by using total mRNA deep sequencing techniques (RNA-seq 258).  
It is also important to consider that the iPSC-based platform does not 
present a stand-alone modelling technique, and to exploit its full potential 
needs to be paired with in vivo analysis. To this end, the establishment of a 
protocol to transplant the iPSC-derived astrocytes rodent animal models is 
currently ongoing. The focus of this particular experiment will be to 
determine whether the mutation carrying astrocytes can affect long-term 
neuronal survival in a wild-type animal and in a TDP-43 fALS rodent 
model. 
The drug-screening capacity of the platform, couple with the longitudinal 
imaging set-up will be also further expanded, including different classes of 
compound to test therapeutic approaches and probe the molecular 
mechanisms of TDP toxicity. The study with the autophagy inducers in 
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collaboration with Steven Finkbeiner’s lab is currently on-going and its 
results will be published shortly. 
 
In conclusion, this study established a novel platform to address the 
biological consequence of somatic mutations on human iPSC–derived MNs 
and astroglia but also to dissect the contribution of glial-neuronal cross-talk 
in neurodegenerative processes. The application of the platform to study the 
non-cell-autonomous component of TDP-43 proteinopathies, and the 
description of a previously unrecognized cell autonomous TDP-43 toxic 
effect on astrocytes further highlight the potential of using patient-derived 
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